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ABSTRACT 
Decision-making per se can be regarded as part art and part science in the development 
of new medicines. In the area of pharmaceutical development, decision-making plays a 
pivotal role in the continuation or the termination of further development or withdrawal 
of medicinal products. The decisions made at each stage have a direct impact on all 
stakeholders namely, pharmaceutical companies, regulators, payers and patients. What is 
lacking at present is a qualified understanding of the subjective decision-making 
approach, influences, behaviours and other factors which impact the decision-making of 
individuals and organisations involved in the delivery of new medicines. The aim of this 
study was, therefore, to develop and validate a generic instrument for appraising the 
quality of decision-making. 
 
Semi-structured interviews were carried out with 29 key decision-makers from the 
pharmaceutical industry, regulatory authorities and contract research organisations 
(CROs). They were invited to discuss all aspects, including their perception of decision-
making and its role in drug development and regulatory review; decision making within 
their organisation; awareness and use of decision-making techniques; and impact and 
monitoring of decisions. Thematic analysis was carried out using NViVO 8 © software.  
A preliminary 94-item instrument was developed from the themes and the sub-themes 
that emerged from the interviews. Content validity was assessed using qualitative and 
quantitative data from an expert panel involving six key decision makers. A separate 
international cohort of 120 individuals working in the pharmaceutical industry, 
regulatory authority or CROs was recruited for factor analysis to reduce items. A further 
78 individuals completed the final version of the QoDOS for construct validity and 
reliability. 
 
Most individuals interviewed were male (55% - n=16) and their level of experience 
ranged from 7 to 35 years. 32 themes and 90 sub-themes of aspects of decision-making 
were identified from the interviews. The median numbers of themes reported by experts 
was 6 (range = 1-10). The key themes included: quality and validity of the data; 
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political, financial, competitor and reward influences; analytical and logical approach; 
overconfidence in own judgement; plunging in or procrastinating with decision-making; 
impact analysis of decisions; education and awareness of evolving decision-making 
techniques; and SWOT and alternate outcome planning. Relationships between the 
themes were identified. 
 
A 94-item generic instrument for assessing the quality of life decision-making, Quality 
of Decision-Making Orientation Scheme (QoDOS) ©, with a 5-point Likert response 
scale was developed. The content validity panel’s rating of each item on a 4-point scale 
for the 4 attributes showed “strongly agreed” or “agreed”  (88%) with an ICC value  of 
.89 (CI = 0.56 – 0.99) suggesting a high agreement between the panel members’ 
responses. This led to the reduction of 20 items and addition of two items as a result of 
cross-referencing with the qualitative data. Thus, the 76 items (version 2) emerged from 
content validation. Factor analysis produced a 47-item measure with four factors. The 
QoDOS showed high internal consistency (n = 120, Cronbach’s alpha = 0.89), high 
reproducibility (n = 20, ICC = 0.77) and a mean completion time of 10 minutes. 10 
hallmarks of “Good Decision-Making Practice” (GDMP) were identified. 
 
The QoDOS is a valuable addition to the decision-making tool box of drug developers 
and regulators and has the potential to fill the missing gap of the entire process which is 
building quality into the lifecycle of medicine.  The identification of ten hallmarks and 
generation of a framework for GDMP are also important contributions of this study to 
the field. 
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GLOSSARY OF TERMS 
ANOVA: Analysis of Variance, which tests for significant mean differences in the 
variables among multiple groups.  
Advisory committee: An expert committee that advises the regulatory authority on the 
safety, quality and efficacy of medicinal products for human use.   
Approval: The approval of a product by a regulatory authority, signified by the granting 
of a product licence.  
Assessment report: This report describes the assessment of the medicinal product and 
states the reasons for the conclusions. It explains why a marketing authorisation 
and each of the proposed indications have been approved or rejected and details 
the benefit-risk considerations for the product. This document also serves as an 
audit trail and should be sufficiently detailed to allow for secondary assessment by 
other Member States experts. 
Assessment template: A standard document or a form used to record data required by 
the quality system of the review process. 
Bartlett’s test of sphericity: Statistical test used in the analysis of variance. 
Benefit: The positive results of a given treatment for an individual or a population. (i.e. 
efficacy, convenience, or even quality of life) 
Benefit-risk assessment: A formal way to analyse benefit and risk consequences and 
their balances from a set of actions and to make choice among actions when risk 
aversion and preferences are specified. 
Bias: Any error that creeps into the data. Biases can be introduced by the researcher, the 
respondent, the measuring instrument, the sample, and so on. 
Category scale: Analyses done to detect cause-and-effect relationships between two or 
among more variables. 
Centralised procedure: The Centralised Procedure is used when a marketing 
authorisation covering the entire EU region is applied for. A marketing 
authorisation application is submitted to the European Medicines Agency. A single 
evaluation is carried out through the Committee for Medicinal Products for Human 
Use (CHMP). If the Committee concludes that quality, safety and efficacy of the 
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medicinal product is sufficiently proven, it adopts a positive opinion. This is sent 
to the European Commission to be transformed into a single market authorisation 
valid for the whole of the European Union. 
Checklist: An informational aid to guide evaluators in determining when qualitative 
methods are appropriate for an evaluation inquiry. 
Clinical section of the dossier: This section consists of the clinical study reports 
including documentation on the clinical trials performed on the product. This 
information is provided in Module 5 of the Common Technical Document. 
Coding: The analytic process through which the qualitative data that you have gathered 
are reduced, rearranged, and integrated to form theory.  
Concurrent validity: Relates to criterion-related validity, which is established at the 
same time the test is administered.  
Conjoint Analysis: A multivariate statistical technique used to determine the relative 
importance respondents attach to attributes and the utilities they attach to specific 
levels of attributes.  
Construct validity: Testifies to how well the results obtained from the use of the 
measure fit the theories around which the test was designed. 
Content analyses: An observational research method that is used to systematically 
evaluate the symbolic contents of all forms of recorded communication.   
Content validity: Establishes the representative sampling of a whole set of items that 
measures a concept, and reflects how well the dimensions and elements thereof are 
delineated.  
Continual improvement: Ongoing activities to evaluate and positively change 
activities, processes and the quality system to increase effectiveness. This term is 
frequently used interchangeably with continuous improvement. 
Convergent validity: that which is established when the scores obtained by two 
different instruments measuring the same concept, or by measuring the concept by 
twp different methods, are highly correlated.  
Correlational analysis: Analysis done to trace the mutual influence of variables on one 
another.  
Cronbach’s alpha: is a coefficient of internal consistency. 
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Deductive reasoning: the application of a general theory to specific case. 
Descriptive statistics: statistics such as frequencies, the mean, and the standard 
deviation, which provide descriptive information about a set of data. 
Development stage: The phase of the research and development encompassing all 
activities between drug candidate selection and approval.  
Discriminant analysis: a statistical technique that helps to identify the independent 
variables that discriminate a normally scaled dependent variable of interest.  
Discriminant validity: that which is established when two variables are theorised to be 
uncorrelated, and the scores obtained by measuring them are indeed empirically 
found to be so.  
Effectiveness: Is the extent to which an intervention does more good than harm when 
provided under the usual circumstances of health care practice.  
Efficacy: Is the extent to which an intervention does more good than harm under ideal 
circumstances.  
European public assessment report (EPAR): The European Public Assessment Report 
is prepared at the end of every centralised evaluation process to provide a 
summary of the grounds for the opinion in favour of a marketing authorisation as 
taken by the Committee for Human Medicinal Products (CHMP). The EPAR is 
derived from the assessment of the documentation submitted by the applicant and 
the scientific discussions undertaken by the CHMP during the evaluation process. 
The European Medicines Agency makes the EPARs available to the public after 
deletion of commercially confidential information. Furthermore, the EPARs are 
updated throughout the life cycle of the product to reflect changes to the original 
terms and conditions of the marketing authorisation.  
External validity: the extent of generalisability of the results of a casual study to other 
field settings.  
Factor analysis: is a statistical method used to describe variability among observed, 
correlated variables in terms of a potentially lower number of unobserved 
variables called factors. 
Face-to-face interview: information gathering when both the interviewer and 
interviewee meet in person. 
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Face validity: an aspect of validity examining whether the item on the scale, on the face 
of it, reads as if it indeed measures what it is suppose to measure.  
Framework: structured stepwise approach to perform a task. 
Good review practice (GRP): GRP is a documented best practice that discusses any 
aspect related to the process, format, content, and/or management of a product 
review. GRPs are developed to provide consistency to the overall review process 
of new products, as well as to improve the quality, efficiency, clarity, and 
transparency of reviews and review management.  
Health Technology Assessment: This is the term used for the assessments made by 
government and insurance reimbursement agencies, hospital formulary committees 
and other bodies representing the payers for healthcare and medicines.  
Inductive reasoning: a process where we observe specific phenomena and on this basis 
arrive at general conclusions. 
Integrated quality management: is the understanding and effective direction of an 
organisation, resulting in the best possible management decisions, so that the 
needs and expectations of all stakeholders and partners are satisfied by the 
optimum use of all resources. 
Interitem consistency reliability: a test of the consistency of responses to all the items 
in a measure to establish that they hang together as a set.  
Internal consistency: homogeneity of the items in the measure that tap a construct. 
Interrater reliability: the consistency of the judgement of several raters on how they 
see a phenomenon or interpret the activities in a situation.  
Interviewing: a data collection method in which the researcher asks for information 
verbally from the respondents.  
Key performance indicators (KPIs): KPIs are quantifiable measures that indicate 
relative performance in relationship to a target goal.    
Kaiser-Meyer Olkin: a test to assess the appropriateness of using factor analysis on 
data. 
Likert Scale: an interval scale that specifically uses the five anchors of strongly 
disagree, disagree, neither disagree nor agree, agree, and strongly agree.  
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List of questions: A consolidated list of questions provided by the regulatory authority 
identifying major objections and / or other concerns identified during a review.  
Literature review: the documentation of a comprehensive review of the published work 
from secondary sources of data in the areas of specific interest to the researcher.  
Marketing Authorisation: Legal approval granted to a company by a national authority 
to market a medicinal product in that particular market. 
Marketing Authorisation Application: An application submitted by a company to 
support the regulatory approval for a medicinal product in a country/region. In the 
US this could also mean a New Drug Application (NDA). 
Measurement: A process of establishing the correspondence between a property and a 
number system. 
Methodology: The system of methods and principles used in a particular discipline. 
Multiple regression analysis: a statistical technique to predict the variance in the 
dependent variable by regressing the independent variables against it.  
Multitrait-multimethod matrix is an approach to examining Construct Validity. 
New Active Substance: A chemical, biological or radio pharmaceutical substance that 
has not been previously available for therapeutic use in humans.  
NVivo:  a qualitative data analysis computer software package designed for qualitative 
researchers working with very rich text-based and/or multimedia information, 
where deep levels of analysis on small or large volumes of data are required. 
Non-clinical section of dossier: This section consists of the non-clinical study reports 
and tests covering the pharmacology, pharmacokinetics and toxicology of the 
drug. This information is included in Module 4 of the Common Technical 
Document.  
Objectivity: interpretation of the results on the basis of data analysis, as opposed to 
subjective or emotional interpretations.  
Parsimony: efficient explanation of the variance in the dependent variable of interest 
through the use of smaller, rather than a larger number of independent variables.  
Peer review: Peer review means an additional evaluation of an original assessment 
carried out by an independent person or committee. Peer review can occur either 
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during assessment of a dossier or at sign-off. Peer review can be internal or 
external.  
Population: the entire group of people, events, or things that the researcher desires to 
investigate.  
Preference values: A quantitative measure of the extent to which an outcome achieves 
an objective, as judged by an individual or group. 
Principal component analysis: a statistical method of analysis which involves finding 
the linear combination of a set of variables. 
Problem definition: a precise, succinct statement of the question or issue that is to be 
investigated.  
QoDOS: Quality of decision-making orientation scheme. 
Qualitative study: research involving analysis of data/information that are descriptive 
in nature and not readily quantifiable. 
Quality assurance: Planned and systematic activities implemented in a quality system 
that provide confidence that quality requirements are fulfilled. 
Quality audit: It involves the assessment of any designated process or activity to obtain 
objective evidence that the existing requirements have been met (for example, 
effective and efficient implementation of processes and resources). Quality audits 
can be internal or external.  
Quality control: Quality control is operational techniques and activities that are used to 
fulfil requirements for quality. It involves techniques that monitor a process and 
eliminate causes of unsatisfactory performance at all stages of the quality cycle.  
Quality section of dossier: This section of the dossier consists of chemical-
pharmaceutical and biological information for chemical active substances and 
biological medicinal products. This information is provided in Module 3 of the 
Common Technical Document.  
Quality policy: Overall intentions and direction of an organisation related to quality as 
formally expressed by top management.  
Quality system: The organisational structure, responsibilities, procedures, processes and 
resources for implementing quality management. 
Quantitative: involving considerations of amount or size; capable of being measured. 
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Questionnaire: a pre-formulated written set of questions to which the respondent 
records the answers, usually within rather closely delineated alternatives. 
Registration: This term is also known as marketing authorisation.  
Regression analysis: used in a situation where one or more metric independent 
variable(s) is (are) hypothesised to affect a metric dependent variable.  
Relative efficacy: the extent to which an intervention does more good than harm under 
ideal circumstances compared to one or more alternative interventions. 
Reliability: attests to the consistency and stability of the measuring instrument. 
Research: an organised, systematic, critical, scientific inquiry or investigation into a 
specific problem, undertaken with the objective of finding answers or solutions 
thereto.  
Review: This term is also known as assessment in which the assessors review the 
dossier in terms of the quality, safety and efficacy of the submitted data. 
Review outcome: The result of the regulatory review in terms of whether or not a 
licence was granted by the authority for marketing the product. 
Rigour: the theoretical and methodological precision adhered to in conducting research.  
Risk: The negative results (adverse outcomes) of a given treatment for an individual or 
population in terms of probability of occurrence having considered the magnitude 
of severity. 
Risk-benefit balance: An evaluation of the positive therapeutic effects of a medicinal 
product in relation to any risk relating to the quality, safety or efficacy of the 
medicinal product as regards patients’ health or public health. A marketing 
authorisation will be refused if the risk-benefit balance is not considered to be 
favourable. 
Risk management plan: It is a set of pharmacovigilance activities and interventions 
designed to identify, characterise and manage risks relating to a medicinal product. 
It consists of an overview of the safety profile of the product, a pharmacovigilance 
plan and a risk minimisation plan.  
Sample: a subset or subgroup of the population. 
Sample size: the actual number of subjects chosen as a sample to represent the 
population characteristics.    
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Scale: a tool or mechanism by which individuals, events, or objects are distinguished on 
the variables of interest in some meaningful way.  
Scientific advice: Advice provided to companies on the conduct of various tests and 
trials necessary to demonstrate the quality, safety and efficacy of the medicinal 
product. The advice covers scientific issues related to the proposed future 
development of the product. 
Scientific assessment: Review of the dossier in terms of safety, quality and efficacy of 
the data submitted.  
Scree (Catrell’s) plot: A visual plot in descending order of magnitude of the 
eignevalues of a correlation matrix which presents the relative importance of the 
factors. 
Self-assessment: This is a carefully considered evaluation resulting in an opinion or 
judgement of the effectiveness and efficiency of the organisation and the maturity 
of the quality management system. Self-assessment is usually performed by the 
organisation’s own management.  
 Spearman’s test: is a nonparametric measure of statistical dependence between two 
variables. 
Standard operating procedures (SOPs): SOPs are written documents that describe in 
detail the routine procedures to be followed for a specific operation, analysis or 
action. 
Submission: The submission of a regulatory dossier to apply for a licence to market the 
product.  
Summary of Product Characteristics (SPC):  The SPC is a document that forms an 
intrinsic and integral part of the marketing authorisation application. The SPC is a 
summary of the dossier and sets out the agreed position of the medicinal product 
as distilled during the course of the assessment process. The SPC is the basis of 
information for health professionals on how to use the medicinal product safely 
and effectively.  
SWOT: A business approach to identify Strength, Weakness, Opportunities, Threats of 
a situation 
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Validation process: The process whereby a regulatory authority verifies that all parts of 
the submitted dossier are present and complete and suitable to be assessed as part 
of the assessment and registration process.   
Validity: evidence that the instrument, technique, or process used to measure a concept 
does indeed measure the intended concept.  
Variable: anything that can take on differing or varying values.  
Variance: Indicates the dispersion of a variable in the data set, and is obtained by 
subtracting the mean from each of the observations, squaring the results, summing 
them, and dividing the total by the number of observations.  
Utility: A subjective measurement that describes a person’s or group’s preference 
(satisfaction, risk attitude, etc.). 
Value function: A function which convert the input data (parameters) in all criteria into 
preference value or utility for the options under evaluation. 
Value judgement: A subjective assessment for appropriateness of values or utility in a 
decision-making problem. 
Weight: Scaling constants assigned to criteria such that the units of scaled preference 
values across all criteria are equal. 
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BACKGROUND 
“From vision to decision, Pharma 2020”........was the title of the PWC pharmaceutical 
strategy report issued in late 2012. The opening paragraph of the report states “Pharma’s 
future has never looked more promising – or more ominous. Major scientific, 
technological and socioeconomic changes will review the industry’s fortunes in another 
decade, but capitalising on these trends will entail making crucial decisions” (PWC, 
2012). There is constant discussion, debate and published material on the current and 
future productivity projections of pharmaceutical industry research and development 
(R&D). At present, there are several formidable internal and external factors that are 
facing the industry including items such as increasing stakeholder pressures. These 
include the current patent expiration, the market dynamics, the in-licensing/out-licensing 
of assets, the outsourcing of complete R&D activities to service providers and the 
emergence of non-ICH countries as being key players in the delivery and the demand for 
pharmaceutical products. So, in regard to the changing pharmaceutical arena, it begs the 
question, will pharma improve the quality of its decision-making in the future and 
therefore aim to make its future more promising rather than more ominous? 
 
The development of a new drug from molecule to market is a complex stepwise process 
that is dependent on multiple and expert input, knowledge and decision-making by a 
wide range of specialists in various fields. Within the pharmaceutical industry, these 
come from differing functional areas and comprise  individuals with specialised training 
and expertise in areas such as: synthetic chemistry, manufacturing, non-clinical 
pharmacology and toxicology, biostatistics, clinical operations, data management, 
project management, medical affairs, regulatory affairs, benefit/risk pharmacovigilance, 
management teams, health economics, commercial and legal affairs. Within the 
regulatory agencies, the expertise of the individuals will have a particular focus on areas 
such as: chemistry/pharmaceutical and manufacturing controls, non-clinical pharmaco-
toxicology, clinical expertise in differing therapeutic areas, biostatistics, 
pharmacovigilance, regulatory affairs and legal affairs. More recently we are also seeing 
a growing involvement of agency personnel with expertise in areas such as cost-
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effectiveness, pharmacoeconomics and their interaction with Health Technology 
Assessment (HTA) agencies and patient platform groups. 
 
Rapid advances in drug development such as the use of modelling and simulation, 
adaptive clinical trials, specific target therapy properties of drug candidates and a greater 
appreciation of benefit/risk assessment are now common within the drug development 
programme of New Chemical Entities (NCEs) and New Biological Entities (NBEs). The 
traditional ‘Go/No-go’ stage gates are still dominant within the delivery and maturation 
of new medicines. The science and dynamic evolution of development approaches are 
new challenges to pharmaceutical companies and regulatory authorities, but both are 
adapting to the changes (Eichler et al., 2008; Eichler et al., 2012). The drug development 
arena has inherent high risks and uncertainties associated through each stage of 
development (Pritchard et al., 2003).  The decisions made will dictate the continuation 
or the termination of a candidate drug and thus limit patients’ access to new medicines 
(Pritchard et al., 2003; Eichler et al., 2008; Chung-Stein, 2011; Colwrick et al., 2011; 
Eichler et al., 2012). In the regulatory review and the HTA component of the evaluation 
of new medicines, ever increasing efforts are seen to improve the decision-making 
process as it is recognised to be in the interest of all stakeholders. The latest MHRA/ 
Biotechnology Industry Association expert committee report has again highlighted the 
need for improvement in the regulatory decision-making process (MHRA, 2013).  
 
 
PHARMACEUTICAL DEVELOPMENT DECISION-MAKING CHALLENGES 
Industry  
Several decision-making frameworks are available to aid quality decision-making and in 
particular in the benefit-risk assessment of medicines in the post-approval setting. 
Quality of decision-making remains a fundamental issue which has a direct impact on all 
stakeholders (Walker et al., 2007; Mattes et al., 2010) and it is appreciated that “quality” 
is a difficult concept to define and a difficult parameter to establish and monitor 
(Lumpkin, 2000).   
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Pharmaceutical organisations operate in a business environment in which different 
dynamics and forces are present such as: competitors, governmental regulations, 
investors, payers and patients. Each plays a significant role in the company’s 
performance by presenting opportunities and imposing threats on Research and 
Development, manufacturing, clinical and commercial activities. Ironically, although 
innovative drugs with novel mechanisms of action are attractive to all stakeholders, they 
also bring the penalty of being unpredictable with unknown risk (Pritchard, 2008). It is 
therefore in the interest of all stakeholders, that there is an effort to improve decision-
making by “dropping the loser” and “supporting the winner” and thus achieve minimum 
time-to-market. The 2009 European Commission report on the European pharmaceutical 
sector confirmed the decline of new chemical entities reaching the market and identified 
some of the company practices possibly contributing to this decline. The report also 
highlighted the need to address the fragmented decision-making within regional/local 
Member State regulatory agencies and emphasised that this should be addressed at a 
local level (ECORYS, 2009).  
 
Within pharmaceutical R & D, the ‘Go or No-Go’ decisions are based on judgements 
made by a group of individual health experts with varying background knowledge and 
experience (Pritchard et al., 2003; Sarac et al., 2012). Decisions are often made based on 
insufficient or incomplete data, a high degree of uncertainty, time pressure, financials 
and often in a competitive environment. As drug candidates mature through the R&D 
processes, the stakeholder groups will tend to include more external regulatory 
influences and market forces in their decision-making.  High quality or optimised 
decision-making should be considered a cornerstone for effective drug development and 
life cycle maintenance. The industry has developed many decision-making analysis 
techniques including qualitative, quantitative and semi-quantitative approaches to try to 
aid the decision-making process. These techniques include frameworks, value-trees, 
modelling, simulations and other platforms which aim to provide a systematic and 
transparent approach to decision-making.  
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Regulatory 
The remit of regulatory agencies is to protect public health. However, the regulatory 
authorities are increasingly being challenged to find the appropriate balance between the 
need for rapid access to new medicinal products and at the same time to ensure 
comprehensive data on their benefits and risks (Breckenridge and Walley, 2008; Eichler 
et al., 2008; Breckenridge et al., 2010; Eichler et al., 2012). The regulators’ dilemma is 
that of balancing access to market against the requirement for as complete as possible 
data package prior to licensing as outlined in the European Medicines Agency’s (EMA) 
draft roadmap to 2015 (EMA, 2011b). This dilemma is also compounded by the 
increasing novelty, complexity and speciality of some clinical development programmes 
and subsequent regulatory review is becoming an increasing challenge (Eichler et al., 
2012). The challenges and the importance of the decision-making process for the 
regulatory authorities is illustrated by the risk of failure or error in any of the numerous 
decisions taken by the authority (Jefferys, 2000).    
 
Regulatory agencies are actively working on improving the benefit-risk balance model 
by focussing on three major aspects for improvement: ensuring a consistent decision-
making approach, providing a better rationale for the outcome of the benefit-risk 
decision-making review and improving communication with the various stakeholders 
(EMA, 2010; EMA, 2011a; IMI-EFPIA, 2013a).  The EMA is actively supporting other 
areas within the licensing review which could be improved, such as facilitating more 
continuous dialogue during the assessment of a marketing authorisation, providing 
additional transparency of the decision-making undertaken and the outcome of the 
scientific review as summarised in the EU EPARs.  It is also aiming to achieve the right 
balance of protection of commercial confidentiality of proprietary information (EMA, 
2010a). Continuous benefit-risk assessments throughout a medicine’s lifecycle and other 
strategies such as staggered-licensing of new medicines in certain situations are 
discussed in the EMA roadmap (EMA, 2011b). Other initiatives including the option to 
seek joint  scientific advice from CHMP and HTA Agencies from EuNetHTA, has been 
well received by industry and Authorities (EMA, 2013b). These joint meetings may help 
to identify and develop the best clinical development programme and registration 
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strategy that should satisfy the safety, quality and efficacy requirements of the MAA 
submission and in addition the pharmacoeconomic demands of potential payers. An 
example of another initiative which is facilitating transparency on safety/benefit 
expectations of medicines is the establishment of the PRAC advisory meetings (since 
2012) which is helping better define expectations of new MAAs (EMA, 2013b).  
Other initiatives such as the EU benchmarking system, are helping to achieve a 
strengthening of the quality assurance systems in place at the level of all EU regulatory 
authorities (EMA, 2011b). The EU Benchmarking of European Medicines Agencies 
(BEMA) programme has the following broad aim to ‘contribute to the development of a 
world-class medicines regulatory system based on a network of agencies operating to 
best practice standard’. BEMA is based on the assessment of the systems and processes 
in individual agencies against a set of indicators which have been agreed in the 
following areas: management systems, assessment of marketing authorisation 
applications, pharmacovigilance (drug safety) activities and inspection services (HMA, 
2013).  Regulatory Agencies have also recognised and established the importance of a 
strong Integrated Quality Management (IQM) system (FDA, 2006; FDA, 2009; MHRA, 
2009).  Integrated management is the understanding and effective direction of an 
organisation, resulting in the best possible management decisions, so that the needs and 
expectations of all stakeholders and partners are satisfied by the optimum use of all 
resources (MHRA, 2009).  Linked to the integrated management approach and 
benchmarking initiatives, the regulatory agencies issue regular performance metrics. 
These metrics provide a valuable insight into outputs from the regulatory agencies and 
include information on new approvals, review timelines, clinical trial activities, 
inspection reports and orphan product designations.  
Good review practice (GRP) systems are now present within many regulatory agencies 
and are helping to add transparency and a systematic approach to the regulatory review 
(FDA, 2005; FDA, 2006; Dash and Jones, 2010; Molzon et al., 2011; TGA, 2013).  The 
US FDA and EMA have invested considerably over recent years in a quality system 
which is aimed to be integrated, agency-wide and risk-based in order to control, assure 
and improve the effectiveness of the regulatory processes (FDA, 2009; EMA, 2011b).  
7 
 
Pharmaceutical organisations also need to ensure that they establish good regulatory 
practices and that these are being applied. Methods for monitoring and assessing quality 
procedures should be sought with a view to continuous improvement (Korteweg, 2002; 
Walker, et al., 2007).  It is appreciated by all stakeholders that improved transparency in 
the decision-making on new medicines and their life cycle will be of benefit to all 
(Korvivk, 2008).   
 
Decision-Making Issues for The Individual  
Decision-making within medicines development and the regulatory review is made at an 
organisational as well as an individual level. Decision-making is a subjective value 
assessment and judgement and can be regarded as being part science and part art 
(Milkman et al., 2008; Kahneman, 2012; Wethey, 2013). This subjective decision-
making style represents the combination of how an individual interprets and understands 
stimuli and the general way in which he chooses to respond to them. It is linked to an 
individual’s education, knowledge, ability, culture and motivation, their value 
orientation and tolerance for not having valid and reliable information before making a 
decision. Decision-making is usually considered to be the result of cognitive processes 
leading to the selection of a course of action between several alternatives (Dhami, 2003; 
Westaby et al., 2010; Kahneman et al., 2011). It represents a rational or irrational 
reasoning or emotional process based on prior knowledge as well as individual 
assumptions based on normative perspectives, which is held by that individual and no 
other person is privy to that decision-making process. It is this notion that underpins the 
importance of decision-conferencing where individuals share their normative standards 
to reach a shared decision.  
 
The act of decision-making is a multi-stage multi-criteria process which should be 
utilised in ‘Go/No-Go’ processes. The elements of risk and reward depend on the 
information available and the individual’s outlook in regard to acceptable risk and 
reward levels.  It is also important to appreciate that decision-making is not a linear and 
predictive process, but rather a non-linear and evolving one. A person’s behaviour is an 
important factor in an individual’s decision-making and it is influenced by their 
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environment (Kahneman, 2012). Successful decision-making can be expected to require 
a thorough understanding and appreciation of the environment in which that decision 
will be carried out. Without such an understanding, it is impossible to assess the 
probable consequences that may result (Messicks and Bazerman, 1996). Thus, the 
decision environment as defined by the collection of information, alternatives, values, 
and preferences available at the time of the decision (Harris, 2012), will be of 
importance for the actual decision process. Therefore, an ideal decision environment 
would include all possible information, which is accurate and clear and addresses every 
possible alternative (Ivanona and Gibcus, 2003; Milkman et al., 2008; Harris, 2012; 
Wethey, 2013). However, in real world medicines development this ideal position is 
rarely the case in which safety and efficacy evidence is dynamic and development 
timelines are compressed.  
 
Individual Decision-Making Styles: 
On a fundamental level, there are four basic decision-making styles: subjective, 
objective, analytical and non-analytical (Rowe and Bougarides, 1983; Quernk, 2009). 
Many factors that can influence an individual’s approach to decision-making such as: 
• Personal biases which are based on a grounded personal belief or faith and 
include elements such as a person’s political leanings or religious choices  
• Cognitive bias may be present in the form of a selective search for evidence 
or a tendency to think in a certain way. Cognitive biases can lead to 
deviations from a standard of rationality or good judgment  
• Selective perception e.g. where a person discounts certain information too 
quickly and interprets it in the way they want to, rather than looking at the 
bigger picture. This behaviour results in a person tending to "see things" 
based on their particular frame of reference and results in a person 
perceiving what they want in information while ignoring opposing 
viewpoints (Hammond, 2002; Verma, 2009).  
• Information or data overload can result in “paralysis by analysis” from a 
state of over-analysing or over-thinking a situation so that a decision or 
action is never taken, in effect paralysing the outcome. A decision can be 
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treated as over-complicated, with too many detailed options, so that a 
choice is never made, instead of trying something and changing if a major 
problem arises. A person might be seeking the optimal or "perfect" solution 
upfront, and is concerned about making any decision which could lead to a 
bad outcome, which can result in no decision being made, which in itself 
could be considered a bad outcome (Ansoff, 1979)  
• Anchoring is where a disproportionate weighting is given to the first 
information received. This high value assignment or anchoring to initial 
information rather than being receptive to update information and 
performing a re-evaluation which would deliver a more balanced approach  
• Overconfidence, wishful thinking or optimism bias e.g. being over-
confident in one’s own decision-making. Overly confident about the 
accuracy of their prediction and considering too narrow a range of 
possibilities. A major cause of overconfidence is anchoring (Lovallo and 
Kahneman, 2003; Hammond et al., 2011; Kahneman, 2012) 
• Choice supported bias is the tendency of a person to retroactively assign 
positive attributes to an option or decision that the person made in the past. 
The person ignores or downplays the negative aspect of the decision made. 
This bias can arise due a person’s previous experience or memories 
(Hammond, 2002) 
• Recent events or semantic priming: remembering and being overly 
influenced by recent dramatic events 
• Groupthink can occur where a group of people may arrive at a consensus 
decision albeit a bad one. This phenomenon can be caused by the dynamics 
and strong personalities within a group. This can result in even a group of 
intelligent people making a poor decision (Von Bergen and Kirk, 1978; 
McCauley, 1998; Macleod, 2011)   
• Authoritative style: where a single person (leader) makes the decision. This 
decision-making style is useful when the leader possesses all the necessary 
information and has the required expertise to make the best decision. This 
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style can be particularly valuable when a fast decision is required. It can 
also easily result in bad decisions 
• Overweighting or underweighting of probability is observed where a person 
is more concerned about possible “losses than gains” or conversely where 
the person has not performed a qualified or quantified risk assessment of 
possible outcomes (Kahneman and Tversky, 1982; Kahneman, 2012) 
• Inertia or status quo bias results in a person leaving a decision challenge as 
is and perpetuating the current situation by putting the decision-making off 
to later. This later time can be a distant horizon (Samuelson and 
Zeckhauser, 1988; Hammond et al., 2011)  
• Under-estimating inherent uncertainty and over-estimating is the illusion of 
control and is caused by an under-estimation or lack of appreciation of the 
potential items or influences which could impact the decision. This can 
result in  a false sense of security and perception that all is in order, whereas 
in fact the task or decision could be “spinning out of control” (Hammond et 
al., 2011)  
• Confirming evidence is where a person tends to seek out information that 
supports their instinct or point of view while avoiding information that may 
contradict it. The confirming – evidence trap affects where or how we go to 
collect evidence and how we interpret it. Too much weight can be given to 
supportive information and too little to conflicting information  
• Use of intuition of gut-feeling can be regarded as being a sophisticated form 
of reasoning based on a distillation of wisdom and instinct that one gains 
from life-experience, exposure to situations in personal and professional-
life. It is a subconscious, complex, and quick acting phenomenon. It does 
appear directly connected to experience, expertise and deep knowledge 
developed over years (Mintzberg and Westley, 2001).   
 
For individuals involved in drug development, some people who make individual 
decisions will be risk-prone while others will be risk-adverse on a particular issue 
(Mussen et al., 2009).  Since actual decisions concerning the balance between benefits 
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and risks are heavily influenced by the values of the decision makers and are difficult to 
quantify, better methods are needed for quantifying the benefit-risk profile and 
expressing the values involved in decision-making. The decisions made during drug 
development and the regulatory review are based on evolving scientific capabilities and 
clinical judgement. These decisions need to be monitored throughout the life cycle of a 
medicine. It is also important to appreciate that benefit-risk analysis undertaken by 
regulators is not based on a precise mathematical equation and is invariably 
judgemental.  Some people might well reach different decisions on another occasion, 
even when presented with the same data (Hammond, 2002; Milkman K et al., 2008; 
Verma, 2009; Rawlins, 2011).   
 
Decision-making considerations for the organisation: 
The pharmaceutical industry and regulators also appreciate the need for better decision-
making practices and for systematic and transparent approaches to be more evident in 
the delivery of new medicines and industry/agencies and industry/agencies/academia 
initiatives are being progressed (Guo et al., 2010a, IMI-EFPIA, 2013b). The main area 
of collaboration between these stakeholders is in the area of benefit-risk assessment and 
decision-making frameworks. The pharmaceutical industry and the regulatory agencies 
appreciate the need to incorporate the perspectives of stakeholders in the development of 
frameworks intended to aid lifecycle evolution of medicines including the regulatory 
review. Frameworks provide a structured and systematic outline of how to approach a 
task.  In decision-making, they provide the structure and systematic elements and 
provide transparency at each stage of the decision process and by inference an auditable 
trail of the basis of the final decision. Frameworks can facilitate consistency; promote 
reproducibility, reliability, confidence and overall quality in the decision-making 
process. They can delivery a platform for effective communication amongst all drug 
development stakeholders (pharmaceutical companies, regulatory agencies, payers, 
physicians and patients). This effective communication between the industry and 
regulatory agencies should be iterative in its nature.  
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Frameworks for Decision-Making 
The cornerstones of quality decision-making are: a structured approach, transparency, 
quality of information and effective communication and use of frameworks capture each 
of these components in a systematic manner. In general, frameworks are over-arching 
processes which systematically document important elements of decision-making. They 
promote the use of a structured and an effective decision-making approach. An effective 
decision-making process should aim to fulfil the following criteria: 
 
• It focuses on the decision context  
• It is logical and consistent 
• It acknowledges both subjective and objective factors and blends analytical 
with intuitive thinking 
• It requires only as much information and analysis as is necessary to address 
the decision context 
• It encourages and guides the gathering of relevant information and informed 
opinion 
• It is straightforward, reliable, easy to use, and flexible. 
 
The concept and the recognised benefit of decision-making frameworks is evident across 
many business disciplines. The fundamental tenets of good framework are as outlined 
above. Some examples of frameworks used outside of drug development are introduced 
for reference in Figures 1.1 – 1.3. 
 
The L.E.A.D. (Locate, Evaluate, Assemble, Decisions) framework process can be used 
to assemble evidence in a way that is useful to decision makers. The framework 
recommends a standard systematic template approach that can be used to report results 
to decision makers, which prompts for 1) a statement of the question, 2) a transparent 
description of the strategy used to locate the evidence, 3) a table reporting the evidence, 
and 4) a summary of the evidence organised as answers to the derived questions (Figure 
1.1) (Kumanyika et al., 2012).  
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Figure 1.1: The L.E.A.D decision-making framework  
 
 
Another framework is the Genesis strategic decision-making  process (Genesis, 2013) 
showing its component elements as outlined in Figure 1.2.  
Figure 1.2: Genesis strategic decision-making process 
 
The evidence-based decision-making framework is presented as a circular process aimed 
at thinking about how decisions can be strengthened at every step in an improvement 
cycle. Each circle (stage in the cycle) can be considered separately, with revisions and 
improvements within that circle taking place continually. Although the circles show a 
progression in decision-making reflecting the typical phases in planning, implementing, 
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and evaluating a decision, they can also provide a means for reflecting on which areas 
need more attention after improvement initiatives are underway (Figure 1.3).  
Figure 1.3: The Evidence-Based Decision-Making framework 
 
 
There are other general tools and techniques such as Strengths, Weakness,  
Opportunities, Threats (SWOTs), the 7-S framework (structure, systems, style, staff, 
skills, strategy and shared values), Pareto (root cause) analysis, questionnaires, 
checklists, risk analysis and risk management and decision trees used to support 
decision-making processes (Van Assen et al., 2009).  In regard to the delivery of new 
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medicines, the EMA and FDA have been supportive of initiates to develop the decision-
making frameworks. John Jenkins’ (US FDA) conclusion on the regulators perspective 
on benefit-risk assessment was that “Regulatory risk-benefit decision-making is a 
qualitative science grounded in quantitative data. Judgment is required in making 
regulatory risk-benefit decisions and those judgments are influenced by many factors, 
both extrinsic and intrinsic. Clearly outlining the available data and how decisions 
(judgments) were made can improve transparency of the decision-making process” 
(FDA, 2010). He also outlined the desirable properties and attributes of a decision-
making framework as being:   
 
• Simple and user-friendly  
•  Address critical issues 
•  Capture expert views faithfully  
•  Represent transparently 
•  Compatible with quantitative analysis of clinical benefit and 
safety information 
• Facilitate communications (internal and external) 
• Broadly applicable 
 
Jenkins described the desired attributes of the framework as being:  simple (not 
simplistic), supports sound expert judgement (not a replacement for it) identifies areas of 
disagreement and that it captures the decision context.  
 
Decision-making frameworks can be broadly classified into three types: qualitative, 
semi-quantitative and quantitative (Levitan and Mussen, 2012) Qualitative frameworks 
are generally templates, grids or visual displays that present the key benefits and risk 
attributes. They use a process based on internal experts making subjective judgements 
e.g. on the benefit-risk profile of each product and provide a conclusion. A semi-
quantitative framework usually has a qualitative foundation but includes tabular or 
graphical tools to display and summarise the metrics associated with the key benefits 
and risks data. The semi-quantitative metrics-collection component requires the use of a 
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structured or standard working procedure. The decisions made are based on the review 
of the data results followed by expert judgement. Quantitative frameworks used in 
benefit-risk assessments for medicines allow for the calculation of a benefit-risk score 
using weightings, uncertainty calculations and statistical analysis and allows for a 
benefit-risk balance to be generated. The mathematical component in quantitative 
frameworks can be expected to require considerable specialised resource and effort. In 
the end, decisions are again made based on the review of the data results followed by 
expert judgement. The qualitative frameworks and the insights they deliver are the 
foundation for additional decision-making that may be performed using semi-
quantitative or quantitative methods during and throughout the life cycle of a medicinal 
product. 
 
The EMA medicines’ benefit-risk methodology project is aimed at developing and 
assessing tools which could be used to aid informed, science-based regulatory decisions. 
The project has to date consisted of five consecutive work packages. The work packages 
have and continue to assess the applicability of the following qualitative frameworks: 
PrOACT-URL, PhRMA BRAT, the 7-step CIRS, the US FDA benefit-risk framework, 
use of decision tree models and Multi-Criteria Decision Analysis (MCDA) along with 
other alternative quantitative approaches for assessing the benefit-risk balance (EMA, 
2010; EMA, 2010; EMA, 2011a; IMI-EFPIA, 2013b). MCDA can be considered to be 
the principal foundation in regulatory decision-making for a few existing frameworks 
namely, the PRoACT-URL, PhRAM’s BRAT framework and the 7-step CIRS 
framework. A short review of the frameworks is presented with special attention being 
given to the PrOACT-URL technique as  it has established proven value in both 
decision-making at an individual level (personal) and at a professional or business 
(organisational) level.  
 
PrOACT-URL is a generic decision-making guide and its acronym PrOACT-URL 
represents the steps of the framework: (1) determine the decision context and frame the 
Problems; (2) establish Objectives and identify criteria; (3) identify options and 
Alternatives; (4) evaluate the expected Consequences of the options for each criterion; 
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(5) assess the Trade-offs between benefits and risks; (6) report the Uncertainty in 
benefits and risks, and assess the impact of uncertainty on the benefit-risk balance; (7) 
judge the relative importance and the Risk attitude of the decision maker and assess how 
this affects the benefit-risk balance; and (8) consider the decision’s consistency with 
other Linked decisions, both in the past and its impact on future decisions (Hammond, 
2002; Hammond et al., 2011).  
 
The PrOACT-URL approach provides a clear outline for a quality decision-making 
approach. It raises awareness and identification of the known’s and unknowns and the 
intangible aspects relating to the decision situation. The framework helps to transpose 
the facts, judgement values and an individual’s beliefs and feelings into the best possible 
choice option.  The framework is flexible and adaptable and can be used both for 
professional or business decisions as well as personal decisions. It imbues a systematic 
sequential approach to the decision challenge. It presents a “divide and conquer” 
approach by breaking complex or hard decisions into the eight elements outlined. The 
first five (problem, objectives, alternatives, consequences and tradeoffs) represent the 
fundamental tenet of the recommended approach. The three remaining elements – 
uncertainty, risk tolerance and linked decisions, help to clarify decisions in a real-world 
changing environment (Hammond et al., 2011).  The PrOACT-URL approach also 
provided flexibility and adaptability in that not all of its elements need to be used in a 
given decision-making situation but it does present a “pick and choose” option to the 
decision-maker.   
 
Decision tree (and value tree) models incorporate, in diagrammatic displays, decisions 
(options), subsequent uncertain events, consequences and multiple criteria describing the 
consequences of a decision. They show these as branching structures, like trees tipped 
on their sides, with roots (decisions) at the left, and branches to the right showing 
possible outcomes of the uncertain events, followed by more decisions and a repeated 
process until a point representing some time in the future when consequences will be 
apparent. They can be applied to any decision-making scenario. Decision-trees require 
that preference logic is used in each expansion of the decision-options and implies that 
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just two quantities are needed for decisions: numbers that express the relative values of 
possible consequences and numbers showing how likely these consequences are to 
occur. Multiplying utilities by their associated probabilities and summing those products 
over all consequences for a given alternative provides an expected utility figure that is a 
guide to action. The decision-tree approach requires the decomposition of a complex 
statement into its elements and then assessing probabilities and utilities about the 
relevant elements and finally reassembling the pieces using the expected utility 
calculation. That result allows decision-makers to examine their decision preferences 
and present a logically sound approach to decision-making. One problem with decision 
trees is that they can expand exponentially as more and more nodes are included, thereby 
becoming very complex. On the other hand, it is appreciated that if the problem is very 
complex, unaided human judgement can also be questioned as an acceptable alternative. 
 
The PhRMA BRAT framework standardises and supports the decision-making and 
communication of a benefit-risk assessment between pharmaceutical companies and 
regulators through a 6-step process:  
 
Step 1: Define decision context 
Step 2: Identify outcomes 
Step 3: Identify data sources 
Step 4: Customise framework  
Step 5: Assess outcome importance 
Step 6: Display and interpret key benefit-risk metrics (Coplan et al., 2011).  
 
The US FDA BRF (Benefit-Risk Framework) provides the “big picture” to “tell the 
story” by summarising evidence and addressing their implications for decision in a table 
for five decision factors: analysis of condition, unmet medical need, benefit, risk, and 
risk management and is presented in Figure 1.4 (Frey, 2012).  
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Figure 1.4: US FDA Benefit-Risk Framework 
 
 
The UMBRA initiative established by CIRS in 2012  aims to provide a platform for the 
coordinated development of benefit-risk assessment methodologies that can be used 
internationally during the drug development and regulatory review and post-approval 
periods. The goals of the programme are to increase the transparency, predictability and 
consistency with which benefit-risk assessments are conducted. The UMBRA (Unified 
Methodologies for Benefit-Risk Assessment) framework is aimed at establishing a 
unified benefit-risk framework with an 8-step common element process addressed in 4-
stages shown in Figure 1.5. (CIRS, 2012). The four stages involve: 
1. Framing the decision – decision context 
2. Identifying benefits and risks – building and refining the value tree 
3.  Assessing benefits and risks – relative importance of benefits and risks 
evaluating the options 
4. Interpretation and recommendations – evaluating uncertainty, concise 
presentation of results, and expert judgement and communication. 
 An attractive element of the UMBRA descriptive framework appears to be its ability to 
accommodate the perspectives of the pharmaceutical companies, healthcare providers 
and regulatory agencies. 
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Figure 1.5: UMBRA benefit-risk framework 
 
Building the benefit-risk toolbox – CIRS workshop report - 2012 
 
The MCDA (Multi-Criteria Decision Analysis) framework is a qualitative and stepwise 
decision-making process that allows quantification of the overall performance of two or 
more alternatives. It employs some quantification techniques during the process but the 
overall framework is qualitative in its nature. It provides an approach and a set of steps, 
with the goal of providing an overall ordering of options, from the most preferred to the 
least preferred option. MCDA is a way of looking at complex problems and breaking the 
problem context into more manageable pieces to allow data and judgements to be 
brought into the decision task. The elements of the complex problems can be 
reassembled presenting a coherent overall picture to decision makers. The purpose is to 
serve as an aid to thinking and decision-making, but not to take the decision. As a set of 
techniques, MCDA provides different ways of disaggregating a complex problem, of 
measuring the extent to which options achieve objectives, of weighting the objectives, 
and of reassembling the pieces (Dodgson, 2009). In benefit-risk assessments, statistical 
software is regularly used to provide simulation and modelling support to tackle the 
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complex decision context. As applied to the benefit-risk balance of a drug and its 
comparators, performance of the alternatives on the favourable and unfavourable effects 
are judged for their clinical relevance, and all effects are weighted to create a common 
unit of preference value or utility. Applying an MCDA approach to sum the common 
units of benefit and risks provides an overall benefit-risk preference value or utility for 
each alternative, enabling aspects such as the calculation of the difference of the drug 
against the comparators (Mussen et al., 2009; Tony et al., 2011).  The MCDA 
framework involves: 
 
• Establishing the decision context 
• Identifying the options to be appraised  
• Identifying objectives and criteria 
• ‘Scoring’ by assessing the expected performance of each option against 
the criteria. Then assessing the values associated with the consequences 
of each option for each criterion 
• ‘Weighting’ by assigning weights for each of the criterion to reflect 
their relative importance to the decision 
• Combination of the weights and scores for each option to derive an 
overall value 
• Examining the results 
• Performing a sensitivity analysis. 
 
The MCDA approach offers a logical approach which helps to define the problem 
context, helps decision-makers explore their heuristic values, choices and judgements 
through structuring and presenting information in a manner that allows them to consider 
and challenge their considerations. It also identifies a preferred course of action and 
allows for final decision-making to be based on expert judgement. It is not intended to 
replace this expert judgement but acts to compliment it. It also gives structure and a 
step-wise audit trail and transparency to the decision-process. A summary of the 
comparative characteristics of the PrOACT-URL, PhRMA BRAT, US FDA and 
UMBRA benefit-risk assessment frameworks is presented in Table 1.1. 
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Table 1.1 Comparisons of existing benefit-risk assessment frameworks 
Frameworks reviewed 
Core elements 
Framing the 
decision 
Identifying benefits and risks Assessing benefits and risks Interpretation and outcome 
US FDA 
Analysis of conditions 
and unmet medical needs 
Clinical benefits, risks Evidence and uncertainties  Conclusions and 
reasons, risk 
management plans 
EMA PrOACT-URL 
Nature and framing of 
the problem 
Objectives, favourable and unfavourable effects Alternatives 
regarding 
options to be 
evaluated and 
the 
consequences 
Trade-offs 
and benefit-
risk balance 
Evaluating 
uncertainty 
Effects table and 
risk tolerance 
Consistency of 
decisions (linked 
decisions) 
PhRMA BRAT 
framework 
Define decision context Identify 
outcomes, extract 
source data: build 
value tree 
Customise framework: 
refine value tree 
Assess relative importance of 
different outcomes: weighting or 
ranking, other stakeholders 
Evaluating 
uncertainty 
Display and 
interpret key 
benefit-risk metrics 
and validate results 
Decision and 
communication of 
benefit-risk 
assessment 
UMBRA Universal 
benefit-risk framework 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 Step 8 
Decision context Building the value 
tree 
Customising the value tree Weighting of 
benefits and 
risks 
Scoring 
the options 
Evaluating 
uncertainties 
Concise 
presentation of 
results 
(visualisation) 
Expert judgment 
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The pharmaceutical industry and regulatory agencies agree that frameworks facilitate 
the provision of quality decisions and transparency.  The IMI-PROTECT project (IMI-
EFPIA, 2013b) has recommended that frameworks should contain the following four 
components as shown in Figure 1.6. 
 
Figure 1.6: IMI-PROTECT Evaluation components for evaluation techniques / 
frameworks 
 
ESFPI/PSI Benefit-Risk Special Interest Group meeting, 2012 
In the development and lifecycle of medicines there is still no single framework for 
decision-making that fulfils the requirements and perspectives of the regulatory and 
pharmaceutical stakeholders in making and communicating benefit-risk decisions.  
1. FUNDAMENTAL PRINCIPLES 
- Logically sound 
- Increased transparency 
- Statistical uncertainty estimate 
-Includes other sources of uncertainty 
- Principles easily understood 
- Handling of multiple options 
2. FEATURES 
- Balance of benefits and risks 
- Several benefit and risk criteria 
- May include multiple sources of 
evidence 
- Allows sensitivity analyses 
- Time dimension 
- Methods can be formally updated 
- Any unique feature 
3. VISUAL REPRESENTATION MODEL 
- Potential visualisation techniques 
4. ASSESSIBILITY AND ACCESSIBILITY 
- Parameters and results easily 
interpretable 
- How practical is the method when 
used in real-life decision-making 
- Perspective for which the methods 
are useful 
- Can make the method lead to better 
decision-making 
 
24 
 
Any new decision-making framework should aim to capture a number of key elements 
and the following builds on the IMI protect initiative (IMI-EFPIA, 2013b):  
1. Include the perspectives of the stakeholders by involving them integrally in the 
qualitative and quantitative development  and validation stages of the new 
framework (or instrument) 
2. Have logical soundness and presents coherent dimensions to aid rational 
thinking 
3. Provide a structured and systematic approach 
4. Be comprehensive to allow utility in all forms of medicinal products and 
across all lifecycle stages (e.g. discovery, clinical, registration submission, 
regulatory review and post-authorisation) 
5. Present confidence and acceptability by having undergone due validation 
resulting in a structured approach that would allow validity checks and an 
audit trail on stepwise decisions  
6. Possess specificity and sensitivity supported by an underpinning statistical 
perspective  
7. Increase transparency in the decision-making 
8. Have easily understood principles such as an aim to assess the quality of 
decision-making  
9. Incorporate the value judgements of stakeholders (e.g. individual or 
organisational) 
10. Be derived from and include multiple sources of evidence  
11. Allows sensitivity analyses (e.g. use in different populations) 
12. Have a time dimension 
13. Possess flexibility to be adapted  
14. Have the ability for stand-alone use or for combination use with other accepted 
techniques and/or methodologies  e.g. semi-quantitative or quantitative 
frameworks 
15. Present easily interpretable results and facilitate an effective communication of 
the basis of the decision 
16. Add better predictability into the decision-making 
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17. Be practical in real-life decision-making and easy to use 
18. Present a method leading to better decision-making 
19. Have a visualisation technique such as a graphical profiling of an individual’s 
decision-making style to promote understanding and communication  
20. Have a unique feature such as universality, international attraction and good 
branding (e.g. memorable brand name). 
 
Benefit-risk assessments and decisions in the development and approval of medicines 
rely on scientific capabilities and subjective clinical judgements. These decisions need 
to be monitored during the life cycle of a medicine from drug development to post-
marketing and there should be an effective and iterative exchange of information 
between the different stakeholders. The EMA have provided their opinion and 
recommend that any quantitative benefit-risk assessment method or approach should 
have a qualitative framework component. Combinations of such qualitative and 
quantitative approaches could prove useful (Guo et al., 2010a) and an overarching 
benefit-risk assessment framework with the capacity to incorporate various quantitative 
methods would be ideal. A universal overarching framework can be interpreted as a set 
of principles, guidelines and tools to guide decision-making in organising, 
understanding, summarising, quantifying and communicating the basis of the decision. 
Methodologies are tools which assist in conducting the scientific assessment and aid 
the articulation, communication and visualisation of decisions (Walker, 2011).  
 
Results of a study by Leong et al. published in 2013, investigating the need for a 
universal benefit-risk assessment framework for medicines captured the perspectives of 
the pharmaceutical industry and the regulatory agencies and showed valuable insights 
into the current usage of qualitative and quantitative systems. It showed that qualitative 
systems are employed by both industry and agencies and implied that value and 
weighting had generally not been applied in benefit-risk assessment. Assigning weights 
to the different benefits and risks allows transparency, clarification and communication 
of their relative importance and of the overall basis of the final decision. The absence 
of fully quantitative systems, values, weights and visualisation tools is recognised as 
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presenting a challenge to effective communication of decisions to all stakeholders. 
Having a universal overarching systematic framework for decision-making and 
benefit-risk assessment in particular, should provide a formal structure for 
documenting the component processes leading to the final decision and this added 
transparency will allow all stakeholders to make informed quality decisions (Leong et 
al., 2013).  
 
Stakeholder Interest in Improved Quality Decision-Making 
It is evident from current and joint pharmaceutical industry/regulatory agency activities 
over the recent years that there is a definite desire by all stakeholders to improve 
currently used decision-making approaches. Considerable investment of resource and 
effort is evident on the qualitative, semi-quantitative and quantitative frameworks 
intended to help in the benefit-risk assessment of medicines.  Within all of the 
frameworks and underpinning techniques, there remains a subjective element of 
decision-making required at one of the multiple stages of the decision-process. What is 
not fully transparent is how the subjective decisions in drug development and the 
regulatory review are made and whether there are influences, behaviours and other 
latent factors that contribute to the decision-making. These insights into the subjective 
decision-making element may help to promote better quality decision-making.   
 
To date there is limited information on the quality of decision-making and this 
prompted the current research. Therefore, the current unknowns are: do these 
organisations and individuals make good quality decisions? What are the influences 
and approaches they use in their decision-making? Is there a place for a new 
framework to further aid decision-making for use throughout the drug development 
and complete life cycle?  What appears to be currently missing from the drug 
development and review armamentarium is a generic instrument to assess and enable 
quality decision-making. Such an instrument could also facilitate the development of a 
decision-making framework to be used beyond just the benefit-risk assessment and it 
could incorporate the perspectives of the industry and regulatory agencies.  
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AIM AND OBJECTIVES OF THE STUDY 
 
Aim 
The aim of this study is to develop and validate a generic instrument for appraising the 
quality of decision-making.  
 
Objectives 
• Design a framework for the development of a decision-making instrument 
within drug development and the regulatory review 
• Identify decision-making themes from the perspective of the individual and the 
organisation using qualitative techniques 
• Develop a prototype instrument to appraise the quality of decision-making 
using the outcome of the qualitative techniques 
• Determine content validity of the developmental version of the quality of 
decision-making instrument 
• Refine the generic quality of decision-making instrument in the target 
population using factor analysis 
• Development of the final version of the instrument, Quality of Decision-
Making Orientation Scheme (QoDOS). 
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CHAPTER 2 
  
 
 
 
 
Study Rationale and Methodological Framework 
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Part 1: STUDY RATIONALE 
Chapter one highlighted the paucity of previous research studies investigating the 
quality of decision-making undertaken by the regulatory agencies and the 
pharmaceutical industry. Given the importance of global drug development and the 
societal need for new medicine, it is proposed that information is collected on the 
decision-making approaches and influences of regulatory agencies and 
pharmaceutical industry. This will enable: 
 
• Provision of insights into the decision-making approaches and influences of 
pharmaceutical companies and regulatory agencies 
• Generation of an instrument to measure and enable quality decision-making 
within the drug development life cycle 
• Develop an instrument which would allow a visualisation of an individuals and 
their organisation’s decision-making approach which would present an 
articulation, understanding and clarity on areas for development  
• Provide a framework for promoting consistency, transparency and 
communication of the decision-making approach  
• Identification of the hallmarks of good decision-making practice. 
 
The literature review highlighted several past and ongoing initiatives within the 
pharmaceutical industry and the regulatory agencies (and more recently including 
academia) aimed at developing decision-making methodologies. Most of these 
initiatives and aimed at promoting better decision-making and in particular in regard 
to benefit-risk assessment. Several decision-making frameworks and tools developed 
to facilitate decision-making were reviewed.  It was established that there is no 
validated and reliable instrument to assess and enable quality decision-making in the 
drug development and regulatory review, currently available in the public arena. This 
helped to frame the research question and the research message.  
 
PART 2: METHODOLOGICAL FRAMEWORK 
The choice of research approaches depends on the nature of the research question 
and research objectives (Strauss and Corbin, 1998; Patton 2002). The research 
method to be used in this investigation into influences, approaches, behaviours and 
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overall quality of decision-making, will be a mixed-methods approach involving both 
qualitative and quantitative techniques. In the qualitative research, face-to-face 
interviews will be conducted with a variety of key opinion leaders (KOLs) from the 
European Medicines Agency (EMA) and national European regulatory agencies, 
international pharmaceutical companies and contract research organisations. 
Quantitative research methods will be for the psychometric evaluation of the 
instrument and appropriate statistical analyses will be employed for reporting and 
interpretation of the results. A triangulation of research methodologies will underpin 
validation of the final generic instrument. 
 
Study Design 
The selection of a research design is one of the most important decisions that must be 
taken into account in order to answer the research questions. A ‘research design’ is a 
plan of the procedures for an investigation to be conducted, based on the nature of 
the research problem or issues being addressed and the researchers personal 
experience (Creswell, 2003; Meyrick, 2006). The research methodology tells readers 
how the researcher chooses the available methodology and conducts the various 
stages of research. It should reflect the overall process, in which the research 
philosophy, approach, strategy, data collection methods and data analysis are 
consistent (Saunders, 2009). Such an approach is presented for this research and a 
description of the planning, evidence gathering, data preparation, analyses, 
exploration and communication of the research findings and overall conclusion. A 
mixed-methods approach involving an initial qualitative phase followed by a 
quantitative will be used in this research study. 
 
Qualitative and Quantitative Research Methodologies 
According to Cresswell (2003), qualitative research is an inquiry process of 
understanding based on distinct and methodological traditions of inquiry that explore 
a social or a human problem. The researcher builds a complex, holistic picture, 
analyses words, reports detailed views of informants and conducts the study in a 
natural setting (Creswell, 2003). It allows us to gain an understanding and to access 
any latent factors by focusing on the context of people’s everyday life (Barbour et 
al., 2008). Qualitative data consist of items such as:  in depth descriptions of 
circumstances, people, interactions, observed behaviours, events, attitudes, thoughts 
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and beliefs and include direct quotes from people who have experienced or are 
experiencing the phenomenon (Strauss and Corbin, 1998; Patton, 2002; Denzin and 
Lincoln, 2005; Dicicco-Bloom, 2006).  These data are gathered using techniques 
such as focus groups or interviews (Ritchie, 1994; Doyle, 2012).  
Qualitative data help researchers understand processes and latent issues, especially 
those that emerge over time, provide detailed information about setting or context, 
and emphasise the voices of participants through quotes (Doyle, 2012). Qualitative 
methods facilitate the collection of data when measures do not exist and provide a 
depth of understanding of concepts (Strauss and Corbin 1998; Graneheim and 
Lundman, 2004; Ryan, 2007). To understand the processes or the how and why of a 
given phenomenon qualitative research provides the necessary in-depth and 
exploratory tools to achieve a clear picture of the process (Collis, 2009). The overall 
approach is flexible and evolving and caters for the addition of new information and 
perspectives. Also, according to Silverman, qualitative research findings from  
interviews and questionnaires which ask respondents to provide facts, attitudes or 
experiences, have an important part to play in healthcare (Silverman, 2000).  
 
Quantitative data is any data presented in numerical form such as statistics, 
percentages, whole numbers, metrics or other such data outputs. It aims to answer 
typical questions relating to where, what, who, how many and when (Silverman, 
2000). The objective of quantitative research is to develop and employ mathematical 
models, theories and/or hypotheses pertaining to phenomena (Crabtree and Miller, 
1999; Silverman 2000).The process of measurement is central to quantitative 
research because it provides the fundamental connection between the empirical 
observation and a mathematical expression of quantitative relationships (Silverman, 
2000). The approach involves collection and analysis of numerical data answer to 
answer a research question (Crabtree and Miller, 1999; Moule and Goodman, 2009).  
Quantitative research and its mathematical output aims to present results in a factual 
and unbiased manner. The results obtained also allow for an extrapolation from a 
small population (sample size) to a larger and more generalisable population 
(Silverman, 2000). 
  
In mixed-methods studies researchers choose to combine different types of research 
methods.  They combine quantitative (e.g. a survey) and qualitative (e.g. an in-depth 
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interview) research methods, resulting in a combination of statistical and experiential 
data and findings (Hanson et al., 2005). The mixed-methods pragmatic approach to 
be used will have an initial qualitative component followed by a quantitative phase. 
According to DiCicco-Bloom and Crabtree, mixed-methods in which both qualitative 
and quantitative approaches are integrated in a way that contributes to provide a rich 
and comprehensive study. Mixed-methods provide rigorous and methodologically 
sound study designs, with qualitative techniques such as interviews being an integral 
component of an evolving study process that is responsive to emerging insights, 
supported by quantitative analyses (Creswell, 2003; Doyle, 2012).  
 
Research purposes are normally categorised as being exploratory, explanatory and 
descriptive (Creswell, 2003). Exploratory research is undertaken when an issue or 
phenomenon is poorly understood and little research has been done on it (Creswell, 
2003). Normally, an inductive approach is suitable for exploratory purposes to look 
for patterns and ideas (Collis, 2009), and it is employed in exploratory research to 
arrive at a set of assumptions on which to base the research design. This approach 
applies to the current research on the development and subsequent validation of a 
generic decision-making instrument being undertaken.  
 
Descriptive research is conducted to describe the features of the variables of interest 
in a situation (Sekaran and Bougie, 2010). A deductive approach is suitable for 
descriptive research (Sekaran and Bougie, 2010). An explanatory study is used to 
establish relationships between variables, and both deductive and inductive 
approaches can be applied to it (Saunders, 2009). As the differences between 
deductive and inductive research are narrowed down, an approach that combines 
these two is becoming more widely used (Doyle, 2012). A combined approach can 
provide a better understanding of a specific research topic rather than two separate 
ones.  
 
Interpretivism entails that research and reality are inseparable and reality is internal 
and socially constructed (Remenyi et al., 1998; Denzin and Lincoln 2005). The 
interpretative paradigm is viewed as qualitative, inductive and subjectivist, while the 
positivist paradigm is described as quantitative, deductive and objectivist. 
Interpretivists attempt to understand not only what is happening, but also why it is 
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happening (Creswell 2003; Denzin and Lincoln 2005). Pragmatists hold the view that 
it is perfectly possible to work with both philosophies (Saunders, 2009). This 
approach claims that mixed-methods are possible and highly appropriate within 
research and provide more comprehensive evidence than one method  alone can 
deliver (Casey et al., 2011; Doyle, 2012). In this research, in order to satisfy the 
research objectives both qualitative data (which deal with more in-depth and 
insightful exploration with limited number of interviewees) and quantitative data 
(which can be collected from wider samples for generalisation) were collected. The 
philosophical underpinning of pragmatism allows and guides mixed methods 
researchers to use a variety of approaches to answer research questions that cannot be 
addressed using a singular method. Mixed methods research is viewed as the third 
methodological movement and as an approach it has much to offer health and social 
science research. Its emergence has been in response to the limitations of the sole use 
of quantitative or qualitative methods and is now considered by many a legitimate 
alternative to these two traditions. Overall, it can be seen that a mixed-methods 
pragmatic approach was appropriate and was the approach adopted in this research.  
 
PSYCHOMETRIC PROPERTIES OF A MEASUREMENT TOOL 
Psychometrics is the field of study concerned with the theory and technique of 
psychological measurement, which includes the measurement of knowledge, 
abilities, attitudes, behaviours and traits. The field is primarily concerned with the 
construction and validation of measurement instruments such as questionnaires, tests, 
and personality assessments. It involves two major research tasks, namely: (i) the 
construction of instruments and procedures for measurement; and (ii) the 
development and refinement of theoretical approaches to measurement. 
Psychometric evaluation will be performed on the developmental generic instrument. 
 
In this research, the development of the generic decision-making instrument will 
have exploratory, descriptive, explanatory and confirmatory purposes. Firstly, this 
research will be exploratory as there are no currently validated instruments available 
for assessing the quality of decision-making. This research will employ an inductive 
approach in the qualitative stage involving the proposed conduct of interviews and 
subsequent thematic analysis. Secondly, this research will be descriptive, as it will 
aim to describe any emergent decision-making themes.  A deductive approach will 
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be used in the mixed-method qualitative and quantitative data analyses techniques to 
test results emergent from the research stages. Thirdly, this research will be 
explanatory, as it is aimed at establishing the relationships between different 
decision-making factors and themes which may emerge from the analysis of the 
results obtained from the different stakeholders. Fourthly, it is hoped to be 
confirmatory in that it will investigate construct validity and reliability of the generic 
developmental instrument.  
 
DATA SOURCES AND COLLECTION 
MEDLINE, PUBMED and other internet-based search engines were used to perform 
a systematic literature review to identify methodologies for measuring the quality of 
decision-making within the drug development arena and the regulatory review. An 
extensive and systematic literature search was performed to identify such 
methodologies. These platforms were used to find scientific publications, books, 
academic conference proceedings. Country specific drug regulatory internet sites 
were also searched. Key search words included: decision-making (and decision-
making), drug development, tool, instrument, validated, risk-benefit, regulatory, 
pharmaceutical, quality, framework, best-practice and influences. Search inclusion 
criteria used were 1) only English language publications, 2) with focus on drug 
development and the regulatory review of drugs and 3) decision-making analysis and 
techniques. Exclusion criteria included; veterinary-medicine publications, cosmetics, 
homeopathy, and animal studies. The perspective of the decision-making literature 
interrogation was not limited to that of any one stakeholder. It is believed that this 
literature review corroborated the research into the development of a tool to facilitate 
improved decision-making in the pharmaceutical and regulator target audience.  
 
The literature interrogation helped generate the appropriate framing of the research 
problem context. This allowed for the rationale of the proposed research approach, 
the evolution of the research investigation, the proposed methodology,  the target 
study population and the potential target audience that could benefit from the 
availability of a validated new generic decision-making tool to be identified. In 
addition to the literature interrogation, direct contact was also made with 
organisations such as the Cochrane Collaboration, Stanford University, professional 
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networks specialising in “Decision-Making” and also through the researchers own 
professional networks to determine if there was a suitable decision-making 
instrument available in the public domain.  
 
Data Collection Techniques  
Qualitative research techniques involving semi-structured interviews, use of expert 
panels and thematic framing will be used in a complimentary manner to the 
quantitative techniques which will comprise primarily of several different types of 
statistical analyses. A tabular summary of the data collection techniques to be 
employed in the research is presented in Table 2.1 
Table 2.1: Overview of the data collection techniques used in the generic decision-
making instrument research 
Data collection and Analysis Mode Research Objectives Thesis 
Chapter 
 Semi-structured interviews with  
Key Opinion Leaders 
Qualitative research  
To identify emergent themes relating to the 
decision-making research 
Generate a developmental version of an 
instrument for measuring the quality of 
decision-making 
Generation of a thematic map 
3 
Qualitative research involving  an 
expert panel /qualitative research 
Content validation of the developmental 
decision-making instrument 
4 
Qualitative and quantitative research Factor analysis  
Item reduction 
5 
Qualitative and quantitative research Reliability and construct validity testing of the 
developmental instrument 
Identification of the hallmarks of  good 
decision-making practice 
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Decision-Making Instrument: Data Collection Technique  
Qualitative and quantitative data collection techniques will be used in this research 
including interviews with Key Opinion Leader’s (KOLs) from the regulatory 
agencies and pharmaceutical arena. Digital recordings, the NVivo computer 
relationship database (Bazeley, 2007; Casey et al., 2011) and web-based 
questionnaires (Richards, 2005). Thematic mapping (Attridge- Stirling, 2001; Braun 
and Clarke, 2006; Casey et al., 2011), construct validation and triangulation of the 
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qualitative and quantitative research finding will be used to compound the 
interpretation of the overall research outcome. 
 
Qualitative Techniques: Semi- Structured Interviews & Questionnaires  
 
There are three recognised different types of interviews: structured, unstructured and 
semi-structured. Semi-structured interviews strike a balance between a structured 
interview and unstructured interview. In the semi-structured interviews the questions 
are open ended and do not limit the respondents/interviewees choice of answers.  The 
purpose is to provide a setting/atmosphere where the interviewer and interviewee can 
discuss the topic in detail.  
 
The advantages of face-to-face interviews include the flexibility afforded in 
presenting a series of questions ranging from “closed” to “open”, verbal interactions 
and enhanced assurance on understanding of question asked, It has  been shown that 
individuals are more likely to be interviewed rather than complete a questionnaire, 
especially when the topic is seen to be interesting and relevant to their own current 
work (Holstein, 2001; Dicicco-Bloom, 2006). Interviews are also a good method of 
building rapport and are non-judgemental and can be improved by showing a 
genuine interest in the responses and appreciation of the time-investment of the 
interviewee.  Semi-structured interviews are generally organised around a set of 
predetermined open-ended questions or checklist, with other questions emerging 
from the dialogue between the interviewer and interviewees. Semi-structured in-
depth interviews are the most widely used interviewing format for qualitative 
research and take between 30 minutes to several hours to complete (Dicicco-Bloom, 
2006). Semi-structured interviews will be used in this research. 
 
The individual interview technique is also a qualified research data collection method 
used in new instrument development purposes (Patton, 2002; Patrick et al., 2011a). 
The main advantages of individual interviews are that they allow face-to-face 
communication and   help to obtain more in-depth and detailed information about an 
individual’s experience.  It is also recognised that potential “downsides” to  the 
individual interview approach are:  time-sacrifice involved, it may take longer to 
collect the data, limited to one participant’s view at a time; no peer comparison, cost 
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(e.g. travel, transcription fees) (Patrick et al., 2011b). Individual interviews are ideal 
for concepts that are sensitive or target populations/people are unlikely to volunteer 
or share information in a group setting (Patrick et al., 2011b).  This is a pertinent 
consideration for this research in which confidential, sensitive and subjective 
discussion items will be raised.  
 
Semi-Structured Interview Procedure 
In this research, individual face-to-face interviews using a semi-structured interview 
checklist will be used in the majority of the interviews with the senior decision-
makers. Where this is not possible, the interviews will be held by teleconference. The 
face-to-face interviews should allow for a respect, understanding and rapport to 
develop between the interviewee and the researcher performing the interviews. It is 
hoped that the use of this checklist and interviews will provide a free-flowing 
dialogue and discussion forum between the interviewee and interviewer. 
 
Before  the scheduling  of any  interview,  each interviewee will be sent by e-mail a 
copy of the research outline. This research outline will provide detail on the: research 
background, research objective, research methodology, informed consent and 
confidentiality assurance, estimated time needed for the conduct of the interviews, 
the time window during which interviews are planned, data collection, next steps 
details in the overall research and inform interviewees that the results of the overall 
research investigation would be made available in due course. This approach is in 
line with good research practice (Mathers, 2002; Meyrick, 2006). At the start of all 
interviews, confidentiality will be assured and a request made to record the 
interviews. 
 
An Olympus WS-6505 digital high quality voice recorder will be used to record all   
the interviews with the senior decision-makers. The interview transcripts will form 
the basis of the qualitative research component (Wellard and McKenna, 2001; 
Mathers, 2002; Halcomb and Davidson, 2006). The use of audio recording in concept 
elicitation interviews is well established and helps to fully capture the context and 
content of each session as well as to produce transcripts that form the data for 
analysis. Audio recordings facilitate participant anonymity and are generally 
comfortable for participants, particularly when sensitive topics are being discussed. 
38 
 
Participants are assured of confidentiality and limited use of the recorded materials 
from their interviews. Recording also frees the interviewer from note taking so that 
he or she may engage fully with participants (Wellard and McKenna, 2001; Patrick 
et al., 2011b). 
  
Web-based survey questionnaire platforms will be used during the developmental 
and validation stages of the generic instrument research. This web-based method 
involves posting a questionnaire onto a website allowing the respondents to complete 
remotely (Diem, 2002a). The advantages of this method include: quick responses are 
possible; it can be inexpensive if the correct software and tools are available; postage 
is reduced or eliminated; and it is easy for respondents to reply. The Survey-Monkey 
web-based survey platform will be used in this investigation (Survey Monkey, 2013). 
The commonly reported techniques aimed at improving questionnaire response rates 
will be used if needed for each of the questionnaire surveys conducted (Schleyer and 
Titus K.L., 2000; Diem, 2002b; Boynton, 2004). Data will be collected through the 
web-based questionnaires and the survey-monkey functionality. All questionnaire 
returns should be completed directly into the Survey-Monkey database and 
anonymity and confidentiality will again be respected and assured throughout the 
data collection, analyses and reporting stages. 
 
Information Sources 
The generic developmental instrument will involve gathering information from at 
least 10 regulatory agencies and more than 60 international pharmaceutical 
companies.  
 
Study Instruments 
As detailed in Chapter 1, there is currently no existing validated instrument available 
to measure the quality of decision-making within the drug development and 
regulatory arena. There are many instruments in the medical decision-arena  
especially relating to quality of life. Many were reviewed for their applicability and 
value in the current research question and some example instrument articles are 
referenced (Guyatt, 1993; Pijls-Johannesma et al., 2005; Langham et al., 2008; Ruiz 
et al., 2008; Rothman et al., 2009; Kriston et al., 2010; Bhatti et al., 2013a; Bhatti et 
al., 2013b). A tool developed to monitor the Centralised Procedure for submission of 
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marketing authorisation application (EMA, 2000) was also reviewed but again, the  
tool was not considered fit-for-purpose to address the research aim relating to the 
quality of decision-making. 
 
A thorough search of the internet will be performed to investigate many of the web-
sites given over to decision-making, decision-analysis and decision-techniques. 
Some of these sites could be helpful in providing extra dimension considerations to 
the research question although the sites are not aimed at the drug development or 
general healthcare arena. It is recognised that the audience for most of these websites 
appears to quite broad ranging from the “general public” to persons with specific or 
academic expertise in an area of the decisions sciences or strategic management/ 
business leadership area (Web, 2012; MindTools, 2013; Government, 2013; Stanford 
University, 2013; UCI, 2013; Stellenbosch University 2013b).  
 
Generic Instrument Development Techniques  
Conceptual Model and Hypothesis 
The origin of the conceptual framework was an appreciation of the lack of research 
performed to date investigating the actual quality of decision-making by stakeholders 
involved in the research, development and delivery of new medicines. An initial six 
themes were generated for the interview checklist based on value judgments which 
formed the basis of the qualitative interviews and in turn the construction of the 
developmental decision-making instrument. The objectives of the conceptual 
framework were to explore the ways in which individuals (decision-makers) and 
different companies/organisations manage decision-making and to identify the 
hallmarks of good decision-making practice. The steps involved in the development 
of the generic decision-making instrument are presented in Figure 2.1. 
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Figure 2.1:  Development of The Generic Decision-Making Instrument  
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Psychometric Evaluation of The Study Instrument 
As the generic instrument is a new instrument it will be examined to ensure it has 
adequate measurement properties relevant to decision-making from the perspective 
of the individual and the organisation. The applicability, practicality, acceptability, as 
well as four validity aspects of the instrument will be evaluated at several stages 
through its development (Nunnally and Bernstein, 1994; Simon et al., 2006; NIH, 
2012). Qualitative and quantitative research components will be employed in the 
stepwise development and validation of the instrument.    
 
Validity can be established in several ways and addresses the issue of whether what 
we are trying to measure is actually measured. Published measures for various 
concepts usually report the kind of validity that has been established for an 
instrument, so that the user or reader can judge the “goodness” of the measure 
(Streiner and Norman, 2008; Bougie, 2010).  
 
Face validity 
Face validity simply indicates whether, on the face of it, the instrument appears to be 
assessing the desired qualities. The criterion represents a subjective judgement based 
on a review of the measure itself by one or more experts, and rarely are any 
empirical approaches used (Streiner and Norman, 2008). Face validity will be 
performed at each stage of the instrument development. Face validity measurement 
can be considered as a basic and a very minimum index of content validity. In 
questionnaire and instrument development, each component item is reviewed by a 
person or team familiar with the target research area and asked to validate whether in 
their judgement that the questionnaire/instrument content, layout, language and 
format are appropriate. A positive review and acceptance provides an implicit 
assessment of face validity.  
 
Content validity 
Content validation is an important process whereby a new measuring instrument is 
examined for its focus and emphasis relating to the target population (Streiner and 
Norman, 2008; Bougie, 2010).  In questionnaire or instrument development, it is 
used to ensure that the questionnaire includes a representative and adequate set of 
items to uncover the concepts in the research questions. The more the scale items 
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represent a related field or domain of the concept being measured, the greater the 
validity. The use of expert judges to solicit opinions on the suitability of the measure 
is used to establish content validity.  It is a fundamental requirement of instrument 
validation and also inherently supports construct validity and generalisability of a 
new instrument. The content validation exercise to be performed will involve a panel 
of not less than four experts reviewing and providing their feedback on the language 
clarity, completeness, relevance, and scaling of the developmental instrument items.  
Quantitative assessment techniques can be used to complement the subjective 
reviews of the expert panel. The techniques that will be used are: calculation of the 
Content Validity Index (CVI) and Scale Content Validity Index (S-CVI). In addition, 
intraclass correlation coefficients (ICC) and reliability (Cronbach’s alpha) testing 
will be determined using SPSS statistical software. Content validation will be 
described in more detail in Chapter 4.  
 
Criterion-related validity 
Criterion-related validity is established when the measure differentiates individuals 
on  a criterion it is expected to predict. There are two types of criterion-related 
validity; predictive and concurrent validity (Streiner and Norman, 2008) Predictive 
validity indicates that a future criterion can be replaced by a current measurement on 
a scale. Concurrent validity refers to a relationship between a predictor variable and 
a current variable, both of which are assessed at the same time (McDaniel and Gates, 
2002. In other words, when testing different individual variables that are known to 
be different, they should score differently on the results (Sekaran and Bougie, 2010).  
 
Construct validity 
Construct validity is concerned with how well the results obtained from the use of a 
measure fit the theoretical foundations from which it is designed (Meehl, 1955; 
Trochim, 2006). It associates the practical components of an instrument test score 
obtained from with some underlying theory of behaviour (Salkind, 2006; Trochim, 
2006). Constructs are underlying latent variables which cannot be directly observed 
but encompass the foundation dimensions of a psychometric instrument. Construct 
validation contains two validity sub-categories (convergent and discriminant). 
Convergent validity is the degree to which the concepts that should be related 
theoretically are interrelated in reality. Discriminant validity is the degree to which 
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concepts should not be related theoretically and are in fact not interrelated in reality  
and is established when two variables which are predicted to be uncorrelated or to 
have low correlation (Westen and Rosenthal, 2003; Trochim, 2006; MacKenzie et 
al., 2011).   Evidence of construct validity can be presented using a multi-trait-multi-
method matrix (MTMM). The MTMM is an approach which examines convergence 
(evidence that different measurement methods of a construct give similar results) and 
discriminability (ability to differentiate the construct from other related constructs) 
(Campbell and Fiske, 1959; Trochim, 1989).  
 
Sensitivity 
The sensitivity of the instrument is the ability to measure any degree of change 
(Streiner and Norman, 2008). Sensitivity assessments will be performed during the 
development of the generic instrument. 
 
Responsiveness 
Responsiveness assesses the ability to measure important change. According to 
Liang (2000), it is the ability of an instrument to measure a meaningful or clinically 
important change in a clinical state (Liang, 2000). Patrick and Chiang, view 
sensitivity and responsiveness as a form of construct validation, assessing the 
hypothesis that the instrument is capable of detecting meaningful change (Patrick, 
2000).  
 
Practicality 
The practicality of the study instrument should also be addressed when evaluating 
the suitability of a measure and this includes considerations such as respondent 
burden, the cost in administering, mode of administration of the instrument (e.g. 
interviews or self-administered), the ease with which the measure can be scored and 
whether it is readily understood (Holstein, 2001; Dicicco-Bloom, 2006).  
 
Reliability 
Reliability of a measure indicates the extent to which it is without bias and therefore 
ensures that consistent measurements across time and various items in an instrument 
i.e. it helps to assess the “goodness” of a measure (Sekaran and Bougie, 2010).  It 
refers to the extent to which the instrument is measuring consistently and producing 
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the same result on repeated trials (Higginson, 2001) and assesses that a test is 
measuring something in a reproducible fashion; it says nothing about what is being 
measured.   
 
Measures of internal consistency are the most widely used indices of reliability. The 
reliability coefficient expresses the proportion of the total variance in the 
measurement which is due to ‘true’ differences between subjects (Streiner and 
Norman, 2008).   
Thus the formal definition of reliability is  
  Reliability =  𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑉𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦
𝑆𝑢𝑏𝑗𝑒𝑐𝑡 𝑉𝑎𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 +𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑚𝑒𝑛𝑡 𝐸𝑟𝑟𝑜𝑟   
 
Reliability is expressed as a number between 0 and 1, with 0 indicating no reliability, 
and 1 indicating perfect reliability (Streiner and Norman, 2008; Eisinga et al., 2013).   
Cronbach’s alpha coefficient testing is the most popular test of inter-item consistency 
reliability (Salek et al., 1996; Streiner and Norman, 2008).  It measures how united 
the items are in a test or assessment and is determined by Cronbach’s alpha 
coefficient (Salkind, 2006). Cronbach’s alpha testing will be used in the validation 
testing of the new generic instrument. Internal consistency is also a relative measure 
of reliability and reflects the scale’s ability to differentiate among people. Split-half, 
parallel (Davidshofer and Murphy, 2005) and Guttman (Davidshofer and Murphy, 
2005) reliability testing are also widely used in qualitative psychometric research and 
will be used in the battery of reliability tests to be performed on the developmental 
instrument. The internal consistency of measures is indicative of the homogeneity of 
the items in the measure that tap the construct. In other words, the items should 
“hang together as a set” and be capable of independently measuring the same concept 
so that the respondents attach the same overall meaning to each of the items, thus 
supporting construct validation.  This can be seen by examining whether the items 
and the subsets of items in the measuring instrument are correlated. The internal 
consistency reliability is a test of the consistency of respondents’ answers to all the 
items in a measure. It presents an estimate of degree of inter-correlation between 
independent measures of the same concept. The consistency over repeated measures 
of the same test can be assessed with the Spearman’s correlation coefficient and the 
equivalence of different versions of the same measure can be indexed by a statistical 
45 
 
correlation. The internal consistency, which addresses the relatedness/homogeneity 
of a single test form, may be assessed by correlating performance on ‘two halves of a 
test’, which is termed split-half reliability. The value of this Pearson product-moment 
correlation coefficient for two half-tests is adjusted with the Spearman–Brown 
prediction formula to correspond to the correlation between two tests (John and 
Benet-Martinez, 2000b).  
 
Intra-class correlations (ICC) is the ratio of variance of measurements of a given 
target to the variance of all targets and is a complimentary method for assessing 
reliability. ICC describes how strongly the items in the same grouping correlate or 
resemble each other.  It is used to assess the consistency, or conformity, of 
measurements made by multiple observers measuring the same quantity. ICC will be 
measured as one of the battery of tests performed to evaluate reliability. 
 
Manual Review and Coding of The Transcripts 
The transcripts from each of the interviews with the KOL’s will form the basis of the 
qualitative research component of this study. Each resultant interview transcript will 
be carefully read, reviewed and manually coded for emergent decision-making 
themes and sub-themes. This will involve a line by line review of the transcripts and 
particular noteworthy quotations will be noted. The time to manually code the 
transcripts is expected to take on average three hours per interview script.  A 
standard manual systematic coding approach will be followed comprising of five 
steps (Ritchie, 1994):  familiarisation, identification of a thematic framework, 
indexing, grouping, mapping and interpretation: 
 
Stage 1: Familiarisation: the process by which the reviewer becomes familiar and 
then wholly immersed in the transcripts of the data collected.  Throughout this 
process there is a growing awareness of the key ideas and recurrent emergent themes  
(Basit, 2003).  
 
Stage 2: Identification of a thematic framework: this occurs after familiarisation 
with the data set and when the emerging themes are recognisable. The themes and 
sub-themes emerge as those that have been expressed by the participants and form 
the basis of a thematic framework.  Following the identification of the thematic 
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framework, the themes and subthemes can be refined. Refining a thematic 
framework is not an automatic or mechanical process, but involves both logical and 
intuitive thinking. It involves making judgments about meaning, about the relevance 
and importance of themes and about implicit connections between ideas (Ritchie, 
1994).  
 
Stage 3: Indexing:  is the process of assigning portions, phrases or sections of the 
data to a particular theme or sub-theme heading. This data management step assists 
with the more formal allocation of themes and sub-themes into defined theme 
groupings. 
 
Stage 4: Grouping is the arrangement of the indexed themes and sub-themes under a 
specific heading.  The naming of the theme heading is an important process and 
naming is best done using the language of the interviewees as closely as possible, 
because the names of the concepts represent the perspectives of interviewees and not 
that of the developers. This naming approach will be followed for emergent decision-
making themes. 
 
Stage 5: Mapping and interpretation: Mapping involves the linkage of the emergent 
theme outputs to allow an interpretation and analysis of key emergent characteristics. 
This analysis should be able to provide a schematic diagram of the 
event/phenomenon emergent themes thus guiding interpretation of the overall data 
set (Ritchie, 1994). It is at this mapping and interpretation stage that the objectives of 
the qualitative analysis are identified in terms of defining concepts, theme 
associations, thematic mapping, providing explanations as well as helping to 
developing future strategies.  
 
Data management, processing and analysis 
Data Management  
Interviews will be transcribed into Word format. The transcription of the individual 
interviews from the audio-recording to Word format is expected to take on average 
eight hours per interview script. The transcripts will be transferred into the 
qualitative software package NVivo 8 for data management and processing. 
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The computer software package NVivo 8, will be used to analyse all the interview 
data and support thematic evolution and coding (Richards, 2005; Bazeley, 2007). 
NVivo is a specialist package developed solely as a computer aided qualitative data 
analysis system (CAQDAS) and is recognised globally as a reputable tool for 
managing and supporting this type of analytical work (Richards, 2005). It will be  
used to organise, transcribe data,  facilitate coding, to perform analyses and assess 
inter-coder reliability. The NVivo functionality does not assign codes to the data and  
manual subjective coding will be required in this research (Richards, 2005; Bazeley, 
2007).  
NVivo has two principal benefits: efficiency (time burden of manual approach) and 
transparency (NVivo facilitates the maintenance of a clear audit trial). NVivo is a 
type of database known as a ‘relational database’ which facilitates the linking of all 
relevant imported data (audio and transcripts). It allows a researcher to map out a 
project, set up frameworks, organise ideas and establish a range of queries and 
themes. The functionality allows for non-numerical and/or unstructured data to be 
organised and analysed. In turn, the software allows for  the classification, sorting 
and arrangement of information; examination of relationships in the data; and 
combination of analysis with linkage to themes and concepts using a “Node and 
Node Tree approach” coding approach. The Node approach identifies trends, themes 
and allows cross-examination of information in various ways. This type of database 
facilitates linking all relevant data generated during the data gathering and 
importation process. The NVivo system enables the researcher to also add notes to 
transcript imports. 
Data Processing 
The NVivo 8 software will also be used for data processing. NVivo 8 provides a 
“tree branch”, that is, a hierarchal nodal-coding system for emerging themes and 
links to their main category (conceptual core domain). A colour coding system in this 
software allow for large amount of text data to be organised in a consistent standard 
manner. This data text being meticulously analysed word-by-word and line-by-line 
from the large body of the verbatim transcription text. Subsequently, all the  
interview transcripts data will be combined in order to build a broader picture of 
different emerging aspects of decision-making themes. Various decision-making 
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themes that emerge will be coded and grouped into core decision-making categories. 
A thematic map of the emergent themes will be generated which should allow a 
holistic visualisation of the research subject themes and sub-themes. 
 
Coding Framework and Content Analysis 
The interview transcript information obtained will be qualitatively coded into nodes, 
major categories and domains. Thereafter, it will be analysed, summarised and 
quantified in the form of numbers and percentages to provide statistical meaning to 
the data. 
 
Quantitative techniques: Data processing and analyses Used on The New 
Generic Instrument 
Data processing and statistical analysis will be carried out using Microsoft Excel and 
SPSS for the QoDOS development instrument research. Various descriptive statistics 
techniques will be used in the analyses, interpretation and reporting of quantitative 
data. Descriptive tables and bar charts, spider plots and “Box and Whisker plots” will 
also be used to illustrate key features in the distribution of data. The Box-and-
Whisker plot graphically describes the shape and characteristics of the distribution of 
comparative data. It is a valuable tool for presenting the distribution of related 
datasets.  A general guide to interpreting a Box-and-Whisker plot is presented in 
Figure 2.2 (Salek et al., 1996; Zuckerman, 2006).   
 
A spider graph (also known as a radar chart) is a graphical method of displaying 
multivariate data in the form of a two-dimensional chart of quantitative variables 
represented on axes starting from the same point. The relative position and angle of 
the axes is typically uninformative. They are used in profiling quality improvement 
programmes and performance metrics (Basu, 2004; Zuckerman, 2006).   
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               Figure 2.2: Guide to interpreting a Box-and-Whisker plot 
 
 
Statistical programming and descriptive statistics will be employed in the exploratory 
and confirmatory factor analyses and construct validation. Descriptive statistics 
apply transformations of the obtained data into a form which can provide the 
characteristics of large sets of data. The descriptive statistics to be used in the 
research include Cronbach’s alpha (reliability), Kaiser Meyer-Olkin (KMO), 
Barlett’s test of Sphericity, Scree plots, Spearman Rank Correlation Coefficient, 
intraclass correlation coefficient (ICC) techniques, ANOVA, discriminatory, 
convergent and regression analysis. 
 
Cronbach’s alpha determinations will be used to measure the internal consistency 
reliability of the evolving developmental instrument and this testing will also provide 
supportive evidence for the retention and deletion of the items during a planned 
factor analysis (Pallant, 2005; Petter, 2007; Streiner and Norman, 2008). Scree plots 
provide a useful and easily interpretable impression of the number of factors within 
each extraction result.  Factor rotation will be performed using the Varimax 
technique and Kaiser-Meyer-Olkin (KMO) and Bartlett’s test of sphericity 
measurements will be taken to demonstrate that adequate sampling is being 
performed for each extraction stage (Field, 2009). Reliability testing using intraclass 
correlation coefficient (ICC) techniques will be used to evaluate inter-rater scores.  
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Hallmarks of Good Decision-Making Practice 
It is hoped that the insights gained during the development and validation of the 
generic instrument could also facilitate the identification of the hallmarks of quality 
decision-making. It is anticipated that the decision-making themes that emerge from 
the qualitative interviews and corroborated by quantitative research may allow for 
best practice recommendations and approaches to be generated. If these hallmarks of 
good decision-making practice do emerge from the research then an attempt will be 
made to transpose them into a new decision-making framework. The framework 
would present a systematic and structured approach to decision-making.   
 
 
SUMMARY 
• A detailed outline of the systematic development approach of the generic 
decision-making instrument is provided including the conceptual phase, 
interview stage, item generation phase, content validation, web-based 
questionnaires conducted, factor-analyses, item reduction, construct 
validation, and reliability testing of the new instrument  
• The various qualitative methodologies and techniques that will be used in the 
research have been described 
• Methodological choices relating to interviews, transcriptions, database 
management, data processing, data reporting, data analyses and data 
interpretation have been evaluated and detailed  
• The different types of psychometric properties that will be tested with the 
new instrument were discussed    
• The various quantitative methodologies and statistical techniques proposed to 
be used in the generation, processing and interpretation of output results from 
the various research components have been evaluated and detailed 
• The secondary study outcome, relating to potential identification hallmarks of 
good decision-making and creation of a new framework for quality decision-
making has been detailed. 
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CHAPTER 3 
 
 
 
 
 
Development of a Generic Decision-Making Tool: 
Qualitative Study 
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INTRODUCTION 
Decision-making among the regulators of medicines and members of the 
pharmaceutical industry is driven by various factors.  Regulators must adhere to a 
remit to positively impact public health whilst remaining mindful of precedents and 
adhering to laws, regulations and policies (Eichler et al., 2008; Breckenridge et al, 
2011). Pharmaceutical industry members, on the other hand, are motivated by the 
need to predictably and transparently develop medicines that will fulfil patients’ 
needs and regulatory requirements whilst delivering profit to shareholders 
(Breckenridge and Woods, 2005; PWC, 2012).  
 
The challenges to medicines development for both regulators and industry have been 
well documented and include increasing dossier complexity, the need for expedited 
approval timing, escalating costs in the face of constraints on capital, patent expiries, 
dwindling pipelines and stakeholder scrutiny with resulting demands for access, 
proven value, productivity and return on investment (PWC, 2012).  Any support for 
quality decision-making in the face of these sometimes conflicting drivers and 
challenges would benefit all stakeholders (Walker et al., 2007).  
 
Decision-making per se, can be regarded as being part science and part art, with art 
in this case being the subjective human component within the decision-making 
process. This subjective decision-making style reflects the combination of how an 
individual perceives and comprehends stimuli and the general manner in which he or 
she chooses to respond to it. It is linked to an individual’s knowledge, ability,  
motivation, their value orientation and tolerance for ambiguity (Kahneman, 2012).  
Decision-making is usually considered to be the result of cognitive processes leading 
to the selection of a course of action among several alternatives (McDermott, 2008). 
It also represents a rational or irrational reasoning or emotional process based on 
prior knowledge as well as a person’s individual assumptions. In a normative 
perspective, decision-making deals with the logics and rationality of the outcome 
related to the individual or collective choice made.  
 
In another sense, decision-making may be regarded as the result of problem-solving 
processes, which ends in an assumed rational choice (Kahneman, 2003; Kahneman, 
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2012). In most specialist or science-based professions, decisions are commonly 
made, continuously or at points or gates in the development of a specific product or 
service. In the pharmaceutical industry, decision-making involves making judgments 
on specific scientific data sets on the development of a novel molecule or 
pharmaceutical in order to take appropriate actions in respect to company objectives 
(Pritchard et al., 2003).  
 
By its very nature, drug development has many inherent risks and effective decision-
making is required to successfully deliver new medicines. In the drug development 
arena, decisions commonly have to be made based on insufficient data, a high degree 
of uncertainty, time pressure, significant economical stakes, and often in a 
competitive environment where several stakeholders are competing to be first on the 
market with their specific drug candidate (Pritchard et al., 2003; Chung-Stein, 2011). 
(Pritchard et al., 2003, Chung-Stein, 2011). Other potential factors such as the nature 
of the sponsor organisation and target patient characteristics of the treatment 
indication add increasing variability to the outcome such that different decision-
makers could make different decisions faced with the same set of criteria 
(Kostopoulou and Wildman, 2004).  
 
Investigation into the decision-making approaches of individuals and organisations 
involved in medicines research and delivery may provide useful insights into how 
both the person and the company make decisions.  This enhanced understanding may 
facilitate a clearer understanding of decision-making approaches and this in-turn may 
help to identify or enable better decision-making practices for both the individual and 
the organisation. A structured systematic research study may help reveal 
determinants of the decision-making process as well as providing research 
participants with a structured reflection on their own decision-making style and 
approach. This enhanced understanding may also help them to improve their future 
decisions.  
 
At a fundamental level, there are four basic decision-making styles: subjective, 
objective, analytical and non-analytical, with numerous academic sub-styles such as 
directive, analytical, conceptual and behavioural (John and Benet-Martinez, 2000a; 
Kahneman, 2012). Linked to these styles, numerous qualitative, semi-quantitative 
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and quantitative decision approaches have evolved such as the PROACT-URL and 
Multi-Criteria Decision Analysis (Guo et al., 2010b; EMA, 2013a; Leong et al., 
2013). Frameworks are recognised as being helpful in decision-making and several 
are being developed on an ongoing basis.   
 
The overall aims of this study were to develop a generic questionnaire instrument to 
assess and enable higher quality decision-making. The research question being, 
“could the development and availability of a decision-making instrument, enrich the 
quality of decision-making by individuals and organisation stakeholders from the 
medicines development arena”. The aim of this initial qualitative component of the 
research was to investigate fundamental considerations as to how individuals and 
organisations working in the drug delivery arena manage decision-making.  
 
 
METHODS 
Research Design and Methodological Framework 
The overall research was exploratory and descriptive in nature. Since there are no 
well-established theoretical frameworks for determining the “quality of decision-
making” and as limited research has been conducted on the component factors, an 
inductive approach exploring the research question was followed. The initial 
qualitative stage involved the conduct of semi-structured interviews. Thematic 
analyses of the output from the interviews delivered in-depth insight into decision-
making themes and considerations. The research consisted of the quantification and 
analysis of decision-making outputs. The content analysis performed, provided a 
systematic way of identifying and organising relevant data into meaningful 
information on decision-making.  
 
 
Conceptual Model and Hypothesis 
A conceptual framework is used in research to outline possible courses of action or 
to present a preferred approach to an idea or thought. Conceptual frameworks 
(theoretical frameworks) are a type of intermediate theory that attempt to connect to 
all aspects of enquiry (e.g. problem definition, purpose, literature review, 
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methodology, data collection and analysis). Conceptual frameworks can act like 
maps that give coherence to empirical enquiry. It is hoped that such a thematic map 
could be generated for decision-making domains as part of this qualitative research. 
Thematic maps can also ease the tension between human judgement and statistical 
analysis in qualitative research (Trochim, 1989; Attridge-Stirling, 2001).  
 
The conceptual framework presented in this research is that the quality of decision-
making could be enriched by the use of a generic decision-making instrument. This 
would initially involve an exploration of the decision-making approaches of senior 
decision-makers and the regulatory agencies or organisations in which they are 
employed. This exploration may lead to a better understanding of how these 
individuals and their organisations manage decision-making. In turn, this 
understanding could facilitate the development of an appropriate generic 
questionnaire for use in decision-making considerations of individuals and 
organisations.   
 
The origin of the conceptual framework was an appreciation of the lack of research 
performed to date investigating the quality of decision-making of stakeholders 
involved in the research, development and delivery of new medicines. An expert 
panel met and identified six decision-making items based on value judgments, to be 
researched in the study. The six items formed the basis of the initial interviews and 
in-turn the construction of the generic instrument. These six items were: 
• General understanding or perception of decision-making 
• Decision-making within the drug development arena 
• Decision-making within the regulatory review 
• Decision-making within their organisation 
• Awareness and use of decision-making techniques  
• Impact and monitoring of decisions.  
 
The underpinning principles of the conceptual framework were as follows: 
• Identification of the decision-making themes relevant to the research 
question 
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• Improvement in the quality of regulatory submissions and reviews by 
improving the decision-making approach and techniques employed within the 
drug development process and regulatory review 
• A final research output being the delivery of an instrument to people working 
within the pharmaceutical arena and regulatory agencies. The instrument could 
be used by them as a convenient tool with inherent generalisable properties to 
monitor and improve quality decision-making in routine and challenging 
decision-making situations. 
 
Choice of Sample and Design of Interview Checklist  
The initial operational phase of the qualitative research involved the conduct of semi-
structured interviews with experienced decision-makers employed within the 
pharmaceutical arena and regulatory agencies. The participants were appropriate as it 
reflected a sub-set of the intended target population (pharmaceutical industry and 
regulators) to be further investigated in a follow-on research study. The criteria 
adopted for recruitment of the study were: 
• Individuals employed in a senior position of authority within a regulatory 
agency or pharmaceutical industry organisation 
• Having more than five years experience in  a managerial role 
• Located in either the EU or USA 
• English language speaker 
• Willingness and availability to participate in a 45 – 90 minute interview. 
 
A six-item checklist detailed previously was designed for semi-structured interviews. 
Content validation was performed on the developmental instrument by an expert 
panel (Denzin and Lincoln, 2005; Hayes et al., 1995). The content validation 
exercise ensured that the construction and format of the questionnaire allowed 
information relevant to the purposes of the study and the target population to be 
obtained with appropriate reliability and validity. The language, redundancy, 
formulated questions, terminology, format and layout of the questionnaire were 
reviewed and agreed by the expert panel. It adhered to appropriate best approach 
recommendations (Patrick et al., 2011a; Patrick et al., 2011b).  
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In advance of all interviews, a copy of the research study outline was sent by e-mail 
to each of the prospective interviewees. This research outline provided details on the 
background, objectives, methodology, voluntary consent, anonymity and 
confidentiality assurance, estimated time needed for the conduct of the interviews, 
the time-window during which interviews were planned, data collection and the next 
steps in the overall research. Mention was included that the results of the overall 
research investigation would be made available to the interviewees in due course. A 
copy of the research outline given to participants is provided in Appendix I. 
 
Data Collection 
Each interview was audio-recorded and in-turn transcribed verbatim into Word 
format within 1-week of the conduct of the face-to-face interview whenever possible. 
The transcription of the individual interviews from the audio-recording to Word 
format took eight hours on average per interview script.  Thematic coding on each 
transcript was performed using the NVivo8 relational database (Bazeley, 2007) and 
by manual review and coding.  
 
Computer Assisted Coding of The Interview Transcripts 
The proprietary relational database NVivo8 was used in the computerised coding 
exercise (Bazeley, 2007). NVivo8 software and functionality allowed for the 
interview transcripts to be analysed and for the identification and quantification of 
emergent decision-making themes and sub-themes. The functionality of NVivo8 
automatically facilitated the following: coding of similar themes (thematic coding), 
identification of a thematic framework, indexing of the emergent themes and 
subthemes and grouping of the themes under category headings, comparison and 
quantification (frequencies) of emergent data to be generated. This automated coding 
approach was complimentary to the manual coding also performed on the transcripts. 
Manual Review and Coding of The Transcripts 
Each interview transcript was carefully read, reviewed and manually coded for 
emergent decision-making themes and sub-themes. This involved a line by line 
review of the transcripts and identification of the decision-making themes. Particular 
quotations from the interviewees were noted. The time to manually code the 
transcripts took on average three hours per interview script.  A standard manual 
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coding approach was followed comprising of five steps (Ritchie, 1994); 
familiarisation, identifying a thematic framework, indexing, grouping, mapping and 
interpretation.  
 
Overall, all the information obtained by the interview techniques described was 
qualitatively coded into themes and sub-themes and quantified in the form of 
numbers and percentages for ease of interpretation. 
 
RESULTS 
The interviewees who participated were all at a managerial or senior executive level 
within their respective organisations. The interview checklist captured socio-
demographic details of the interviewees such as; their name, their job role, the 
organisation in which they are employed and the number of years of experience they 
have within pharmaceutical development or within regulatory agencies. The 
interviewees were from European Medicines Agency (EMA), Medicines Human 
Regulatory Agency (MHRA), Irish Medicines Board (IMB), EU and US 
Pharmaceutical companies and US Contract Research Organisations. A summary of 
the demographics of the study participants is presented in Table 3.1. 
 
Table 3.1: Socio-Demographics of study participants 
Organisation, number of 
participants and gender 
Job Title Range Years of Experience 
Regulatory Agency  
(n = 9, 6M/3F) 
 
Group Head – Head of Agency 9 – >35 years 
Pharmaceutical Company 
 (n=10, 5M/5F) 
 
Manager – Global Function 
Head 
8 - >35 years 
CRO  (n=10, 5M/5F) 
 
Manager – Global Function 
Head 
7 - >30 years 
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The objectives of the conceptual framework are to explore the ways in which 
individuals (decision-makers) and different organisations manage decision-making.  
The conceptual framework and methodology used in this qualitative research are 
outlined in Figure 3.1. 
 
Figure 3.1: Qualitative development of a generic decision-making tool 
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Conduct of Semi-Structured Interviews  
A total of 29 semi-structured interviews were conducted investigating the decision-
making approaches and considerations of the study participants and their 
organisations. The semi-structured interviews were conducted between September 
2011 and January 2012. The interviews on average lasted around 50 minutes. 
In the qualitative interviews, the emergent theme saturation level was achieved after 
completion of 29 interviews. No additional decision-making themes were seen to 
emerge from the 27th, 28th or 29th interview performed and the 29th was the final 
interview conducted. Analyses of the decision-making themes and sub-themes evident 
in the interview transcripts were performed using NVivo8 and its automated thematic 
coding functionality. Manual review and subjective evaluation of apparent themes and 
associated coding of these emergent items were also performed.  The NVivo8 
automated coding  and the manual evaluations of the transcripts  from the interviews 
with the senior regulatory and industry key opinion leaders provided quantified 
outputs and valuable insights into the decision-making approaches of the study 
participants  and that of their organisation.  
 
NVivo8 Relational Database Thematic Coding  
NVivo8 thematic output provided details of emergent decision-making themes and 
sub-themes from the transcripts data set. Information on the prevalence of what was 
cited (number of times referenced in the data-set themes and sub-themes) and also by 
how many of the 29 person participants was recorded (Table 3.2). Here, the number of 
citations made by an individual included those relating to one or more of the sub-
themes. This results in the total number of citations not being the same as the sum-
total of all sub-theme citations due to the possibility of overlapping of citations in a 
case where a person made more than one reference to that theme/sub-theme.  
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Table 3.2:  Emergent themes and sub-themes from the NVivo8 analysis 
Theme Sub-Theme Citations* Individuals** 
1.Analytical   
Analytical Tools 
SOP’s Templates - Stepwise Procedures  
31(Total)  
20 
23 
19 (Total) 
13 
14 
2. Benefit Risk   
Critical Understanding of issue or decision 
Mitigation approach  
Qualitative approach 
Quantitative approach 
Structured approach  
52 (Total) 
10 
2 
11 
20 
19 
13 (Total) 
6 
2 
7 
9 
7 
3. Champions   
Champion as Project leader  
19 (Total) 
19 
17 (Total) 
17 
4. Consensus   
Consensus is the normal goal targeted  
Cultural considerations with consensus 
approach. 
Weaknesses related with trying to reach 
consensus 
41(Total)  
29 
3 
 
12 
24(Total) 
22 
3 
 
7 
5. Critical nature of the 
decision  
 
Clear understanding of the impact of the 
decision  
Effective communication and 
comprehension 
10 (Total) 
9 
 
1 
7 (Total) 
7 
 
1 
6. Culture   
Autocratic  
Disciplined governance  
Global Culture  
Hierarchical  
Innovative & ability to challenge & 
recommendations  
Portfolio therapeutic specialisation  
Traditional conservative  
54 (Total) 
8 
13 
10 
23 
1 
 
1 
8 
25 (Total) 
5 
9  
7 
12 
1 
 
1 
6 
7. Decision-making  
Analytical in approach 
Defined relationships 
Objective approach  
Structured approach to decision-making 
Subjective approach  
43 (Total) 
7 
5 
9 
23 
14 
10 (Total) 
7 
3 
7 
10 
6 
  8. Drug development 
portfolio & 
differentiation  
 
Understanding of drug development  
Understanding of portfolio management  
26 (Total) 
25 
     19 
21 (Total) 
21 
12 
*The number of items listed in the dataset 
**Number of interviewees who mentioned a specific theme or sub-theme 
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Table 3.2:  Emergent themes and sub-themes from the NVivo8 analysis cont’ 
Theme Sub-Theme Citations Individuals 
9. Engagement   
Engagement linked to understand of task  
Stakeholders  
24 (Total) 
10 
14 
19 (Total) 
7 
13 
10. Experience   
A person’s inexperience & associated risk  
Talent, track record & professional 
experience  
23 (Total) 
3 
 
22 
14 (Total) 
2 
 
14 
11. Enhancements   
Decision Criteria 
Extrinsic factors e.g. patient choice  
Impact analysis 
Qualification of the decision makers  
Qualitative approach  
Quantitative approach  
Structured approach  
Successful communication & clarity of 
language  
Training & awareness 
Understanding of critical nature of issue 
49 (Total) 
1 
8 
5 
2 
2 
7 
7 
6 
 
1 
8 
13 (Total) 
1 
7 
5 
2 
2 
4 
5 
4 
 
1 
5 
12. Facilitators  
Facilitators are not used in the organisation  
26 (Total) 
12 
25 (Total) 
12 
13. Facilitators are 
used on rare or 
exceptional occasions  
 
External facilitators are used  
Internal facilitators are used  
5 (Total) 
1 
4 
5 (Total) 
1 
4 
14. Facilitators are 
used routinely in the 
organisation  
 
External facilitators are used  
Internal facilitators are used  
3 (Total) 
0 
0 
3 (Total) 
0 
0 
15. Framework   
Framework templates  
Structures approach to decision-making  
15 (Total) 
9 
11 
7 (Total) 
5 
5 
16. Human factors 
and considerations 
 
Experience and maturity of decision-making  
Gut feeling intuition 
43 (Total)  
5 
39 
29 (Total) 
5 
28 
17. Individual   
Human or personal factors  
Preferred approach  
25 (Total) 
16 
13 
10 (Total) 
5 
5 
18. Mechanisms and 
procedures  
 
Standard mechanisms or procedures  
30 (Total) 
30 
8 (Total) 
8 
*The number of items listed in the dataset 
**Number of interviewees who mentioned a specific theme or sub-theme 
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Table 3.2:  Emergent themes and sub-themes from the NVivo8 analysis cont’ 
Theme Sub-Theme Citations Individuals 
19. Metrics and  
benchmarks  
 
Benchmarking is not used  
Benchmarking is used  
33 (Total) 
2 
33 
25 (Total) 
2 
23 
20. Milestones  
Milestones employed in the decision- 
making 
Milestones not used  
12 (Total) 
12 
 
1 
7 (Total) 
7 
 
1 
21. Poor quality 
decisions  
 
Bad decisions experienced 
Escalation of commitment  
25 (Total) 
1 
25 
22 (Total) 
1 
22 
22. Quality   
Lack of quality  
Quality enhancements 
Quality factors  
24 (Total) 
0 
9 
16 
7 (Total) 
0 
5 
5 
23. Review or impact 
analysis  
 
Retrospective impact analysis and lessons  
Review steps or time-outs employed 
Review steps during a decision-making 
task 
15 (Total) 
10 
6 
6 
9 (Total) 
7 
3 
3 
24. Situation   
Differing situations require different 
approaches 
29 (Total) 
28 
14 (Total) 
14 
25. Strategy   
Appreciation of preferred outcome  
Organisation strategy    
22 (Total) 
1 
22 
14 (Total) 
1 
14 
26. Subjective   
Approach to the decision-making  
Human factors & considerations  
43 (Total) 
37 
17 
17 (Total) 
14 
8 
27. Team or group   
Advantages of team based decision-
making  
Decision made on team basis 
Disadvantages of team based decisions 
116 (Total) 
29 
 
70 
17 
27 (Total) 
20 
 
26 
15 
*The number of items listed in the dataset 
**Number of interviewees who mentioned a specific theme or sub-theme 
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Table 3.2:  Emergent themes and sub-themes from the NVivo8 analysis cont’ 
Theme Sub-Theme Citations Individuals 
28. Process   
Standard approach or process not 
employed  
Standard processes  
45 (Total) 
0 
 
45 
23 (Total) 
0 
 
23 
29. Tools  
 
 
Awareness  
Unawareness  
Usage of tools  
Usage of tools in decision-making  
53 (Total) 
5 
35 
5 
4 
20 (Total) 
5 
11 
4 
4 
30. Training   
No training received  
Perceived benefit of training  
Training received  
47 (Total) 
53 
11 
2 
24 (Total) 
24 
9 
1 
31. Understanding   
Background & task  
Science or issue in question  
Understanding of expectations  
28 (Total) 
10 
7 
12 
13 (Total) 
8 
6 
7 
32. Influences   
Competitors 
Human nature  
Incentives rewards penalties  
Money /costs /politics  
Origin of project  
Patients expediting delivery of medicines  
People & talent  
Precedents  
Regulatory & legal 
Stakeholder motivation  
Strategic fit  
Timelines  
69 (Total)  
1 
1 
14 
18 
15 
4 
4 
14 
11 
20 
8 
2 
20 (Total) 
1 
1 
6 
11 
6 
4 
3 
7 
6 
17 
6 
2 
. 
*The number of items listed in the dataset 
**Number of interviewees who mentioned a specific theme or sub-theme 
 
 
The NVivo8 decision-making thematic analyses provided data for both the individual 
interviewees and for 29 person study participants.  An illustrative example of the 
NVivo8 output for an individual from the study is provided in Figure 3.2. 
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Figure 3.2: Example NVivo8 data output for an individual interviewee 
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Automated NVivo8 and Manual Review and Evaluation of The Interview 
Transcripts 
The automated thematic coding resulted in the identification of 32 emergent 
decision-making themes and more than 90 sub-themes from the interview transcripts. 
A manual content analysis and subject evaluation of the interview transcripts was 
also performed and this produced a complimentary list of decision-making themes 
from the study participants transcripts.  
 
Validation of The NVivo Output 
The validation of the NVivo output i.e. consolidation of the 32 themes and sub-
themes and manual content analysis of the interview transcripts, resulted in the 
identification and emergence of 19 overarching decision-making themes. The manual 
review and coding approach was performed as detailed (in Chapter 2) i.e. 
familiarisation, thematic framework identification, indexing and grouping of the 
decision-making themes. Following the familiarisation and complete immersion into 
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the transcribed narrative outputs from the interviews, 32 themes were identified and 
further consolidated into the following 19 overarching themes given below: 
1. Quality and validity of data  
2. Time considerations  
3. Organisational, hierarchical and cultural influences 
4. Analytical and logical approach 
5. Qualification and experience in previous decision-making 
6. Subjective and personal considerations 
7. Political, financial, competitor and reward influences 
8. Precedents for similar previous decisions 
9. Perpetuating previous decision-making mistakes  
10. Plunging in or procrastination with decision-making 
11. Clear understanding or lack of understanding of the decision in question  
12. Overconfidence in own judgement 
13. Group successes and group failures 
14. SWOT and alternate outcome planning in decision-making 
15. Impact analyses of decisions 
16. Decision-making audit trail 
17. Education and awareness of evolving decision-making techniques 
18. Individual versus Corporate decision-making 
19. Quantitative frameworks. 
 
An illustration of the relationship between these 19 decision-making themes and the 
themes and sub-themes identified in Table 3.2 is as follows: ‘Clear understanding or 
lack of understanding of the decision in question (Number 11 from list above) with 
Table 3.2 “Critical nature of the decision” (item 5) and “Critical understanding of 
issue or decision” (Subtheme of item 2), “Understanding of critical nature of issue” 
(Sub-theme of item 11). 
 
The approach adopted by which the sub-themes were grouped into themes for each 
of the resultant 19 decision-making domains is expanded below accompanied by 
relevant supportive example verbatim quotes from the study participants.  
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Quality and Validity of Data  
The expectation and need for good quality, reliable data on which a person can make 
a decision was raised in the majority of interviews. This theme encompassed items 
such as reliability and validity of the source data and trustworthiness of the 
information provided on which to base a decision. The need for valid and ideally 
high quality data of suitable integrity was evident. The theme of what constitutes a 
“quality” decision and the challenge with defining quality in this context was also 
apparent. 
 
“Valid data is a fundamental requirement for good decision-making”....Regulatory 
Agency 
 
“You need to be able to trust the data you are being asked to review and upon which 
you are being asked to make a decision”.......Pharmaceutical Company 
 
Time Considerations  
The reality of having to make timely or real-time decisions was raised in several 
interviews as was the need to adhere to “review timelines”. The Regulatory Agency 
personnel also specifically advised that there is an obligation for them to work to 
defined review timeframes.  In addition, Regulatory Agency personnel also advised 
that on occasion, they need to make fast decisions. Items which have a spontaneous 
safety concern, need quick action and timely/quick decision-making. The sub-theme 
of workload and time sacrifice/time allocation for making decisions was raised. The 
challenge of needing to be able to “multi-task” on several projects was raised. This 
multi-tasking impacts the time allowance or tolerance that can be allocated to 
individual decision-making exercises. 
 
“We have a public health remit and there are times when we need to make a decision 
in a rapid manner. Sometimes we do not have all the background information 
available but still we need to make that decision”.........Regulatory Agency 
 
Organisational, Hierarchical and Cultural Influences 
Several themes emerged relating to the philosophy and organisational approach to 
decision-making. Items such as cultural influences, in particular in the larger 
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organisations were raised. The use of scientific committees was mentioned by all the 
regulatory agency interviewees. From an industry perspective, the formal 
requirement for decision-making to be escalated upwards to the appropriate 
management executive empowered with the actual decision-making was apparent. 
 
 “In larger companies, you have more stakeholders in place and therefore it is 
important to know the decision-making approach because there is likely to be more 
of a commonality of opinions. Political astuteness is also vital in a large Pharma 
organisation”...........Pharmaceutical Company 
 
Analytical and Logical approach 
The use of frameworks to assist with the decision-making process and the use of 
analytical and step-wise decision-making approaches were apparent. The potential 
that such approaches may add transparency to the decision-making process was 
raised.   
 
“A quantitative assessment and analytical procedures will improve transparency in 
decision-making”…..Regulatory Agency 
 
“A general best-practice framework for decision-making within the drug 
development arena or in the regulatory review would comprise an awareness of the 
implications of decision-making and the need to approach decision-making in a 
logical manner”....Pharmaceutical Company 
 
Qualification and Experience in Previous Decision-Making 
Bias based on a person’s previous experience in decision-making was apparent. It 
was clearly evident that past experience in the decision-making arena and exposure 
to similar challenges in the past are important factors for both individuals and 
organisations.  In addition, the theme of qualification of the decision-maker to make 
those decisions (scientific, strategic, benefit/risk...etc.) was raised. The academic 
qualifications complimented by practical “on the job” experience were cited as being 
important. The theme of “intuition” and “gut-feeling” also overlapped with the theme 
of Qualification. It was apparent that this intuition/gut-feeling appears to also 
develop with a senior decision-makers’ increasing experience. This intuition/gut-
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feeling theme was captured under the “overconfidence” theme discussed later on in 
this section. 
 
”What makes one person out to be a good decision-maker?   What qualifies that 
person to make decisions? Is it scientific or professional training? How much does a 
person require, in order for that person to make better decisions?  It is a subjective 
matter and worth investigating”.....Pharmaceutical Company 
Subjective and Personal Considerations 
Personal preferences relating to the subjective interpretation of the decision-making 
task in question and the personality of the decision-maker were apparent. The 
individual human element of a person’s beliefs, the values important to that person 
and their preferred approach to decisions were evident.    
 
 “I like to review all the available background information before starting on the 
decision-making exercise”..........Pharmaceutical Company 
 
Political, Financial, Competitor and Reward Influences 
Internal and external factors that impact on decision-making were evident. Items 
were apparent which were considered somewhat outside of the control of the 
decision-maker but which did impact the decision-making. Considerations such as 
go/no–go decisions based on financial sales predictions, return on investment (RoI) 
and continuation of a project because of some internal or external political 
considerations were raised. The concept of “reward” for achieving milestones and 
the impact this has on decision-making emerged from the industry but not from the 
agency representatives. 
 
“A lot of go/no-go decisions are based on political reasons. We do not always like to 
say this is the case but in reality it is”..........Pharmaceutical Company 
 
 “Everyone monitors the competition in drug development”........Pharmaceutical 
Company 
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Precedents for Similar Previous Decisions 
Previous precedent emerged as a decision-making theme. Precedents in terms of 
traditional drug development or drug-class considerations were apparent from the 
perspective of both the agency and industry personnel. In addition, the need and 
desire for consistency was evident in regard to drug approvals. 
 
“Previous approvals in that therapy area are always reviewed during our 
assessment”........Regulatory Agency 
 
“We have a standard proven approach to internal decision-making. This is what we 
follow”......Pharmaceutical Agency 
 
Perpetuating Previous Decision-Making Mistakes  
Repeated mistakes or lack of learning from previous experience, or not applying 
“lessons learned” were apparent. The challenge of following a previous unsuccessful 
course of action which has a high probability of a negative outcome was evident. 
 
“We are all guilty of this but at least we recognise our errors” ..........Pharmaceutical 
Company 
 
Plunging-in or Procrastination with Decision-Making 
The impact of procrastination and the inability of a person to make a decision at a 
suitable time were apparent. The potential for information or data “overload” relating 
to a decision which could result in a decision not being made, or being postponed or 
leading to a request for even more information was evident. The polar theme, where 
a person may make a snap-decision without having suitable salient facts was raised. 
The “plunging-in” was also linked with the potential theme of self over-confidence 
relating to the perspective of both the individual and the organisation. 
“The good assessor will make a regulatory decision and make a good 
recommendation, the poor assessor will sit on the fence and write a report and say it 
is up to the advisory committee”.....Regulatory Agency 
 “Paralysis by analysis is resulting in the death of creativity”.........Pharmaceutical 
Company 
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Clear Understanding or Lack of Understanding of the Decision in Question  
The need to clearly understand the context of the decision that one is being asked to 
make was apparent.  The use of appropriate language and instruction in 
communicating what a decision-maker is being asked to do was evident. 
  
“People need to understand what they are being asked to do and also the factors 
involved in the decision that they are being asked to make”.....Pharmaceutical 
Company 
 
Over-Confidence in Own Judgement 
Several themes relating to both over-confidence and use of “intuition / gut-feeling” 
emerged. Over-confidence and use of intuition were not seen in a negative context 
but merely one that needs to be appreciated, managed and balanced.  
  
“Intuition and gut-feeling have a place but it is often an educated gut-feeling and 
educated intuition in decision-making. It is not something that you are born with. It 
comes about with the experience of the job environment over 10, 20, 30 years”... 
...Pharmaceutical Company   
 
“We might say that decision-making is all science and that it is all quantitative and it 
is all black and white, it is not. The very sophisticated blend of intuition or gut-
feeling comes into good decision-making practice as well”......Regulatory Agency 
 
Group Successes and Group Failures 
The use of teams or groups for several aspects of decision-making was apparent. The 
use of scientific advice committees by regulatory agencies, internal steering 
committees and executive committees emerged. In addition, the pros and cons of 
aiming for consensus approach on important decisions were raised. The theme of 
using tools such as “facilitators” and decision-conferencing to facilitate decision-
making emerged. The dynamics of a group decision-making approach and the 
challenge to terminate such a decision-making exercise being conducted by a group 
was also apparent. 
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“Project teams can be very possessive and defensive of their baby (project) which 
can make it a very challenging situation when tough decisions need to be made on 
the continued viability of the project”....... Pharmaceutical Company 
 
“Sometimes you are better just to go with a more extreme decision rather than a 
compromise one, and this will mean that some people may be unhappy.  I am not 
sure that aiming to reach consensus always is a good thing or always results in the 
best decision.......Regulatory Agency 
 
SWOT Analyses and Alternate Outcome Planning in Decision-Making 
The use of identifying the strengths, weaknesses, opportunities and threats, within 
the decision-making framework emerged from the study. The need to identify the 
pros, cons and the options relating to a decision and to have contingency 
considerations in place for a decision outcome were apparent. 
“We routinely use SWOTs, they are what we used during our restructuring 
exercise”.........Regulatory Agency 
 
“You always need a back-up plan, SWOTs and contingency planning should always 
be part of decision-making”.........Pharmaceutical Company 
 
Impact Analyses of Decisions 
The value in identifying good decision practices adopted as well as bad decision 
practices was apparent.  The need and value of reviewing and examining the impact 
of decision-making outcomes is also important.  With hindsight, could or should a 
different approach have been adopted for a particular task?  
 
“It is important that organisations look back at the decisions they made 10 years ago 
and review whether in hindsight, these were good or bad decisions”...Pharmaceutical 
Company 
 
“We should all take time to perform impact analyses and try to learn from the good 
and the bad”........Regulatory Agency 
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Decision-Making Audit Trail 
The value of maintaining an audit trail for important decisions was apparent. The 
step-wise path of the decision exercise undertaken relating not only to major Go/No-
Go decisions but also those decisions which may need to be reviewed or examined at 
a later date emerged. Transparency in the process and the potential for better 
predictability in future judgments were linked to having a record / audit trail of 
previous successes. 
 
“Transparency, the justification for decisions, and understanding why a decision has 
been made need to be documented, it is good practice”.......Regulatory Agency 
 
Education and Awareness of Evolving Decision-Making Techniques  
The value and benefit of receiving training in the science of decision-making and 
also on the tools and techniques that are currently available to facilitate decision-
making were identified.  
“It is important that we are trained in decision-making. We also need understanding 
and practical application of the tools which can assist our decision-making. So, I 
think it should be part of people’s ongoing professional training”.....Pharmaceutical 
Company 
 “Modelling and simulation is becoming ever more the norm in drug development.  
One of the challenges we have, is in keeping pace with advancements in drug 
development and the models employed in decision-analysis”.........Regulatory 
Agency 
 
Individual Versus Corporate Decision-Making  
The different decision-making approaches of the individual compared with that of 
the organisation were apparent. The challenge with understanding how the individual 
and the organisation reach their decisions was evident. 
 
“There is a difference between the corporate decision-making process and that of the 
individual.  For example, we have a good understanding of how a committee makes a 
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decision but we do not necessarily understand how individuals on that committee 
have made their own position or decision”........Regulatory Agency 
“We need to have a better understanding on how an individual reaches their own 
conclusion this is particularly important in regard to benefit-risk decision-
making”......Regulatory Agency 
 
Quantitative Frameworks 
The value of assigning weightings (relative importance) to the decision-making 
exercise in situations such as benefit-risk assessments and the transparency that such 
a quantitative weighting process could bring to a decision was evident. 
 
“The concept of weighting is a nice framework for benefit-risk decision-
making”.....Regulatory Agency 
 
“I am a firm believer in quantitative assessment to improve transparency in 
decision-making…....Regulatory Agency 
 
Thematic Map 
A secondary objective of the qualitative investigation was to generate a thematic map 
of the decision-making themes that emerged from the study. Thematic networks are 
web-like illustrations that summarise the main themes constituting a piece of 
research. The thematic mapping network technique is a robust and sensitive tool for 
the systematisation and presentation of qualitative analyses (Trochim, 1989, 
Attridge-Stirling, 2001, Braun and Clarke, 2006). In instrument development, maps 
can help with structural conceptualisation to articulate the expected relationships 
between constructs that are being measured and are a tool for defining the conceptual 
domains (Marquart, 1989; Davis, 1989). The thematic map generated from the study 
is presented in Figure 3.3. 
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Figure 3.3: Thematic map of decision-making themes from the qualitative research 
 
 
Decision-Making Results from the Perspective of The Individual and The 
Organisation 
In addition to the composite results obtained for the 29 participants, unique results for 
each individual participant were also generated in the NVivo8 system. However, it 
should be noted that assurance was provided to the interviewees that confidentiality 
would be respected and that results which could identify an individual or their 
organisation would not be presented. Therefore, limited presentation of source 
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individual interviewee results are provided in this thesis. The individual commentary 
in the form of the verbatim quotes from individuals’ interview transcripts is intended 
to provide valuable insights into the perspective of the individuals who volunteered to 
participate in this research. 
 
The consolidated output of the qualitative research comprised the identification of 
almost 100 themes and sub-themes relating to decision-making approaches. This 
combination of the automated and manual subjective thematic coding results was used 
to form the basis for the decision-making instrument which would be subjected to 
further development and validation. A total of 94 items were agreed for inclusion in 
the first version of the instrument. The further development and validation of the 
instrument is reported in Chapters 4 – 6. A copy of the 94-item checklist including the 
rating scale used on each items is presented in Appendix III.  
  
 
DISCUSSION 
The goal of this qualitative research study was to investigate and gain insight into the 
decision-making approaches used by the Pharmaceutical Industry and Regulatory 
Agency decision-makers, in their professional work. This goal was successfully 
achieved. In addition, the identification and application of the decision-making themes 
which emerged from the research should enable the generation of a generic 
developmental decision-making instrument.  
 
The qualitative research approach involved the conduct of semi-structured interviews 
with a variety of key opinion leaders from the EMA, national European regulatory 
agencies and international pharmaceutical industry. These interviews generated 
valuable insights into the decision-making approaches both from the perspective of the 
individual and their organisation. The interviewees were engaged and supportive of 
the study and were accommodating with their time-sacrifice and flexibility to 
participate in the interviews. The beneficial and advantageous approach of face-to-face 
interviews is well documented and this was the case also in this study (Holstein, 
2001). It is also noteworthy, that the interviews allowed for respect, understanding, 
rapport and relationship-building to develop between the interviewee and the 
researcher performing the interviews. 
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The complimentary combination of the NVivo8 and the manual thematic coding 
helped to detail a wide-spectrum of decision-making components and emergent 
themes from the study. It was evident that this coding process did not deliver the same 
amount of subjectivity as generated by the manual review of the interview transcripts. 
However, the combination of both the automated computerised NVivo8 system and 
the subjective manual evaluation of the interview transcripts did ensure that all 
decision-making themes contained within the interviews were explored. Almost 100 
decision-making themes and sub-themes were apparent from the data analyses. This 
allowed for the generation of a 94-item developmental version of the instrument which 
will form the basis for a larger sample-size and more powerful research investigation 
into the decision-making approaches of individuals and their organisations.  
 
Of particular note, some of the decision-making themes that emerged from the 
interviews may be somewhat surprising bearing in mind that most of the study 
participants worked in a highly regulated working environment where regulations, 
directives, SOPs and other guidance documents are the norm. Some particularly 
important themes and decision-making aspirations received from the study participants 
are detailed below:  
 
The desire for enhanced transparency, consistency and predictability within the 
decision-making approaches used by individuals, committees and organisations 
overall. 
 
The use of intuition or “gut-feeling” in the decision-making process of individuals 
even though they are working in an evidenced based and systematic drug development 
environment. This intuition was seen as a positive attribute which matures and appears 
to become more beneficial and accurate, the longer the individual has been working in 
his or her profession. Linked with intuition was the assertion that for many 
individuals, the more experience gained in their professions, the higher the quality of 
their decision-making and the easier the decision-making process is for them. The 
experienced professional is less likely to procrastinate over a decision and appears to 
have a greater appreciation of the consequences of the decision-making process that 
they are being asked to make. An area of contention linked with experience was that 
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of, “what qualifies an individual to be a good decision-maker in a given situation?” 
Academic, clinical or professional qualifications linked with the subjective personality 
and astuteness of the individual emerged as important facets for being a “good 
decision-maker”. 
 
The recognition of the value of training in the science of decision-making and a 
greater understanding and appreciation of the tools available to support decision-
making was echoed by many of the study participants. Simple tools such as SWOTs 
and decision-trees were routinely used by some people, while some other participants 
advised they never employ such techniques. There appears to be a lack of training 
offered within the profession (Agency and Industry) but it was the belief of many that 
they and their organisation would benefit from such training. 
 
Ensuring an understanding of the decision-context, determining the internal and 
external influences which might be relevant to the decision being asked, awareness of 
one’s own personal decision-making preferences, appreciation of previous similar and 
most importantly, the validity and integrity of the information that one is being asked 
on which to base the decision were key items that emerged from the interviews. 
 
Other items such as re-evaluating as new information becomes available,  reviewing 
the impact of decisions made and applying “lessons learned” to new projects and 
decisions were thought to be beneficial. The pros and cons of group decision-making 
and seeking a consensus approach were raised along with the potential value of 
assigning quantitative weightings within a step-wise decision-making approach while 
at the same time, ensuring that there is a audit record trail maintained of each decision-
step.  
 
The simple thematic map generated captured the decision-making themes that 
emerged from the qualitative research. It is appreciated that thematic mapping can 
help to ease tension between quantitative and qualitative measurements by combining 
statistical analysis and human judgements. The main strength that mapping offers in 
the validity exercise of an instrument is that it allows relationships to emerge and these 
emergent categories are more data driven than they are in a traditional content 
analysis. The thematic map can help in formalising a choice in a syntax/context 
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relationship (Jackson and Trochim, 2002). The generated thematic map can also 
contribute to the construct validation of the developmental instrument. Construct 
validity refers to how operationalisations in research reflect the theoretical constructs 
they are supposed to reflect. In determining if there is construct validity, researchers 
should have an idea of the interrelationships among constructs (Jackson and Trochim, 
2002).    
 
 
The decision-making themes discussed in this chapter were not the conclusive list of 
considerations which were volunteered by individuals during the qualitative research. 
However, the items raised by the study participants did provide supportive justification 
and validation of the research being performed. This study has demonstrated that the 
area of decision-making in the medicinal product development and life cycle is under-
researched. The potential benefits of improved decision-making within both the drug 
development arena including the regulatory review would benefit all concerned 
stakeholders. Improved and better quality decision-making could be expected to 
expedite the delivery of new medicines. These improvements could be initiated by 
individuals and organisations, having a better fundamental understanding of the 
principles and themes of decision-making. 
 
Overall, this study has achieved its aim of exploring decision-making from the 
perspective of the individual and the organisation working in the drug development 
arena. The detailed content analysis in the research produced vital information for the 
development of a novel concept for a decision-making instrument.  Decision-making 
themes and considerations have emerged which can be incorporated into a generic 94-
item decision-making checklist which will undergo further content validation, field 
testing and refinement. The supportive engagement of the participants involved in this 
study is also positive endorsement of the value of this research. 
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SUMMARY 
• This chapter provided information about how data was collected for the 
conceptualisation and development of a decision-making tool 
• Twenty-nine interviews were conducted with senior decision-makers from  
regulatory agencies and the pharmaceutical industry to investigate how they 
manage decision-making at an individual and/or organisational level 
• NVivo8 qualitative software was used for managing the large quantity of data 
and for content analysis 
• Thematic coding of the interview transcripts was performed using NVivo8 
and manual content analysis which resulted in an enhanced understanding and 
appreciation of the decision-making considerations and identified thirty-two 
themes from the perspective of the of individual and their organisation  
• The emergent decision-making themes and commentaries volunteered by the 
study participants provided evidence of the need for a more systematic 
approach to decision-making within the regulatory and pharmaceutical 
environment 
• Positive endorsement of the study was received from the study participants 
which provided further impetus and validity to the continuation of the 
development of a generic decision-making instrument 
• A 94-item decision-making theme checklist was generated  
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CHAPTER 4 
 
 
 
 
Development of a Generic Decision-Making 
Tool: Content Validation 
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INTRODUCTION 
Content validation helps to examine whether the measurement tool possesses the 
right emphasis and focus for the concept being measured and the target population.  
This evaluates whether a scale has enough items and covers each of the domains 
being measured. The items of a new instrument should be relevant and representative 
of the target population and/or construct (Streiner and Norman, 2008). Content 
validation is a primary validation step which helps to compliment, endorse and 
increase the probability of obtaining high construct validation in the development of 
an instrument (Denzin and Lincoln, 2005).  
 
The process of establishing content validity of an instrument by using a panel of 
experts to determine the suitability of an instrument or questionnaire items is a well 
established procedure in instrument development. The opinion and judgement of 
experts to modify or remove items from a developmental instrument helps to ensure 
the appropriateness of such a tool.  The opinion of the experts is also sought to verify 
that the scale is appropriate for the intended purposes. (Strauss and Corbin, 1998; 
Streiner and Norman, 2008).  Haynes et al (1995),  defined content validity as: “the 
degree to which elements of an assessment instrument are relevant to and 
representative of the targeted construct for a particular assessment purpose” (Hayes 
et al., 1995). Instrument content validation is a process which may encompass both 
“quantitative” and “qualitative” approaches and is a vital part of the overall 
instrument validation process.  Items should be reviewed and judged by a panel of 
experts using an assessment scale covering item relevance, representativeness, 
specificity and clarity. The use of these content validation expert panels  may help to 
eliminate early items which if left in the questionnaire might be “outliers” at a later 
stage of analysis and which could contribute to  spurious or incorrect study findings 
(Hayes et al., 1995).  
 
In this validation exercise, the content validity was evaluated by a complimentary 
triangulation of methods to ensure appropriate reliability and validity of the 94-item 
developmental version of the decision-making instrument.  
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METHODS 
The 94-item developmental version of the decision-making instrument was carefully 
reviewed for the four attributes of: language clarity, completeness, relevance, and 
scaling.  These item attributes are well established in the content validation 
investigation of new instrument development (Norusis, 1993; Graneheim and 
Lundman 2004; Pallant, 2005; Simon et al., 2006; IBM, 2011; Patrick et al., 2011a; 
Bhatti et al., 2013b).  
 
The content validity of the 94-item developmental version of the instrument was 
carried out in two separate stages, i.e. an initial qualitative stage followed by a 
quantitative stage.  In the qualitative assessment, the expert panel members were 
asked to review and make comment on the developmental version of the instrument. 
In the quantitative part, the panel members were asked to complete a formalised 
scale to assess each item and the instrument as a whole. The results from the 
qualitative and quantitative parts were used to make changes to the 94-item 
developmental version to ensure that items were relevant and appropriate to the 
decision-making construct. 
 
The 94-item developmental version of the instrument was initially examined for 
content validation by a team of six experts. Their task was to review the instrument 
and to use their subjective judgement to rate each  of the 94-items using  a 4-point 
Likert scale (strongly agree, agree, disagree and strongly disagree) for its language 
clarity, completeness, relevance and scaling (Denzin and Lincoln, 2005; Bougie, 
2010; Bhatti et al., 2013b). The experts were encouraged to suggest appropriate 
changes as necessary in order to develop an instrument which could accurately 
measure what was intended to be measured. The identification, communication and 
selection of the independent expert panel were performed in an appropriate manner.  
The six member panel “quorum” was in line with best practice reported in the 
literature (Lynn, 1986; Polit, 2006).  
 
Part I: Qualitative Assessment 
A six member expert panel of experienced and senior decision-makers from the 
regulatory agencies and pharmaceutical and CRO industry carried out the content 
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validation.  The pharmaceutical (two) and Clinical Research Organisation (two) 
panel members were all experienced professionals at advanced managerial level and 
all with more than seven years experience (7 – 30 years). The regulatory agency 
experts (two) were experienced “Assessors” with more than seven years Regulatory 
Agency experience. All of the experts considered themselves experienced and 
experts in ‘decision-making’. 
 
Procedure 
All of the expert panel members were initially contacted either by a face-to-face 
meeting or by telephone to determine their willingness and availability to participate 
in the validation exercise. Following their agreement, they were all sent by email, 
additional background on the research, a copy of the developmental questionnaire 
and instructions on how to complete it (a copy of each is provided in Appendices II 
and III). 
 
Each expert member participated in two ways: firstly, by individually completing the 
94-item development questionnaire and the rating of each item using a 4-point scale. 
Secondly, by participating in an all panel round-table discussion meeting once all six 
feedback forms had been analysed. 
 
The rating guidance given for assessing each of the 94-item development 
questionnaire using a 4-point scale for its language clarity, completeness, relevance 
and scaling is as follows: 
 
Language Clarity: The sentence and wording should be clear, understandable, 
straightforward and simple. Completing the questionnaire should not require reading 
skills beyond that of a 12-year-old to avoid missing values and unreliable answers. 
 
Completeness: The sentence structure should be complete not broken and should 
end properly. 
 
Relevance: Each item should be relevant to the subject area and target population.  
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Scaling: Panel members should rate the scaling system as to whether or not the 
response options fit the statements/item on the 4-option scale. 
 
 Part II: Quantitative Assessment 
In the quantitative stage, the completed questionnaires from each of the six panel 
members were transposed from Word format questionnaires into Excel. Excel results 
were generated for each individual panel member as well as the composite panel. 
The results from these scores were used to generate the relevance scale which was 
computed using Content Validity Index (CVI), Scale Content Validity Index (S-
CVI), using Excel. Intraclass correlation coefficients (ICC) and reliability 
(Cronbach’s alpha) measurement were determined using SPSS statistical software. It 
is appreciated that there are very different opinions in the literature about whether 
Kappa measurement versus the ICC technique is better for inter-rater reliability. For 
non-quantitative data (categorical/nominal), the kappa coefficient is the techniques 
of choice. The ICC is more appropriate and better than the kappa technique for 
analysing data obtained from ratings using any scale (e.g.1 to 10) (Bhatti et al., 
2013a; Bhatti et al., 2013b) and it was used for the qualitative phase to measure the 
level of agreement (inter-rater reliability) among the panel of judges. 
 
RESULTS 
The results of the content validity are presented in two parts; quantitative and 
qualitative. The quantitative results are those obtained directly on the questionnaire 
feedback rating forms. The qualitative results comprise the comments made by 
individual panel members and also the outcomes of discussions at the expert panel 
meeting. The changes made to the 94-item developmental version of the 
questionnaire are discussed taking into account both the quantitative and the 
qualitative components. 
 
The completed questionnaire feedback forms with the comments from each expert 
panel member were returned in advance of a pre-scheduled expert panel meeting. At 
this meeting, a summary of the background and framework of the research project 
was outlined for the expert panels in line with good practice (Terwee et al., 2007). 
The panel meeting reviewed the composite feedback received from all panel 
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members and following panel discussion, resulted in the reduction/removal of 
several items from the 94-item instrument. In addition, some changes were made to 
the language of some items. The panel also provided their opinion on the time 
sacrifice needed for “time-to-complete” the questionnaire. 
 
Part I: Quantitative Assessment 
The results for the quantitative assessment were based on the returned questionnaire 
feedback forms (n=6). The results for each of the four rating criteria: language, 
clarity, completeness, relevance and scaling were analysed. Each of the six judges 
rated the 94 items.  The feedback results of each of the six individuals are 
summarised in Table 4.1.  
Table 4.1: Summary of percentage rating results given by each expert rater 
 Expert 
1 
Expert 
2 
Expert 
3 
Expert 
4 
Expert 
5 
Expert 
6 
Strongly Agree 86% 22.% 57% 50% 32% 74% 
Agree 6% 61% 36% 37% 50% 20% 
Disagree 6% 14% 7% 13% 17% 5% 
Strongly Disagree 2% 3% 0% 0% 1% 1% 
Combined  
Strongly Agree/Agree  
92% 83% 93% 87% 82% 94% 
Strongly disagree/disagree  8% 17% 7% 13% 18% 6% 
   
Language Clarity 
When the judges were asked whether the items showed good language clarity, there 
were 385 ratings (68.3%) for strongly agree, 93 (16.5%) for agree, 68 (12.1%) for 
disagree and 14 (2.5%) for strongly disagree. Three (0.5%) were missing (not 
completed) and were not included in the analysis. A sum of 85% was obtained for 
the “strongly agree/agree” scores suggesting that the expert panel agreed with the 
clarity of the language.   
 
Completeness 
The rating of the items for completeness revealed that there were 213 ratings (37.8%) 
for strongly agree, 259 (45.9%) for agree, 80 (14.2%) for disagree and 8 (1.4%) for 
strongly disagree. Four (0.7%) were missing and not included in the analysis. A sum 
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of 84% was obtained for the ”strongly agree/agree” scores suggesting the experts 
agreed on the completeness of the scale.  
 
Relevance 
When the judges were asked whether the items were relevant, there were 183 ratings 
(32.4%) for strongly agree, 292 (51.8%) for agree, 77 (13.6%) for disagree and 7 
(1.2%) for strongly disagree.  Five (0.9%) were missing and not included in the 
analysis. A sum of 84% was obtained for the “strongly agree/agree” scores 
suggesting the experts agreed on the relevance of the scale.  
 
Scaling 
With regard to scaling, there were 399 ratings (70.7%) for strongly agree, 158 (28%) 
for agree, 2 (0.4%) for disagree and 0 (0%) for strongly disagree. Five (0.9 %) were 
missing and not included in the analysis. A sum of 99% was obtained for the  
”strongly agree/agree” scores suggesting the experts agreed on the scaling of the 
scale.  
 
A tabular summary of the judges’ ratings of the 94 items across the four content 
validation criteria is presented in Table 4.2 
Table 4.2: The judges’ ratings (n=6) of the 94 items across four criteria 
Judges’ response 
option 
Language 
Clarity 
Completeness Relevance Scaling 
Strongly agree 385 (68.3%) 213 (37.8%) 183 (32.4%) 399 (70.7%) 
Agree 93 (16.5%) 259 (45.9%) 292 (51.8%) 158 (28%) 
Disagree 68 (12.1 %) 80 (14.2%) 77 (13. 6%) 2 (0.4%) 
Strongly Disagree 14 (2.5%) 8 (1.4%) 7 (1.2%) 0 (0%) 
Missing 3 (0.5%) 4 (0.7%) 5 (0. 9%) 5 (0.9%) 
Strongly Agree / 
Agree 
476 (84.8%) 472 (83.7%) 475 (84.2%) 557 (99%) 
Strongly 
Disagree/Disagree 
82 (14.6%) 88 (15.6%) 84 (14.9%) 0 (0.0%) 
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Of the 94-items, the items which had the most number of “Disagree and Strongly 
Disagree” ratings emerged from the results and were discussed during the expert 
panel meeting. Twenty such items emerged and will be discussed in the next section.  
 
Content Validity Index 
In addition to the subjective testing performed on the developmental instrument, the 
additional content validation tests of: content validation index (CVI) and the content 
validity of the whole scale (S-CVI) were applied to the qualitative data (Polit, 2006).  
 
CVI=  Number of items on which expert raters Agreed 
  Total number of expert raters 
 
The CVI and S-CVI have been used in healthcare research for the determination of 
content validity in the development of multi-item scales rated by multiple expert 
raters (Polit, 2006). There is a general agreement about the calculation of the CVI. A 
panel of content validation experts is asked to rate each scale item in terms of its 
relevance to the underlying construct. These items are typically on a four point scale 
to avoid having a neutral and ambivalent midpoint although a five or three point 
scale may be used (Lynn, 1986). A requirement of CVI is that a minimum of three 
expert raters are involved in the rating exercise and twice this amount was used in the 
validation exercise. The CVI can be calculated on an item level (I-CVI) and scale 
level (S-CVI). The item content validity index (I-CVI) is calculated as a level of 
agreement between a panel of judges for each individual item i.e. the proportion of 
experts who rate it as content valid. It is calculated by the number of experts giving a 
positive rating  (“strongly agree” or “agree” in the case of the developmental 
instrument) divided by the number of experts (n=6), therefore calculating the 
proportion of judges in agreement about relevance” (Polit, 2006).  
 
Individual Items 
The range of the CVI is from -1.00 to +1.00, with +1 indicating perfect item-
objective relevancies. The minimum acceptable I-CVI value for items varies 
depending on the number of judges involved but a minimum value of 0.70-0.8 is 
recommended (Lynn, 1986). For the validation exercise, a minimum value of 0.8 was 
used. Items with an index of less than 0.8 were discarded from the measure to 
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improve its validity. Of the 94-items, a total of 20 items had an I-CVI of less than 
0.8. These items were: 
• My decision-making is in line with that of the organisation 
• I am "engaged" in my decision-making 
• My organisation is engaged in its decision-making 
• Training in the science of decision-making would benefit me 
• My organisation would benefit from training in the science of decision-making 
• I quantify the cost implications of my decision-making 
• My organisation quantifies the cost implications of its decision-making 
• I consult with colleagues before making a decision 
• In my organisation, consultation with colleagues is encouraged in decision-making 
• My decision-making is quantifiable 
• My organisation's decision-making approach is quantifiable 
• My organisation questions the integrity of its decision-making 
• My decision-making is balanced 
• My organisation’s decision-making is balanced 
• I qualify the cost implications of my decision-making 
• My organisation qualifies the cost implications of its decision-making 
• My over-optimism results in me underestimating the outcome of a decision 
• My organisation's over-optimism results in underestimating the outcome of a 
decision 
• I systematically analyse how I make decisions 
• Decision-making within my organisation is systematically analysed. 
 
The twenty items with an I-CVI value of less than 0.8 were complimentary evidence 
of those items observed by the subjective review of the 94-items with the highest 
number of “strongly disagree /disagree” ratings. 
 
Overall Instrument (94-items) 
The scale content validity index (S-CVI) is defined as “the proportion of total items 
judged content valid” (Lynn, 1986). For the developmental instrument this would be 
the number of “strongly agrees” and “agrees” and is calculated by the average of the 
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I-CVIs (Polit, 2006). The S-CVI for the 94-item developmental instrument was 
calculated as 0.85, which is an acceptable value to suggest the scale is content valid. 
 
Statistical Testing of Agreement 
The 94 items of the developmental version of the instrument were rated on a 4-point 
ordinal scale for four different content validation criteria by six judges. It is 
important to establish the inter-rater reliability between the ratings given by the 
expert panel. This will indicate the level of consistency between the panel of judges 
and whether the data produced by the judges’ ratings can be relied upon. 
 
The most commonly used measures of agreement for quantitative data (the rating 
results) are the Intraclass Correlation Coefficient (ICC). This was appropriate due to 
the type of rating method/scale used (ordinal scale) in the questionnaire assessment.  
SPSS 20 statistical software was used to calculate the ICC and the reliability of the 
results from the six ratings by determination of Cronbach’s alpha. The ICC analysis 
between all six raters showed an ICC of 0.894 (p<0.0001. CI=0.561 to 0.993), 
indicating a high level of agreement between the six raters for the four criteria 
(language, scaling, relevance and completeness) and supporting the content validity 
of the items chosen for the developmental version of the instrument. 
 
The Cronbach’s alpha reliability measurement of the six-rater sample results was 
0.91, indicating a high level of reliability and further endorsement of content validity 
for the developmental instrument. 
 
 
Part II: Qualitative Assessment 
The results from the questionnaire feedback forms (“written feedback”) were 
collated and discussed at the expert panel meeting. The members of the panel 
participated in free and open discussion which resulted in consensus 
recommendation on retaining 74 items and the removal of 20 items from the 94-item 
developmental instrument. Editorial language changes were recommended to some 
of the 74 remaining items. In addition, two further items were added giving a total of 
76-items. 
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The items chosen by the panel for removal were all those that had been identified in 
as having a CVI of less than 0.8 and discussed previously. In addition, to the CVI 
and S-CVI testing performed, the subjective test of “Face validity” was also 
performed by the expert panel. Face validity is an intuitive type of validity in which 
the experts provided their feedback on whether the developmental instrument 
actually appears to reflect the concept that it is intended to measure. It indicates that 
the items that are intended to measure a concept, do, on the face of it, look as though 
they measure the concept (Patton, 2002; Denzin and Lincoln, 2005; Bougie, 2010). It 
is considered a basic and minimum index of content validity (Streiner and Norman, 
2008). All six raters provided their positive opinion that the developmental 
instrument does appear to measure the “decision-making” concept and this face 
validity further helped to provide useful support for the instrument development 
process. 
 
 
Revisions to The Original Developmental Instrument 
The expert panel meeting was interactive and constructive. All of the panel members 
actively participated and aired their opinions while at the same time allowing and 
agreeing on consensus recommendations on revisions to the instrument. Twenty 
items were removed from the original 94-item developmental version of the 
instrument (Version 1) and the majority of these were done so by clear consensus 
and did not warrant much panel discussion. However, three of the 20 items which 
were removed did require notable discussion time as there was originally no clear 
consensus on whether to retain or to remove them. These items were: 
• Training in the science of decision-making would benefit me 
• My organisation would benefit from training in the science of decision-
making 
• I systematically analyse how I make decisions. 
 
As part of a lengthy panel review and discussion, the final consensus was to remove 
these three items. In addition, the panel recommended the re-wording of six of the 74 
retained items as presented in Table 4.3. 
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Table 4.3:  Item wording changes recommended by the expert panel 
Original item wording Revised item wording 
I use tools which facilitate my decision-
making 
I use tools e.g. modelling or decision trees 
which facilitate my decision-making 
I understand the instructions before making 
a decision 
I understand the context of the decision I am 
being asked to make 
My organisation re-evaluates its decision-
making as new information becomes 
available  
My organisation re-examines its decision-
making as new information becomes 
available 
In my decision-making, I perpetuate the 
same mistakes as made in the past 
In my decision-making, I make the same 
mistakes as made in the past 
In my organisations decision-making, it 
perpetuates the same mistakes as in the past 
In my organisations decision-making, it 
makes the same mistakes as made in the past 
I communicate effectively the decisions I 
make 
I effectively communicate the decisions I 
make 
 
The expert panel also recommended the addition of two new items to the 
developmental instrument. These were: 
• My decision-making approach in practice tends to focus on discussions 
rather than actual decisions  
 
• Decision-making in my organisation tends to be final and not open to 
reinterpretation or discussion  
 
Following the expert panel meeting, the output and recommendations of the expert 
panel to the developmental instrument were reviewed and it was agreed to 
incorporate the changes to the developmental instrument. This resulted in the 76-item 
developmental instrument that would then undergo further psychometric testing. 
During the expert panel meeting, the panel advised that 30 – 40 minutes would be a 
time estimate needed to complete the revised 76-item questionnaire, based on their 
experience of completing the original 94-item questionnaire. 
 
Branding of The Decision-Making Instrument 
The expert panel were introduced to the proposed brand name of “QoDOS” (Quality 
of Decision-Making Orientation Scheme) assigned to the instrument and advised that 
the proposed name was “strong and appropriate” for the decision-making instrument. 
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A copy of the post-content validation 76-item QoDOS developmental instrument 
(Version 2) is presented in Appendix IV.  
 
DISCUSSION 
The content validation of the developmental version of the decision-making 
instrument was an essential process for it to be fit-for-purpose. The design of the 
process was in line with best practice recommendations reported in the literature for 
content validation of a new instrument i.e. qualitative and quantitative components, 
use of a multi-expert panel, structural element assessment of the scale by evaluating 
language clarity, completeness, relevance and scaling in addition to overall face-
validity assessment. 
 
The inclusion of panel experts from the three different disciplines (regulatory 
agency, pharmaceutical industry and CRO) was reflective of the proposed final target 
audience for the decision-making instrument. The heterogeneity of the panel 
members provided extra robustness to the content validation exercise being 
evaluated. The panel experts were all experienced professionals with many years of 
experience in decision-making. All of the panel members were supportive and 
participated actively in the two stage review process (questionnaire completion and 
expert panel meeting).   
 
The use of I-CVI, S-CVI, ICC and reliability measurements provided complimentary 
and quantitative statistical support for the overall robustness of the content 
validation.  The statistical evaluation and the triangulated qualitative assessment of 
the expert panel resulted in changes being made to the original developmental 
instrument and resulted in a shortened version.  
 
Overall, the expert consensus was that the content of the developmental version of 
the instrument was straight forward and appropriate in relation to the specific 
decision-making concepts and was relevant to the target population. This agreement 
among the expert panel members was reassuring and encouraging. It also provided 
confidence that the outcome of this stage was satisfactory in terms of establishing 
content validation and proof-of-concept of the shortened developmental version and 
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supported further psychometric testing of the instrument through item reduction 
using factor analyses.  The resulting 76-item instrument was given the name, 
“Quality of Decision-making Orientation Scheme” with the abbreviation “QoDOS”. 
The expert panel opinion was that this was an appropriate and strong acronym for the 
decision-making instrument. 
 
SUMMARY 
• The 94 items resulting from the quantitative study (Chapter 3) were reviewed 
for language clarity, completeness, relevance and scaling. Content validation 
was performed on the original 94-item developmental version of the instrument 
using a panel of six experts  
• Qualitative and quantitative methods were used in the content validation study 
• The scale content validity index of 0.85 suggested that the content validity of 
the scale was high 
• The test of agreement between raters (ICC) was 0.89 (p<0.0001. CI=0.561 to 
0.993), indicating a high level of agreement between the raters 
• The expert panel review resulted in the reduction of the original 94 items to 76 
items (QoDOS Version 2) 
• Content validity and the sub-component of face-validity was successfully 
evaluated and the developmental instrument deemed fit-for-purpose and 
suitable for further item reduction investigation 
• The brand name ‘QoDOS’ (Quality of Decision-making Orientation Scheme) 
was assigned to the instrument. 
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CHAPTER 5 
 
 
 
 
Development of The QoDOS: 
Factor Analysis 
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INTRODUCTION  
Factor analysis is a statistical technique used to analyse, investigate and identify the 
relationships between a set of variables (items) measured or observed, in particular 
for those with similar concepts (Cattell, 1978; Floyd, 1995; Bhatti et al., 2013b).  It 
is used to help confirm the grouping of the instrument items that have been based on 
subjective opinion through use of mathematical modelling.  A factor is a group of 
items that may be said to belong together (Hazard, 2011). Factor analysis is widely 
used to reduce a large number of correlated variables to a more manageable number, 
and is regularly used to reduce the number of items in questionnaires. The use of 
factor analysis is not designed for testing hypotheses or for judging whether one 
group is significantly different to another (Pallant, 2005).  It is a statistical technique 
used to identify a relatively small number of factors that can be used to represent 
relationships among a set of many interrelated variables. In other words it allows for 
a large number of individual scale items and questions to be refined and reduced to a 
smaller number of derived items (Pallant, 2005; Field, 2009; Bhatti et al., 2013b). 
For the purposes of this current research, factor analysis was used to reduce the 
number of items in the current 76-item developmental QoDOS instrument and also 
to identify underlying factors within the reduced set of items. 
 
Factor analysis is an established approach used in the development of new 
instruments in various research areas and in particular for those with a psychometric 
or a Quality of Life component (Fayers and Hand, 1997; Nedert et al., 2001; 
Fredheim et al., 2007; ESPRINT Group., 2007; Coyne Karin S., 2012). Factor 
analysis was employed to refine the QoDOS (Version 2) prior to its full scale 
psychometric evaluation. This psychometric evaluation included construct validity, 
responsiveness, reliability and interpretability testing.  
 
METHODS 
There were two distinct research component phases involved in the factor analysis 
and item reduction of the 76-item QoDOS instrument (Version 2) as detailed in 
Chapter 4. These phases were as follows: 
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Component phase 1: Conduct of a research study survey using the QoDOS 
instrument in a large sample population to investigate the decision-making approach 
of individuals and their respective organisations. Each prospective participant was 
contacted in advance and provided with background information on the research 
project and given assurance on anonymity and confidentially on all research related 
materials. The same confidentiality commitment as detailed previously in Chapter 3 
was provided to all would-be participants. 
 
Survey Monkey was used for the issuance of the QoDOS (Version 2) questionnaire 
to all participants and in-turn for the automatic compilation of completed 
questionnaire returns. A 100% response rate was achieved and this can be expected 
to be due to the functionality within Survey Money which requires that a 
questionnaire must be fully completed before it can be sent into its central database. 
It will not accept data from partially completed questionnaires. The Survey Monkey 
question structure used a Likert response format as exemplified in Figure 5.1.    
Figure 5.1: Survey Monkey Likert format used in the research  
 
 
 
The time-window for the issuance and completion of the QoDOS developmental 
survey was July 2012 to October 2012. 
 
Survey Monkey and Excel were used in the quantitative analysis of this component 
of the research. An Excel database was used to compile the completed questionnaires 
received from each of the research participants. The functionality of the Excel 
database facilitated the data management and interpretation of the study results. The 
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combined Survey Monkey survey and Excel functionality allowed for the generation 
of results in various formats including spider graphs, bar charts and ‘Box and 
Whisker’ plots for the research sample data. 
 
Component phase 2: The quantitative data generated in Component 1 research was 
transposed into statistical format ready for factor analysis and item reduction.  
 
Data Capture, Processing and Analyses (Component Phase 2) 
Data processing and statistical analyses were performed using the well established 
methodology involving SPSS 20 statistical software for Windows (Norusis, 1993; 
Pallant, 2005; IBM, 2011).  
 
Exploratory factor analysis (EFA) using the “principle component analysis” was 
performed using SPSS20 statistical software. EFA is used to investigate whether 
there is any correlation among a set of items and to identify the dimensions or factor 
structure of the new measure and to can be used to reduce items (Fayers and Hand, 
1997; Pallant, 2005). It can also be used to support construct validation of new 
instruments (Bhatti et al., 2013b). For the QoDOS (Version 2), EFA was used to 
explore the underlying structure, to reduce the number of items (inappropriate ones 
that may not contribute to the underlying factors) and to support its appropriateness 
(construct validity).  
 
Using the SPSS 20 software, a correlation and component matrix was created for the 
dataset. Descriptive statistical techniques were used to measure the Kaiser-Meyer-
Olkin (KMO) measure (which comparatively measures the magnitudes of the 
observed correlation coefficients to the magnitudes of the partial correlation 
coefficients) and Bartlett’s test of sphericity for adequate sampling.  A multi-step 
factor analysis was performed and Scree plots were generated at each extraction 
stage. The Scree plots provided a useful, easily interpretable impression of the 
number of factors within each sequential extraction result.  Factor rotation was 
performed using the Varimax technique and Kaiser-Meyer-Olkin (KMO) and 
Bartlett’s test of sphericity measurements were measured at each extraction stage. 
Reliability testing was performed by measuring Cronbach’s alpha to measure the 
internal consistency and intraclass correlation coefficient (ICC) to evaluate inter-rater 
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reliability. The Cronbach’s alpha testing also provided supportive evidence for the 
retention and deletion of the items during the factor analysis (Pallant, 2005; Petter, 
2007; Streiner and Norman, 2008).  
 
The following steps and rules were applied during the factor analysis: 
 
1. Reliability test (Cronbach’s alpha) of items was carried out before at each factor 
analysis step.  
 
2. Factor analysis was performed on the remaining items. 
 
3. Analysis criterion: Only factor loadings of ≥ 0.4 were progressed.  Items which 
failed to load on any component were removed. Items with “corrected items-total 
correlation” (factor loadings) values <0.4 were deemed not to be discriminating well 
/ poorly fitting and were removed. As a rule of thumb, the eigenvalue of 0.32 is 
considered to be a minimum loading for an item (Costello and Osborne, 2005) but in 
this study, due to the large number of variables, a value of 0.4 was assigned and 
considered appropriate to represent strong correlation.  
 
4. Items which loaded on multiple components with not much difference between 
values (weak complex variables) were removed. However, items with significantly 
higher loading were retained. 
 
5. Further factor analysis was carried out to see whether or not the remaining items 
with a similar concept fitted together under the appropriate corresponding 
components. 
 
6. Successive factor analyses were carried out to examine the difference (similarities, 
number of items removed and the types of items removed).  
 
7. Items were retained of removed based on their loading score. A table was 
generated showing the ranking of items based on loading scores. This was used to 
decide which items should be deleted and which should be retained for additional 
analysis. This assessment on whether to retain or remove an item was performed 
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simply by “eyeballing” the ranked included in the table. Items were deleted, retained, 
merged or rephrased on statistical, conceptual and philosophical grounds. 
 
8. After the final analysis, any item that did not conceptually fit in the final extracted 
components was manually moved to ones that were more appropriate and 
meaningful to that component. This allowed for a logical ordering of concepts to be 
generated.  
 
RESULTS 
Study Participants 
Six hundred individuals were contacted and invited to participate in the study. A total 
of 130 responded, of which 120 were evaluable. This included 76 from the EU and 
US pharmaceutical industry, 19 from the regulatory agencies (European Medicines 
Agency, Danish Agency, Irish Medicines Board, UK MHRA, Singapore Ministry of 
Health and the UAE Ministry of Health),  23 from  CROs (EU and US) and two from 
academia. The research results obtained from the 120 evaluable participants provided 
insights into decision-making from the perspective of the individual and also that of 
the organisation in which they were/are employed.  The results also allowed for 
comparisons to be made across the three main organisations that participated in the 
study i.e. the Regulatory Agencies, Pharmaceutical Companies and CROs.  
 
Organisation and Individual Related Item Responses 
Composite results for the 120 person research sample were generated for each of the 
76-items in the developmental questionnaire. The results provided a quantitative 
response rate to the Likert scale ratings used in the questionnaires for each item. It 
was possible to separate the composite results into two distinct categories: those 
responses which were answered from the perspective of the Organisation and those 
which were responded to from the perspective of the Individual.   
 
A selection of four organisational related item responses and four individual related 
item responses are presented in Figures 5.2 – 5.8 respectively for reference and 
example purpose. 
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A structured approach to decision-making (Figure 5.2) appeared to be routine 
practice in approximately 50% of cases (always/often), 33% on a “sometimes” basis 
and rarely or never up to 15% of occasions. 
Figure: 5.2: My organisation uses a structured approach in its decision-making 
 
 
Re-evaluation of decision-making with the availability of new information (Figure 
5.3) appears to be standard practice in 15% of cases and an often/sometimes basis for 
an additional 70%. It appears not to be the standard approach in about 15% of 
decision-making exercises.   
Figure 5.3: My organisation re-examines its decision-making as new information 
becomes available  
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It would appear that organisations only consistently review the probability of success 
in their decisions in just over 10% of cases. It appears to be rarely/never performed 
in around 12% of occasions. This could infer that organisations are either not 
familiar with the advantages of re-examination as it appears not to be used on a 
standard basis (Figure 5.4). 
Figure 5.4: My organisation quantifies the probability of success in its decision-making  
 
 
 
Organisations appear to perform a relatively routine assessment of the impact of the 
decision-making. It appears not to be performed in 10% of cases (Figure 5.5). 
Figure 5.5: My organisation evaluates the impact of its decisions 
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From the perspective of the individual it appears that the majority of individuals 
(around 85%) felt as though they could make better decisions ranging from a 
sometimes to an always basis (Figure 5.6). 
Figure 5.6: I feel that I could make better quality decisions 
 
 
 
The use of intuition as a standard practice appears to be the case in around 25% of 
people. Less than 15% appear to use it only on a ‘rarely/never’ basis and 75% on a 
‘sometimes/often’ basis. It is recognised that different situation will call upon 
different decision-making approaches but still this is an interesting finding  
considering the background of the individuals and the evidence based medicines 
arena. 
Figure 5.7: I use intuition or “gut-feeling” in my decision-making 
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More than 35% of persons who participated in the research advised that they had not 
received any training in the science of decision-making. Less than 10% of persons 
advised that they received training on often/always basis (Figure 5.8). This is an 
interesting and somewhat disappointing finding when one considers the evolving and 
innovated nature of drug development and the regulatory review and the increasing 
convergence of industry and regulators in effective delivery of new drugs. 
Figure 5.8: I receive training in the science of decision-making 
 
 
The collection of all the item response data in Excel format allowed for the 
quantification of the response metrics per response option for each of the 
organisations. A tabular summary of the response metrics for the organisations is 
given in Table 5.1. 
Table 5.1: Response metrics for individuals from the three organisations* 
 Regulatory Agencies 
(n=19) 
Pharmaceutical 
Companies (n=76) 
CROs (n=23) 
Never  99 (6.9%) 203 (3.5%) 63 (3.6%) 
Rarely 242 (16.8%) 934 (16.2%) 278 (15.9%) 
Sometimes 378 (26.2%) 2030 (35.1%) 608 (34.8%) 
Often 367 (25.4%) 1768 (30.6%) 537 (30.7%) 
Always 225 (15.6%) 714 (12.4%) 221 (12.7%) 
Not Applicable 133 (9.2%) 127 (2.2%) 40 (2.3%) 
* The results of the Academics (n=2) were excluded in the metric and statistical analyses due to such low participant numbers. 
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The percentage of “Affirmative” responses received from the individuals from the 
three organisations was 67% (Regulatory Agencies), 78% (Pharmaceutical 
companies) and 78% (CROs). 
 
Comparative statistical analyses were performed on the organisation data to generate 
items such as correlation information and comparative “box and whisker” plots on 
the distribution of the data. The correlation coefficients for the associations between 
the results of the organisations were high as shown in Table 5.2. 
Table 5.2: Correlation coefficients for the three organisations 
 Regulatory Agencies 
(r, p<0.001) 
Pharmaceutical 
Companies (r, p<0.001) 
CROs               
(r, p<0.001) 
Regulatory Agencies - 0.98 - 
Pharmaceutical 
Companies 
0.98 - 0.99 
CROs  0.98 0.99 - 
 
Comparative ‘box and whisker’ plots of the three different organisation results were 
generated. The plots were generated using Minimum, 25%, Median, 75% and the 
Maximum of the datasets (Figure 5.9). A ‘Box and Whisker’ plot presents summary 
information about the distribution of the data or results. It plots the minimum, the 
25th percentile, the median, the 75th percentile and the maximum results and scores 
that are far removed from the rest (outliers). Fifty per cent of the results are within 
the coloured boxed areas. The length of the box corresponds to the inter-quartile 
range (IQR) which is the difference between the 75% and 25% percentiles. The IQR 
is an established technique used for enabling comparisons to be made among several 
groups of data. In addition to distribution or spread of results, they also give 
information on the central tendency of the data set (Sekaran and Bougie, 2010). The 
Box-and-Whisker plots present a visualisation of the distribution in responses 
between the organisations and the close comparison between the CRO and the 
Agency distribution is noteworthy.   
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Figure 5.9: Box and Whisker plot for the distribution of the results from the three 
organisations 
 
 
Statistical Factor-Analysis  
The 76-item QoDOS (Version 2) contained questions relating directly to the 
decision-making approach adopted by “organisations” (Regulatory Agencies and 
Pharmaceutical Industry)  and that used by “Individuals” (from within the Regulatory 
Agencies and Pharmaceutical Industry). Eight different SPSS analyses approaches 
were attempted on the 76-item instrument using SPSS 20. The approaches 
investigated the use of PCA, item reduction, Scree plots, KMO, Bartlett’s Sphericity 
testing, statistics descriptive techniques, ICC and several different rotation 
techniques. The factor analyses did not result in satisfactory item convergence of 
item reduction. In the draft instrument, the questions were presented in a composite 
manner and not separated on the basis of whether the question item related to the 
“Individual” or the “Organisation”.   
 
Factor Analysis of The Composite 76-item Instrument 
The factor-analysis attempted on the 76-item instrument, commenced with 
generation of a Scree plot. A rule-of-thumb in interpreting Scree plot outputs is that 
the “bend in the elbow” or “point of inflexion” is indicative of the number of latent 
factors within the item set. The Scree plot for the 76 items inferred the presence of 
nine or ten latent factors (Figure 5.10).  
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Figure 5.10: Scree plot for the 76-item composite instrument 
 
The Cronbach’s alpha for the 76-items instrument was 0.861 which inferred good 
reliability (Pallant, 2005). As indicated in Table 5.3, the KMO which measured the 
adequacy of the proposed factor analysis for the 76 items was 0.553.  This KMO 
result was above the 0.5 threshold of acceptability, although it did infer that the 
sample size was “mediocre” in nature (Pallant, 2005; Field, 2005). Bartlett’s test of 
sphericity tests whether the correlation matrix is an identity matrix, which would 
indicate that the factor model is inappropriate. 
Table 5.3: KMO and Bartlett’s Test results for 76 items 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.553 
Approx. Chi-Square 6007.891 
Significance (‘p’) 0.0001 
Organisation Versus Individual Factor Analysis Methods 
Following the unsuccessful factor analysis attempts and item reduction of the 76-
item QoDOS developmental instrument, the items were separated into two groups 
depending on whether the item related to organisational or individual level decision-
making. This split the 76 items into two separate blocks, one containing 35 
organisational items and the other 41 individual related items. The two blocks were 
given the coding nomenclature d1 – d76 in the SPSS procedural analysis approach 
with d1 – d36 comprising the Organisational level items and d37 – d76 the  
individual level items (Table 5.4). This in essence, produced two new distinct 
domains of the QoDOS instrument. One for Organisational related items (d1 – d36 
(excluding d15, which was an organisational item)) and another one for Individual 
related items (d37 –d76).  
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Table 5.4: Mapping and separation of the 76 QoDOS items to their organisational level 
(35) and individual level (41) items 
Organisation level 
items  Individual level items 
Q2 d1 
 
Q1 d37 
Q4 d2 
 
Q3 d38 
Q6 d3 
 
Q5 d39 
Q7 d4 
 
Q13 d40 
Q8 d5 
 
Q15 d41 
Q9 d6 
 
Q16 d42 
Q10 d7 
 
Q18 d43 
Q11 d8 
 
Q19 d44 
Q12 d9 
 
Q21 d45 
Q14 d10 
 
Q22 d46 
Q17 d11 
 
Q24 d47 
Q20 d12 
 
Q25 d48 
Q23 d13 
 
Q26 d49 
Q28 d14 
 
Q27 d50 
Q31 d16 
 
Q29* d15 
Q33 d17 
 
Q30 d51 
Q35 d18 
 
Q32 d52 
Q37 d19 
 
Q34 d53 
Q39 d20 
 
Q36 d54 
Q41 d21 
 
Q38 d55 
Q48 d22 
 
Q40 d56 
Q49 d23 
 
Q42 d57 
Q51 d24 
 
Q43 d58 
Q53 d25 
 
Q44 d59 
Q54 d26 
 
Q45 d60 
Q56 d27 
 
Q46 d61 
Q58 d28 
 
Q47 d62 
Q60 d29 
 
Q50 d63 
Q63 d30 
 
Q52 d64 
Q65 d31 
 
Q55 d65 
Q68 d32 
 
Q57 d66 
Q70 d33 
 
Q59 d67 
Q72 d34 
 
Q61 d68 
Q74 d35 
 
Q62 d69 
Q76 d36 
 
Q64 d70 
   
Q66 d71 
   
Q67 d72 
   
Q69 d73 
   
Q71 d74 
   
Q73 d75 
   
Q75 d76 
*Q29 (my procrastination has resulted in a negative outcome) was assigned inadvertently as out of sequence “d” reference 
number but this did not impact the analyses. 
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Factor Analysis of The Organisational Related Items 
A 12-step factor analysis was performed on the 35 organisational related items using 
SPSS 20. This helped to explore the underlying structure of the 35 items, to confirm 
appropriateness (construct validity) and to further develop the instrument by 
reducing inappropriate items that did not contribute to underlying domain factors of 
the instrument.  Reliability testing using Cronbach’s alpha and ICC were measured 
along with KMO and Barlett’s testing. Scree plots were generated at each factor 
analysis stage. The Scree Plot for the 35 Organisational related items is presented in 
Figure 5.11 and inferred the presence of six or seven latent factors for the 35 items. 
Figure 5.11: Scree plot of the 35 organisational level items 
 
 
 
The reliability statistics performed resulted in a Cronbach’s alpha of 0.776 for the 35 
Organisational items which was a satisfactory robust result. As indicated in Table 
5.5, the KMO for the 35 Organisation item solution was 0.743 and was satisfactory.  
The Bartlett’s test result obtained rejected the hypothesis (at p≥0.0001) that the 
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correlation matrix is an identity matrix. This supported the appropriateness of the 
factor model.  
 
Table 5.5: KMO and Bartlett’s test results for 35 organisational item 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.743 
Bartlett’s Test of Sphericity                  595 
 Significance (‘p’) 0.0001 
 
The ICC Reliability coefficient describes how strongly items in the same group 
resemble each other. The ICC Reliability coefficient ICC = % of variance in the 
scores results from “true” variance among subjects. ICC ranges from 0 (no 
agreement) to 1 (perfect agreement). The "single" measure gives the reliability of the 
scale that is scored by just one of several raters or at one of several occasions and the  
"average" " measures  provided the reliability of a scale that is made up as the 
average of the different raters. The average ICC value for the organisational items 
was above 0.77 which is considered acceptable.  
 
Factor Analysis 1:  
This included all 35 organisation-related items. The initial factor analysis performed 
based on the Kaiser’s rule, yielded 9- factors with  eigenvalue of at least 1 (Table 
5.6). The resultant nine factors were also supported by the subjective interpretation 
of the Scree plot (factors to “bend in elbow”). Item d23 (Q49) was removed as a 
result of Analysis 1.  
 
Further automatic step-wise extractions were performed on the 35 items and resulted 
in five component factors and 21 items.  As part of the analysis, some Cronbach’s 
alpha measurements were calculated in addition to KMO to add extra robustness to 
the statistical analysis. A summary of the additional nine extraction steps and results 
obtained is presented after Table 5.6. 
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Table 5.6:  Results of factor analysis 1: Total variance explained 
Component Initial Eigenvalues Extraction Sums of squared 
loadings 
 Total % of Variance Cumulative % Total % of Variance 
1 7.881 22.516 22.516 7.881 22.516 
2 4.569 13.054 35.571 4.569 13.054 
3 2.440 6.972 42.542 2.440 6.972 
4 1.790 5.113 47.656 1.790 5.113 
5 1.582 4.520 52.176 1.582 4.520 
6 1.386 3.959 53.135 1.386 3.959 
7 1.220 3.487 59.622 1.220 3.487 
8 1.098 3.138 62.759 1.098 3.138 
9 1.052 3.007 65.766 1.052 3.007 
10 0.984 2.813 68.579   
11 0.944 2.698 71.277   
12 0.838 2.395 73.671   
13 0.829 2.367 76.039   
14 0.772 2.206 78.245   
15 0.702 2.006 80.250   
16 0.668 1.909 82.159   
17 0.580 1.656 83.815   
18 0.551 1.575 85.390   
19 0.547 1.562 86.952   
20 0.510 1.458 88.409   
21 0.460 1.314 89.724   
22 0.438 1.250 90.974   
23 0.411 1.174 92.148   
24 0.365 1.042 93.190   
25 0.349 0.998 94.187   
26 0.319 0.911 95.099   
27 0.296 0.847 95.946   
28 0.265 0.756 96.702   
29 0.250 0.713 97.415   
30 0.195 0.557 97.972   
31 0.173 0.493 98.465   
32 0.165 0.470 98.935   
33 0.152 0.433 99.369   
34 0.134 0.384 99.752   
35 0.087 0.248 100.00   
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Factor Analysis 2: This resulted in item reduction with the removal of two items;   
d12 (Q20) and d33 (Q70). The KMO for the resultant 9-factor solution was 0.736. 
 
Factor Analysis 3: This produced a KMO of 0.722 for a 9-factor solution. 
 
Factor Analysis 4: This used a 2-factor analysis and resulted in the removal of two 
further items; d28 (Q58), d26 (Q54). The resultant KMO was 0.722 for the resultant 
9-factor solution. 
 
Factor Analysis 5: This used a 2 factor-analysis and resulted in the removal of three 
items; d4 (Q7), d34 (Q72), d35 (Q76). The KMO for the resultant 8-factor solution 
was 0.731. 
 
Factor Analysis 6:  This resulted in the removal of one further item namely; d10 
(Q14). The KMO was 0.749 for the resultant 8-factor solution. The Cronbach’s alpha 
was 0.768. 
 
Factor Analysis 7:  This resulted in the removal of three items: d33 (Q17); 
d31(Q65); and d32 (Q68). With KMO of 0.750 for the resultant 6-factor solution and  
23 items. The Scree plot for the 23 item solution is presented in Figure 5.12 and it 
inferred the presence of six factors. 
 
Factor Analysis 8: This resulted in the removal of one further item namely; d29 
(Q60). The KMO was 0.789 for the resultant 6-factor, 22 item solution. 
 
Factor Analysis 9: This resulted in the removal of one further item namely; d7 
(Q10). The KMO was 0.802 and the Cronbach’s alpha was 0.762 for the resultant 5-
factor, 21 item solution. 
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Figure 5.12: Scree plot for the 23 organisational influence items 
 
Factor Analysis 10: This resulted in a KMO of 0.804 for the resultant 21 item 
solution. The Scree plot for the 21 item solution is presented in Figure 5.13 and 
inferred the presence of four factors. 
Figure 5.13: Scree plot for the 21 item organisation level influences 
 
The factor analysis performed, reduced the 35 Organisational items to 21 items. 
Eigenvalues were generated for each of the 21 items (factors). The Scree plot was 
relatively improved compared to the previous extraction.  The eigenvalue loading 
results showed that most loading was accounted for on five factors, with the majority 
loading onto two factors as shown in Table 5.7.  
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Table 5.7: Total variance explained for the 21-item solution 
Component Initial Eigenvalues Extraction Sums of squared 
loadings 
(d) Total % of 
Variance 
Cumulative % Total % of Variance 
1 5.993 28.538 28.538 5.992 28.538 
2 3.862 18.393 46.930 3.862 18.393 
3 1.350 6.427 53.357   
4 1.247 5.936 59.264   
5 1.062 5.056 64.349   
6 0.962 4.582 68.931   
7 0.810 3.859 72.790   
8 0.709 3.374 76.165   
9 0.694 3.306 79.471   
10 0.618 2.941 82.411   
11 0.576 2.741 85.152   
12 0.491 2.338 87.490   
13 0.459 2.184 89.675   
14 0.401 1.911 91.585   
15 0.341 1.624 93.210   
16 0.309 1.470 94.680   
17 0.301 1.432 96.112   
18 0.248 1.180 97.292   
19 0.208 0.992 98.284   
20 0.194 0.923 99.207   
21 0.166 0.793 100.00   
 
The first five component factors explained relatively large amounts of variance 
(especially factors one and two) whereas the subsequent factors explained small and 
reducing amounts of variance. Only the initial two factors had loadings above an 
eigenvalue of 2. 
 
Rotation Factor Matrix  
The component matrix for the 21 extracted variables was rotated using Varimax 
functionality. This Varimax rotation helped to confirm the initial structure of the 
scale and delivered a matrix of the factor loadings for each vairable onto each of the 
two factors. The loading solution showed the variables listed in order of the size of 
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their factor loadings onto each of the two component factors. Loading values with a 
unique value of less than 0.4 were supressed. The rotated matrix 2-factor solution for 
the 21 organisational variables showing the loading of each variable is presented in 
Table 5.8. 
The Varimax rotation maximised the variance of each of the 21 items, so the total 
amount of variance accounted for was redistributed over the two extracted factors. 
Overall, the factor analysis on the Organisational items allowed a reduction from 35 
to 21 items. The analysis was also discriminatory in nature in that different loadings 
resulted for the differing constructs which was also supportive of overall construct 
validity. 
Factor Analysis of Individual Related Items 
The grouping of the original composite 76-item QoDOS (Version 2) into two blocks, 
resulted in 41 individual related items in the “individual” block. Factor analysis on 
the 41 items was performed using SPSS 20. A total of 11 consecutive factor analysis 
item reduction steps were performed on the 41 individual related items. Reliability 
testing using Cronbach’s alpha and ICC were measured along with KMO and 
Barlett’s testing. Scree plots were generated at each factor analysis stage. The Scree 
Plot for the 41individual related items is presented in Figure 5.14 and inferred the 
presence of nine or ten latent factors for the 41 items. 
Figure 5.14: The Scree plot for the 41 individual related items  
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Table 5.8: The organisational item resultant rotated factor loadings (pattern matrix) 
  
Variable Factor1 Factor2 
My organisation’s decision-making is influenced by company 
politics Q11 d8 .796 
 My organisation has suffered a negative outcome due to slow 
decision-making  Q31 d16 .719 
 In my organisation’s decision-making, it makes the same 
mistakes as made in the past Q53 d25 .684 
 My organisation’s decision-making is influenced by vested 
interest of individuals Q9 d6 .668 
 My organisation’s culture has resulted in its inability to make 
a decision Q33 d17 .666 -.373 
My organisation continues with projects which should be 
terminated at an earlier stage Q28 d14 .631 
 My organisation’s decision-making is influenced by 
competitors Q8 d5 .585 .406 
My organisation’s decision-making is influenced by 
incentives or penalty payments Q12 d9 .575 
 My organisation underestimates problems which adversely 
impacts its own decision-making Q56 d27 .569 
 My organisation quantifies the probability of success in its 
decision-making Q37 d19 .382 .710 
My organisation qualifies the probability of success in its 
decision-making Q35 d18 
 
.664 
My organisation encourages innovative decision-making Q63 d30 
 
.637 
My company uses a structured approach in its decision-
making Q2 d1 
 
.634 
My organisation effectively communicates the decisions it 
makes Q74 d35 -.481 .612 
My organisation provides clear and unambiguous instructions 
for decision-making Q39 d20 
 
.612 
My organisation evaluates the impact of the decisions it 
makes Q4 d2 
 
.600 
My organisation’s decision-making approach is transparent Q41 d21 -.375 .587 
My organisation’s decision-making is consistent Q48 d22 -.384 541 
My organisation is open to using better alternatives in its 
decision-making Q51 d24 
 
.539 
My organisation re-examines its decision-making as new 
information becomes available Q49 d23 -.488 .537 
My organisation’s decision-making is influenced by external 
stakeholder’s demands Q6 d3 
 
.520 
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The reliability statistics performed resulted in a Cronbach’s alpha of 0.809 for the 41 
Individual item instrument which was a satisfactory robust result. As indicated in 
Table 5.9, the KMO for the 41 Individual item solution was 0.645 and was “fair”. 
The Bartlett’s test result obtained rejected the hypothesis (at p≥0.0001) that the 
correlation matrix is an identity matrix. This supported the appropriateness of the 
factor model.  
Table 5.9: KMO and Bartlett’s Test results for the 41 individual items 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy 0.645 
Bartlett’s Test of Sphericity                  820 
Significance (p) 0.0001 
 
The Intraclass Correlation Coefficient for the 41 individual items were also generated 
and had an average ICC value of 0.8, which was acceptable. As part of the step-wise 
factor analyses, some Cronbach’s alpha measurements were calculated in addition to 
KMO to add extra robustness to the statistical analysis. A summary of the additional 
11 extraction steps is presented below: 
 
Factor Analysis 1:  41 Individual related items  
The initial factor analysis performed based on the Kaiser’s rule, yielded 12 factors 
with an Eigen-value of at least 1. The 12-factor solution was also supported by the 
subjective interpretation of the Scree plot (factors to “bend in elbow”). Four Items; 
d74 (Q71), d42 (Q16), d43 (Q18), d61 (Q6) were removed as a result of the first 
factor analysis. Further automatic step-wise extractions involving 11 reiterations 
were performed on the remaining items which resulted in 6 component factors and 
22 items.  
 
Factor Analysis 2:  
This resulted in the reduction of three items:   d41 (Q15); d76 (Q75); and  d70 (Q64) 
with KMO value of 0.683 for the resultant 11-factors and 34-item solution. The 
Scree plot for the 34 item solution is presented in Figure 5.15 and inferred the 
presence of 12 latent factors. 
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Figure 5.15: Scree plot for the individual items solution (2nd factor analysis)
 
Factor Analysis 3:   
This resulted in item reduction leading to the removal of one item namely: d72 
(Q67). The KMO obtained post-factor analysis three was 0.695.  
 
Factor Analysis 4:  
This resulted in the removal of one item namely: d66 (Q57). The KMO obtained 
post-factor analysis was 0.700 (good) and the Cronbach’s alpha of 0.809 (very good). 
 
Factor Analysis 5:  
This resulted in the removal of a further one item: d75 (Q73). The KMO obtained 
post-factor analysis was 0.710 (good). 
 
Factor Analysis 6:   
This resulted in item reduction of one item namely: d69 (Q62). The KMO obtained 
post-factor analysis was 0.713 (good). 
 
Factor Analysis 7:   
The KMO obtained post-factor analysis seven, was 0.713 (good) and the Cronbach’s 
alpha was 0.803 (good). The Scree plot obtained and presented in Figure 5.16 
inferred the presence of four factors. 
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Figure 5.16: Scree plot for the individual items (7th factor analysis) 
 
 
Factor Analysis 8:   
This resulted in the removal of five items: d40 (Q13): d48 (Q25); d47 (Q24); d63 
(Q50); and d38 (Q3). The KMO obtained was 0.713 (good). 
 
Factor Analysis 9:  
Factor analysis nine resulted in the removal of two items namely: d45 (Q21) and d61 
(Q46). The KMO was 0.755 (good) with a Cronbach’s alpha of 0.821(good).    
 
Factor Analysis 10:  
Factor analysis ten resulted in the removal of a further single item: d44 (Q19). The 
KMO obtained was 0.765 (good).  
 
Factor Analysis 11: Factor analysis eleven, resulted in no further reduction of items. 
The KMO obtained was 0.762 (good) and the Cronbach’s alpha of 0.796 (good).  
The Scree plot inferred the presence of at least 6 latent factors, two of which were 
most dominant. No clear “point of inference / elbow break” was evident in the Scree 
plot, as presented in Figure 5.17. 
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Figure 5.17:  Scree plot for the individual items (11th factor analysis)
 
The ICC reliability coefficient results describe how strongly items in the individual 
item group resemble each other. The average ICC value was 0.796 which is 
acceptable. The factor analysis performed on the individual items reduced the 
number of items from 41 to 22. The eigenvalue loading resultant from the final 
extraction are presented in Table 5.10 showed that a six component factor solution 
explained relatively large amounts of variance (especially factors one and two) 
whereas the subsequent factors explained small and reducing amounts of variance. 
Only the top two dominant factors had loadings above an eigenvalue of 2 (same 
criteria as applied to the Organisational items).  
 
Rotation Factor Matrix  
The component correlation matrix for the 22 extracted variables was rotated using 
Varimax functionality.  The Varimax rotation helped to confirm the initial structure 
of the scale and delivered a matrix of the factor loadings for each variable onto each 
of the two dominant factors. The loading solution showed the variables listed in 
order of the size of their factor loadings onto each of the two component factors. 
Loading values with a unique value of less than 0.4 were suppressed. The rotated 
matrix 2-factor solution for the 22 individual variables showing the loading of each 
variable is presented in Table 5.11. 
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The Varimax rotation maximised the variance of each of the 22 factors, so the total 
amount of variance accounted for was redistributed over the two extracted factors. 
The reduction of the original 41 organisational items to 22 and followed by their 
loading onto two factors will allow for an individual behaviour title to be allocated to 
the two factors. The analysis was also discriminatory in nature in that different 
loadings resulted for the differing constructs which was also supportive of overall 
construct validity. 
Table 5.10: Total variance explained for the 22 item solution 
Component Initial Eigenvalues Extraction Sums of squared 
loadings 
d Total % of Variance Cumulative % Total % of Variance 
1 4.485 20.385 20.385 4.485 20.385 
2 3.786 17.208 37.592 3.786 17.208 
3 1.675 7.612 45.205   
4 1.303 5.922 51.127   
5 1.225 5.566 56.693   
6 1.037 4.713 61.406   
7 0.972 4.417 65.824   
8 0.867 3.943 69.766   
9 0.817 3.712 73.479   
10 0.727 3.307 76.785   
11 0.716 3.256 80.041   
12 0.620 2.819 82.860   
13 0.542 2.466 85.326   
14 0.502 2.284 87.610   
15 0.473 2.152 89.761   
16 0.441 2.006 91.768   
17 0.380 1.276 93.493   
18 0.376 1.710 95.203   
19 0.349 1.589 96.792   
20 0.284 1.292 98.084   
21 0.224 1.017 99.101   
22 0.198 0.899 100.00   
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Table 5.11: The 22 individual related decision-making factors: following item reduction 
and SPSS extraction 
  
Variable 
Component 
(Factor)1 
Component 
(Factor)2 
My procrastination has resulted in a negative 
outcome  
Q29 d15 .734 
 I have experienced “paralysis by analysis” 
caused by my slow decision-making  
Q30 d51 .720 
 Emotion is part of my decision-making  Q66 d71 .706 
 I have experienced a negative outcome by a 
decision not being made  
Q32 d52 .680 
 In my decision-making, I make the same 
mistakes as made in the past  
Q52 d64 .600 
 Recent or dramatic events  greatly impact my 
decision-making  
Q59 d67 .559 
 My decision-making could be improved by 
assigning weights  
Q42 d57 .532 
 I continue with projects which should be 
terminated at an earlier stage  
Q27 d50 .522 
 I feel that I could make better quality decisions  
 
Q22 d46 .502 
 I underestimate problems which adversely 
impact my decision-making 
Q55 d21 .493 
 
I quantify the probability of success in my 
decision-making  
Q36 d54 .445 
.326 
I qualify the probability of success in my 
decision-making  
Q34 d53 .441 .312 
I understand the context of the decision I am 
being asked to make  
Q38 d55  
.741 
I consider uncertainty and unknowns in my 
decision-making approach  
Q45 d60  .644 
I present contingencies or achievable options 
as part of my decision-making  
Q43 d58  
.642 
My decision-making is consistent  Q47 d62  .635 
My decision-making approach is transparent  Q40 d56  .608 
I use a structured approach in my decision-
making  
Q1 d37  .591 
My decision-making is knowledge based  Q69 d73  .529 
I understand the importance of the decisions I 
make  
Q5 d39  .509 
My professional experience is important when 
having to make challenging decisions  
Q26 d49  
.484 
I generate a SWOT (strengths, weaknesses, 
opportunities, threats ) analysis in my decision-
making 
Q44 d59  
.482 
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Factor Analysis Final Output 
 The factor analysis and item reduction performed on the initial 76-item draft 
instrument resulted in the emergence of the following list of reduced items for the 
Organisation and Individual decision-making categories. 
 
Organisational Related Items (21-items):  
• My organisation’s decision-making is influenced by company politics 
• My organisation has suffered a negative outcome due to slow decision- making  
• In my organisation’s decision-making, it makes the same mistakes as made in the        
            past 
• My organisation’s decision-making is influenced by vested interest of individuals 
• My organisation’s culture has resulted in its inability to make a decision 
• My organisation continues with projects which should be terminated at an earlier         
            stage 
• My organisation’s decision-making is influenced by competitors 
• My organisation’s decision-making is influenced by incentives or penalty  
            payments 
• My organisation underestimates problems which adversely impacts its own   
            decision-making 
• My organisation quantifies the probability of success in its decision- making 
• My organisation qualifies the probability of success in its decision-making 
• My organisation encourages innovative decision-making 
• My company uses a structured approach in its decision-making 
• My organisation effectively communicates the decisions it makes 
• My organisation provides clear and unambiguous instructions for decision-  
            making 
• My organisation evaluates the impact of the decisions it makes 
• My organisation’s decision-making approach is transparent 
• My organisation’s decision-making is consistent 
• My organisation is open to using better alternatives in its decision-making 
• My organisation re-examines its decision-making as new information becomes  
            available 
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• My organisation’s decision-making is influenced by external stakeholder’s  
            demands 
 
Individual Related Items (22-items): 
• My procrastination has resulted in a negative outcome  
• I have experienced “paralysis by analysis” caused by my slow decision- 
            making  
• Emotion is part of my decision-making  
• I have experienced a negative outcome by a decision not being made  
• In my decision-making, I make the same mistakes as made in the past  
• Recent or dramatic events  greatly impact my decision-making  
• My decision-making could be improved by assigning weights  
• I underestimate problems which adversely impact my decision-making  
• I continue with projects which should be terminated at an earlier stage  
• I feel that I could make better quality decisions  
• I quantify the probability of success in my decision-making  
• I qualify the probability of success in my decision-making  
• I understand the context of the decision I am being asked to make  
• I consider uncertainty and unknowns in my decision-making approach  
• I present contingencies or achievable options as part of my decision-making  
• My decision-making is consistent  
• My decision-making approach is transparent  
• I use a structured approach in my decision-making  
• My decision-making is knowledge based  
• I understand the importance of the decisions I make  
• My professional experience is important when having to make challenging  
            decisions 
• I generate a SWOT (strengths, weaknesses, opportunities, threats ) analysis in   
            my decision-making. 
 
Expert Team Review of The Themes that Emerged from The Qualitative Study 
It is appreciated that factor analysis is a complex procedure, which is exacerbated by 
the lack of inferential statistics and the imperfections of “real world” data and can be 
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prone to subjective biases such as during the “eyeballing” stage. To address this a 
panel of expert can be used to review and make judgement concerning the deletion 
and retention of specific items (Denzin and Lincoln, 2005). The research team 
reviewed the initial emergent source themes on Organisational (21) and Individual 
(22) related decision-making behaviour. It was decided to retain some of the 
removed items which were very highly prevalent in the qualitative study. The 
additions below were proposed by the team based on their own personal and expert 
professional perspective and also with cognisance of the output from the key-opinion 
leaders interviews discussed in Chapter 3. These additions were: 
 
Organisational related item additions: 
 My organisation considers uncertainties in relation to decision-making 
 My organisation provides training in the science of decision-making 
Individual related item additions: 
 I receive training in the science of decision-making 
 I use intuition or “gut-feeling” in my decision-making 
 
The outcome of the final factor analysis and the thorough review performed by the 
research team was the delivery of the 47-item QoDOS (Version 3) instrument. The 
instrument comprised of two domains; one for organisational level decision-making 
consisting of 23 items and individual level approaches consisting of 24 items. 
Subsequently each component was grouped into two separate domains representing 
the approach, culture, competence and decision-making style.  
 
Overall, the factor analysis performed allowed for the organisation and individual 
influence items contained within the final instrument to be allocated to one of four 
categories, two relating to the organisation and two relating to the individual:  
 
• Organisational level influences - decision-making approach 
• Organisational level influences - decision-making culture 
• Individual level influences - decision-making competence 
• Individual level influences - decision-making style 
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The complete set of organisational related items and individual related items have 
been incorporated into the QoDOS instrument (Version 3) presented in Appendix V. 
This was tested for final validation which will be reported in Chapter 6. 
 
DISCUSSION 
There were two distinct but linked component stages in the factor analysis performed 
on the 76-item QoDOS (Version 2). The first stage involved the instrument being 
sent using Survey Monkey to over 600 potential research participants. A total of 120 
evaluable individuals participated in this stage of the research and completed the 
developmental QoDOS questionnaire as requested. The research participants 
comprised of individuals from international regulatory agencies, international 
pharmaceutical companies and CROs (and two from Academia).  
 
The timeframe for completion of the questionnaire was a defined four months over 
the summer period and this may have had an influence on the low response rate of 
20%. Several measures reported in the literature (and introduced in Chapter 2) to 
boost response rates were employed including follow-up requests to complete, phone 
contacts and some personal one-to-one interactions (Diem, 2002b; Boynton, 2004; 
Survey Monkey, 2013). Factors other than the summer test period that might have  
influenced the low response rate could have included: the length of the questionnaire 
(76 items and perceived time-sacrifice burden), corporate position not allowing for 
surveys to be completed (as reported by several persons), potential participant apathy 
to the survey and to the research area and other contributory factors which are not 
easy to qualify or to quantify. However, the resultant data from the 120 person 
research sample provided a rich and valuable platform for developing insights into 
the decision-making practices of the individuals and the organisations who 
participated in the research. A wealth of resultant information was generated and this 
allowed several comparative reviews of perspective from that of the individual and 
the organisation.  
 
The Survey Monkey and the SPSS statistical functionality allowed for a large 
amount of quantitative findings to be generated. Quantitative feedback results were 
generated for each of the three main organisations (Regulatory Agencies, 
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Pharmaceutical Companies and CROs) active in the research. The data provided 
insight into the variance in distribution of results to the 76-item question obtained 
from the three organisations. The results provided preliminary insight of differing 
construct dimensions of the decision-making perspective of the organisations 
compared with that of the individual. For Organisations, the Modus Operandi, the 
working environment and the shared beliefs and values of that organisation appeared 
to be important influences. For the Individual, the subjective elements of: 
professional experience, ability, empowerment or autonomy and preference appeared 
to be latent decision-making dimensions.  
  
From the perspectives of the individual it was evident that people felt that they could 
make better decisions and that an investment in training and education in decision-
making would benefit them and their decision-making. There was a lack or routine 
usage of decision-making tools such as SWOTs and limited experience of modelling 
and simulation. Other perspectives that emerged were that the individual felt that 
they were more accountable for their decisions than the organisation was at the 
organisational level. People firmly believed that professional experience was a key 
component that influenced decision-making. The results also showed the importance 
of clearly understanding the context of the decision. In total, the individual’s 
perspective was obtained in response to 41 specific questions on their decision-
making style, approach and factors that impact them.  
 
Similarly, insights were gained from the 120 person sample on the decision-making 
perspective of the organisation. Thirty-five specific questions on organisational 
decision-making were responded to and yielded insights into the factors including: 
the culture of the organisation, the lack of training in decision-making being 
provided within organisations, the internal and external competitor influences, 
performing an impact analysis of decisions made, re-evaluating a decision on the 
basis of new data becoming available and transparency within the decision-making 
process.  A variance in the distribution of the response profiles to the individual and 
organisational focused questions was evident across the three organisations involved 
in the research. The ‘Box and Whisker’ plot results give an interpretable visualisation 
of this variance and also indicated that the pharmaceutical cohort had a wider range 
of “outliers”. This may be linked to the decision-making competence or style 
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approach of some individuals employed in this cohort on items such as use of “gut 
feeling /intuition” and the more competitive environment in which many decisions 
need to be made.  These decision-making drivers will be further explored through the 
development of the developmental instrument. The research was enriching in several 
ways in that it not only successfully investigated the research aim, but it also allowed 
for an enabling, enriching and synergistic networking within the medicinal product 
development community. 
 
The second distinct component stage of this chapter was that relating to the factor 
analysis performed on the original 76-item developmental instrument.  Factor 
analysis was attempted on the 76-item QoDOS (Version 2) containing the combined 
organisational and individual item variables. Although the Cronbach’s alpha result 
obtained (0.861) inferred good reliability (Pallant, 2005), the KMO measure of the 
adequacy value of 0.553 obtained inferred that the sample size was “mediocre” in 
nature. The “mediocre” KMO did not improve much as part of further reiterations 
attempts. This mediocre KMO results were reflective of the challenge of the sample 
size versus the number of items in the developmental instrument. The issue with the 
low KMO results and with failure to achieve successful extractions and item 
reductions, factor analysis and robust statistical analysis on the QoDOS (Version 2) 
appeared to be related to the research sample size data available for the analysis 
(n=120) versus the number of items (76) in the instrument. The 120 sample size was 
apparently too small for the 76 target items and a sample size in the magnitude of 
n=760 (in line with the 10:1 ratio detailed earlier) or potentially n=380 (on a 5:1 
ratio) might have been sufficient to allow successful item extraction (Tabachnick and 
Fidell, 2001). However, the implications of aiming for an n=760 sample size would 
have required, in theory, making contact with 1,500 - 3,800 individuals on the 
premise of a 20% participation rate.  This ideal sample size requirement was 
recognised as being prohibitive and the approach to split the 76-item into two 
separate blocks of 35 (Organisational related items) and 41 (Individual related items) 
seemed a plausible solution. The two blocks were given the coding nomenclature 
related to Organisational level issues Individual level issues. This resulted in the two 
blocks of Organisational and Individual related issues being mapped, analysed and 
presented. This approach of splitting the 76 items into the two component blocks was 
deemed pragmatic and valid.  
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The outcome of the factor-analysis and review was the extraction and reduction of 
items in both groups. Organisational items were reduced from 35 to 23 and the 
reduction of individual items from 41 to 24. The organisational and the Individual 
related domains (n=24) were categorised into two sub-category dimensions. For the 
Organisational items:“Decision-making approach” and “Decision-making culture” 
and “Decision-making competence” and “Decision-making style” for the individual 
items. These subcategory headings appeared to be the influences and behaviours that 
emerged from the questionnaire results and endorsed by the qualitative interviews 
conducted with the Key Opinion Leaders and reported previously. These four 
construct dimensions are deemed acceptable in terms of generalisability and 
applicability to a wider population outside the sample pool directly involved in this 
research. 
 
The resultant outcome of the factor-analysis was the delivery of the final version of 
the QoDOS instrument (Version 3) capturing organisational and individual decision-
making items grouped into two separate construct variable domains representing the 
approach, culture, competence and decision-making style. The factor-analysis was 
discriminatory in that different factor loadings were observed for the latent variables 
which also provided supportive evidence of construct validity.  The reassurance on 
the validity of the four construct domains identified was also supported from the 
complimentary results of the KOL interviews conducted.  In essence, the goal of 
conducting the KOL interviews was to identify the key aspects (or attributes) of the 
construct domain (MacKenzie et al., 2011). Greater discussion on the construct 
validation investigation will be presented in the discussion section of Chapter 6. 
 
The 47-item QoDOS instrument has been developed using a step-wise and 
systematic scientific approach. Statistical validity and integrity were paramount in 
the instrument development. The research approach comprised qualitative and 
quantitative components which have been described in detail and which resulted in 
the duly validated instrument that is now available for final stage psychometric 
evaluation. 
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SUMMARY 
• The post content validation evaluation QoDOS (Version 2) containing 76 
decision-making items was used in this stage of the research. The QoDOS 
(Version 2) contained questions relating to the decision-making approach 
employed by “Organisations” (Regulatory Agencies and Pharmaceutical 
Industry) and that used by the “Individual” in the organisations 
• One hundred and twenty experienced decision-makers from regulatory 
agencies, pharmaceutical companies, CROs and Academia (n=2) completed 
the QoDOS (Version 2) decision-making electronic questionnaire  
• The Survey Monkey package was used in the issuance of the surveys, 
collection and management of the results  which provided comparative 
insights into decision-making at an Individual and an Organisational level  
• The statistical analyses results inferred the presence of differing construct 
dimensions between the decision-making approaches used by Organisations 
versus that used by Individuals 
• Comparative insights were obtained on the decision-making approaches and 
influenced of organisations. 
•  Comparative insights were obtained on the variance of decision-making 
within the Regulatory Agency, Pharmaceutical Companies and CROs 
• Insights were gained into the decision-making approaches and influences of 
individuals 
• Potential gaps in the education and training and development needs of 
individuals and organisations were identified 
• A detailed quantitative response analysis was generated for each of the 76-
item questions contained within the developmental questionnaire 
• Factor analysis  investigation was performed on the 76-item QoDOS (Version 
2) developmental instrument  
• Successful factor analysis and item reduction was performed on the 35 
organisational items leading to a reduced set of 23 variables 
• Successful factor analysis and item reduction was performed on the 41 
individual items leading to a reduced data set of 24 variables 
• Four additional items (two organisational and two individual) from the 
original 76-items were re-instated to post-factor analysis items listings  
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• Two behavioural domain constructs were identified for the Organisational 
items and these related to decision-making approach and culture 
• Two behavioural domain constructs were identified for the Individual items 
and these related to decision-making style and competence 
• The 47-item QoDOS instrument was established. 
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CHAPTER 6 
 
 
 
Reliability and Construct Validation of QoDOS 
and  
Hallmarks of Good Decision-Making Practice 
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INTRODUCTION  
The factor analysis performed on the QoDOS developmental instrument was 
predicated on the belief that a battery of decision-making item tests could be 
described in terms of a smaller number of underlying factors. The underlying 
decision-making constructs caused a number of observable manifestations, which are 
captured within the QoDOS items. The construct domain dimensions revealed by the 
factor analysis were not directly observable from the data but rather were inferred 
from the patterns within the results that emerged.  As a result, the 47-item QoDOS 
instrument yielded 4 construct domains, two relating to the organisation (Approach 
and Culture) and two to the individual (Competence and Style). 
 
The next stage, after factor analysis was the testing, assessment and establishment of 
the reliability and construct validation of the 47-item QoDOS instrument using 
statistical analyses. The reliability and construct validity testing was done using 78 
individuals from regulatory agencies and the pharmaceutical healthcare arena. 
Statistical analyses formed the basis of the construct validation and assessed the 
correlations between the QoDOS construct domains (latent variables). The data 
provided extra quantitative insights into the decision-making approaches from the 
perspective of the individual and the organisations in the cohort and was 
complimentary to the additional research sample results detailed in Chapter 5.  
 
Following the conduct of the assessment of construct validity and reliability, research 
was conducted into the identification and qualification of the Hallmarks of good 
decision-making practice. 
 
METHODS 
The final 47-item version of the QoDOS instrument contained 23 organisational and 
24 individual items and was tested for reliability and construct validity. The QoDOS 
instrument was sent to the study participants using the Survey Monkey online 
questionnaire survey tool as described previously in Chapter 2. Each prospective 
participant was provided with background information on the research project and 
given assurance on the confidentiality on all research related matters.  
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The 78 respondents provided their answers to each of the 47-item questions using a 
Likert 5-response option scale. Both the Survey Monkey functionality and Excel 
were used in the quantitative analysis of this component of the research. An Excel 
database was employed to capture the data returns from each of the research 
participants. The functionality of the Excel database facilitated the data management 
and interpretation of the results. The combined Survey Monkey and Excel 
functionality also allowed the generation of information in various result formats.  
The data were also analysed using the SPSS version 20 to examine the reliability and 
construct validity of the QoDOS.  The reliability and construct validity were tested 
using standard statistical techniques including the Principal Component Analysis 
(PCA), Cronbach’s alpha, Split-Half, Parallel and Gutmann testing for reliability 
accompanied by ICC coefficient and Spearman’s 2-tailed correlation statistics. KMO 
and Bartlett’s Sphericity testing and correlation statistics were also performed. A 
Multi-Trait Multi-Method (MTMM) table was generated capturing comparative 
statistical methodologies and results obtained in this reliability and validity 
examination stage. Excel was used to compute some of the quantitative output and 
generation of graphical outputs.  
 
An extra research arm exercise was conducted to identify the “Hallmarks of good 
decision-making practice”. This involved ranking a set of ten decision-making items 
in order of perceived preference. The hallmarks questionnaire was presented as an 
addendum to the QoDOS instrument questionnaire and was completed by a research 
sample of 78 senior decision-makers from regulatory agencies and the 
pharmaceutical and healthcare area.   
 
RESULTS 
The results obtained from the research sample provided comparative quantitative 
information on the decision-making approaches and influences from the perspective 
of the organisation and the individual. The results presented evidence to support the 
successful construct validation of the instrument and the underlying dimensions. The 
construct validation results are presented for the composite 23-item organisational 
and the 24-item individual decision-making scales followed by the results for each of 
the two latent sub-components contained within each scale. The results are presented 
135 
 
in two sections that relate to the Construct validation (n=78 representing a 100% 
response rate) and to the hallmarks of good decision-making practices (n=78 
representing a 100% response rate). 
Organisational Level Influences: The 23 organisational items, which comprised the 
two organisational level decision-making influence dimensions namely Approach 
and Culture were tested for construct validity (Table 6.1). The statistical results for 
the Cronbach’s alpha, KMO and Bartlett’s test for the 23-item organisational level 
influences in the two constructs were determined. The Cronbach’s alpha level, 
indicative of reliability calculated for the 23 item instrument constructs was 0.746 
which was acceptable/good. The KMO value of 0.794 was also acceptable. The 
Bartlett’s test of Sphericity was 231 and the ICC was 0.746 (good). These results 
demonstrated adequate sample size for the analysis and good reliability from the 
Cronbach’s alpha and ICC results obtained. 
Table 6.1: Organisational level influences 
Organisational Decision-Making 
Approach  Dimension (12 items) 
Organisational Decision-Making 
Culture  Dimension  (11 items) 
1. My organisation evaluates the impact of 
the decisions it makes 
2. My organisation’s decision-making 
approach is transparent 
3. My organisation’s decision-making is 
consistent 
4. My company uses a structured approach 
in its decision-making 
5. My organisation’s decision-making is 
influenced by external stakeholder’s 
demands 
6. My organisation qualifies the probability 
of success in its decision-making 
7. My organisation quantifies the 
probability of success in its decision-
making 
8. My organisation is open to using better 
alternatives in its decision-making 
9. My organisation encourages innovative 
decision-making 
10. My organisation considers uncertainties 
in relation to its decision-making 
11. My organisation provides training in the 
science of decision-making 
12. My organisation re-examines its 
decision-making as new information 
becomes available 
1 My organisation’s decision-making is 
influenced by company politics 
2 My organisation has suffered a negative 
outcome due to slow decision-making 
3 My organisation’s culture has resulted in its 
inability to make a decision. 
4 In my organisation’s decision-making, it 
makes the same mistakes as made in the past       
5 My organisation’s decision-making is 
influenced by the vested interest of 
individuals 
6 My organisation underestimates problems 
which adversely impacts its own decision-
making 
7 My organisation continues with projects 
which should be terminated at an earlier  stage      
8 My organisation’s decision-making is 
influenced by competitors 
9 My organisation’s decision-making is 
influenced by incentives or penalty  payments 
10 My organisation effectively communicates the 
decisions it makes 
11 My organisation provides clear and 
unambiguous instructions for decision- 
making 
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Organisational Level Influence Items: Decision-Making Approach Construct  
Descriptive statistics, reliability testing and correlation testing on the 12 items in the 
organisational decision-making construct were performed. A tabular summary of the 
reliability and correlation testing on the 12 items is presented in Table 6.2.  
 
The Cronbach’s alpha level indicative of reliability, calculated for the 12 item 
construct was 0.731 (0.749 based on standardised items) which was “good”. The 
KMO value of 0.726 was also acceptable / “strong” result. The Bartlett’s test result 
was 55. The average ICC was 0.790. These results demonstrated adequate sample 
size for the analysis and good reliability from Cronbach’s alpha, the other reliability 
tests and ICC results obtained. 
Table 6.2: Summary results for the statistical testing performed on the 12 
organisational approach items 
Reliability 
Assessment (r) 
 
Intraclass Correlation 
Coefficient (ICC) 
KMO 
(Sampling 
Adequacy) 
Spearman’s 2-tailed 
correlation 
Cronbach’s α: 0.821 
(0.786 std) 
 
0.790 (avg. measure 95% 
CI p=.0001) 
0.754 YES 
Split-half: 0.734 / 
0.51 
0.790 (avg. measure 95% 
CI p=.0001) 
 
  
Parallel: 0.790 
(0.794 unbiased) 
0.790 (avg. measure 95% 
CI p=.0001) 
 
  
Guttman Split-Half 
Coefficient 
0.773 
0.790    
 
The nonparametric Spearman’s correlation matrix generated for the 12 organisational 
approach variables is presented in Table 6.3. The data demonstrated the inter-
correlation relationship of each of the items (positive and negative as testing was 
performed using a 2-tailed test). The results showed the statistical associations 
between any two of the variables.  The V1-V12 items are as numbered in Table 6.1. 
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Table 6.3: Spearman’s correlation inter-item correlation matrix for 12 organisational approach items 
  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 
V1 My organisation evaluates the impact of the decisions it 
makes 
1.00            
V2.My organisation’s decision-making approach is transparent 0.209* 1.00           
V3 My organisation’s decision-making is consistent 0.125 0.13 1.00          
V4 My company uses a structured approach in its decision-
making 
0.057 0.11 -.117 1.00         
V5 My organisation’s decision-making is influenced by external 
stakeholder’s demands 
0.188 .137 .042 0.45 1.00        
V6 My organisation qualifies the probability of success in its 
decision- making 
0.134 0.155 0.131 0.162 0.185 1.00       
V7 My organisation quantifies the probability of success in its 
decision-making 
0.175 0.134 0.177 .058 0.153 0.644 1.00      
V8 My organisation is open to using better alternatives in its 
decision-making 
0.254** 0.450** 0.006 .02** .252** 0.106 .139 1.00     
V9 My organisation encourages innovative decision-making 0.211** 0.351** -.052 -.026 .120** -.163 0.046* 0.336 1.00    
V10 My organisation considers uncertainties in relation to its 
decision-making 
0.219* 0.290** -.044 -.002 .194** 0.335 0.281* 0.216** 0.311 1.00   
V11 My organisation provides training in the science of 
decision-making 
0.211* 0.061* 0.54 -.092 0.205 0.275 0.331* 0.184 0.062 0.392 1.00  
V12 My organisation re-examines its decision-making as new 
information becomes available 
0.223* 0.255** -.157 .098 .157** 0.181 0.061* 0.322** 0.322** 0.310 0.157 1.00 
*  Correlation is significant at the 0.01 level    ** Correlation is significant at the 0.05 level 
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Organisational Level Influence Item: Decision-Making Culture Construct Results 
Descriptive statistics, reliability testing and correlation testing were performed on the 11 
items in the organisational decision-making approach construct. A tabular summary of 
the reliability and correlation testing and results on the 11 items are presented in Table 
6.4. 
  
The Cronbach’s alpha level indicative of reliability was calculated for the 11 
organisational culture construct was 0.741 (and 0.719 based on standardised items) 
which was “good”. The KMO value of 0.846 was also acceptable / “very strong” result. 
The Bartlett’s test result was 55 and the average ICC 0.743.  These results demonstrated 
adequate sample size for the analysis and good reliability from Cronbach’s alpha, the 
other reliability tests and ICC results obtained. 
 
Table 6.4: Summary results for the statistical testing performed on the 11 “culture” items 
Reliability 
Assessment (r) 
 
Intraclass Correlation 
Coefficient (ICC) 
KMO (Sampling 
Adequacy) 
Spearman’s 2-
tailed correlation 
 
Cronbach’s α: 
0.743 (0.719 std) 
0.743 (avg. measure 95% CI 
p=.0001) 
0.846 YES 
 
Split-half: 0.802 / 0.06 
 
0.743 (avg. measure 95% CI 
p=.0001) 
  
 
Parallel: 0.743 
(0.748 unbiased) 
 
0.731 (avg. measure 95% CI 
p=.0001) 
 
  
 
Guttman Split Half 
Coefficient 
0.469 
   
 
The nonparametric Spearman’s correlation matrix generated for the 11 organisational 
construct variables is presented in Table 6.5. The data demonstrated the inter-correlation 
relationship of each of the items (positive and negative as testing was performed using a 
2 tailed test). The results showed the statistical associations between any two of the 
variables. The V1-V11 items are as numbered in Table 6.1.
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Table 6.5: Spearman’s correlation inter-item correlation matrix for 11 organisational culture items 
  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 
V1 : My organisation’s decision-making is influenced 
by company politics 
1           
 
V2: My organisation has suffered a negative outcome 
due to slow decision-making 
.537 1          
V3: My organisation’s culture has resulted in its 
inability to make a decision. 
.296** .446 1         
V4: In my organisation’s decision-making, it makes  
the same mistakes as made in the past 
.266* .279** .271 1        
V5 My organisation’s decision-making is influenced 
by vested interest of individuals 
.291** .197** .293** .653** 1       
V6 My organisation underestimates problems which 
adversely impacts its own decision-making 
.395** .320* .287 .321 .202* 1      
V7 My organisation continues with projects which 
should be terminated at an earlier  stage      
.307 .281** .202 .379 .286** .566** 1     
V8 My organisation’s decision-making is influenced 
by competitors 
.324** .422** .207 .324** .277** .413* .507** 1    
V9 My organisation’s decision-making is influenced 
by incentives or penalty  payments 
.309** .330** .202 .312** .196** .520* .449** .513** 1   
V10 My organisation effectively communicates the 
decisions it makes 
-.24** -.41** -.211 .288** .005** -.197* .073** .161** -.118 1  
V11:My organisation provides clear and unambiguous 
 instructions for decision-making 
.378 .154 .202 .392 .482 .353* .284 .309 .301 .232 1 
*  Correlation is significant at the 0.01 level    ** Correlation is significant at the 0.05 level 
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Individual Level Influences Results 
The two individual level decision-making influence dimensions which were reported 
post factor-analysis were tested for construct validity (Table 6.6). 
 
The statistical results for Cronbach’s alpha, KMO and Bartlett’s test for the 24 item 
individual level influences in the two constructs were determined: the Cronbach’s 
alpha calculated for the 24 item instrument constructs was 0.785 which was “good”. 
The KMO value of 0.751 was also acceptable. The Bartlett’s test was 276. The 
average measure ICC was 0.785. These results demonstrated adequate sample size 
for the analysis and good reliability from the Cronbach’s alpha and ICC results 
obtained. 
Table 6.6: Individual level influences 
Individual Decision-Making 
Competence Dimension (14 items) 
Individual Decision-Making 
Style Dimension (10 items) 
1. I quantify the probability of success in my 
decision-making  
2. I qualify the probability of success in my 
decision-making  
3. I understand the context of the decision I 
am being asked to make  
4. I consider uncertainty and unknowns in my 
decision-making approach  
5. I present contingencies or achievable 
options as part of my decision-making  
6. My decision-making is consistent  
7. My decision-making approach is 
transparent  
8. I use a structured approach in my decision-
making  
9. My decision-making is knowledge based 
10. I understand the importance of the 
decisions I make  
11. My professional experience is important 
when having to make challenging 
decisions.  
12. I generate a SWOT (strengths, weaknesses, 
opportunities, threats ) analysis in  my 
decision-making 
13. I receive training in the science of 
decision-making 
14. I use intuition or “gut-feeling” in my 
decision-making 
1. My procrastination has resulted in a 
negative outcome  
2. I have experienced “paralysis by 
analysis” caused by my slow decision-
making  
3. Emotion is part of my decision-making  
4. I have experienced a negative outcome 
by a decision not being made  
5. In my decision-making, I make the same 
mistakes as made in the past  
6. Recent or dramatic events  greatly 
impact my decision-making  
7. My decision-making could be improved 
by assigning weights  
8. I underestimate problems which 
adversely impact my decision-making  
9. I continue with projects which should be 
terminated at an earlier stage  
10. I feel that I could make better quality 
decisions 
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Individual Level Influence Item: Decision-Making Competence Construct  
Descriptive statistics, reliability testing and correlation testing on the 14 items in the 
individual decision-making competence construct were performed. A tabular 
summary of the reliability and correlation testing performed on the 14 items is 
presented in Table 6.7. 
 
The Cronbach’s alpha level, for the 14 item construct was 0.731 (and 0.749 based on 
standardised items) which was “good”. The KMO value of 0.726 was also an 
acceptable/good result. The Bartlett’s test result was 55. The average ICC was 0.743 
(good). These results demonstrated adequate sample size for the analysis and good 
reliability from Cronbach’s alpha, the other reliability tests and ICC results obtained. 
Table 6.7: Summary results for the statistical testing performed on the 14 
“competence” items 
Reliability 
Assessment (r) 
 
Intraclass Correlation 
Coefficient (ICC) 
KMO (Sampling 
Adequacy) 
Spearman’s 2-tailed 
correlation 
Cronbach’s α: 
0.731 (0.749 
std) 
0.731 (avg. measure 95% CI 
p=.0001) 
 
0.726 YES 
Split-half: 0.517 
/ 0.739 
0.731 (avg. measure 95% CI 
p=.0001) 
 
  
Parallel: 0.731 
(unbiased .736) 
0.731 (avg. measure 95% CI 
p=.0001) 
 
  
 
The nonparametric Spearman’s correlation matrix generated for the 14 individual 
decision-making influence variables is presented in Table 6.8. The data demonstrated 
the inter-correlation relationship for each of the items (positive and negative as 
testing was performed using a 2-tailed test). The results showed the statistical 
associations between any two of the variables.  The V1-V14 items are as numbered 
in Table 6.8. 
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Table 6.8: Spearman’s correlation inter-item correlation matrix for 14 individual competence items 
  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 
V1: I quantify the probability of success in my decision-making 1              
V2: I qualify the probability of success in my decision-making  .209* 1             
V3 I understand the context of the decision I am being asked to 
make  
-.125 .13 1            
V4 I consider uncertainty and unknowns in my decision-making 
approach  
.057 .11 .117 1           
V5: I present contingencies or achievable options as part of my 
decision-making  
.188* .137 ,042 .045* 1          
V6 My decision-making is consistent  .134 .155 .131 .162 .185 1         
V7: My decision-making approach is transparent  .175 .134 .177 .058 .153 .644 1        
V8: I use a structured approach in my decision-making  .254** -.450** .006 ,020** .252** .106 .139** 1       
V9: My decision-making is knowledge based .211* -.351** -0.52 -.026* .120** -.163 .046* .336** 1      
V10 I understand the importance of the decisions I make  .219* .290** -.044 -.020* .194** -.335 .281* .216** .311 1     
V11 My professional experience is important when having to 
make challenging decisions.  
.211* .061 .054 .092* .205 .275 .331* .184 .062 .392* 1    
V12 I generate a SWOT (strengths, weaknesses, opportunities, 
threats ) analysis in  my decision-making 
.223* .255** -.157 .098* .157** .181 .061* .322** -.323 .310* .157 1   
V13 I receive training in the science of decision-making .154 .280* .262* -.222 .118* .114 .81 .371* .350 .382 .103* .225 1  
V14: I use intuition or “gut-feeling” in my decision-making .323* .258 -.085 .005* .144 .158 .107* .334 .196 .303* .187 .384 .257* 1 
*  Correlation is significant at the 0.01 level    ** Correlation is significant at the 0.05 level 
143 
 
Individual Level Influence Item: Decision-Making Style Construct Results 
The Cronbach’s alpha calculated for the ten item construct was 0.731 (and 0.749 
based on standardised items) which was “good”. The KMO value of 0.726 was also 
an acceptable/good result. The Bartlett’s test result was 55. The average ICC was 
0.743 (good). These results demonstrated adequate sample size for the analysis and 
good reliability and from Cronbach’s alpha, the other reliability tests and ICC results 
obtained. 
Table 6.9: Summary results for the statistical testing performed on the 10 items 
Reliability 
Assessment (r) 
Intraclass Correlation 
Coefficient (ICC) 
KMO (Sampling 
Adequacy) 
Spearman’s 2-
tailed correlation 
Cronbach’s α: 
0.822 (0.825 
std) 
 
0.822 (avg. measure 95% CI 
p=.0001) 
0.832 YES 
Split-half: 0.758 
/ 0.693 
 
0.822 (avg. measure 95% CI 
p=.0001) 
  
Parallel: 0.822 
(unbiased .825) 
 
0.822 (avg. measure 95% CI 
p=.0001) 
  
 
The nonparametric Spearman’s correlation matrix generated for the 10 individual 
style variables is presented in Table 6.9. The data demonstrated the inter-correlation 
relationship for each of the items (positive and negative as testing was performed 
using a 2-tailed test). The results showed the statistical associations between any two 
of the variables.  The V1-V10 items are as numbered in Table 6.10. 
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Table 6.10: Spearman’s correlation inter-item correlation matrix for the individual style items 
  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 
V1: My procrastination has resulted in a negative outcome  1          
V2 I have experienced “paralysis by analysis” caused by my 
slow decision-making  
.177 1         
V3 Emotion is part of my decision-making  .351** .363** 1        
V4 I have experienced a negative outcome by a decision not 
being made  
.350** .357** .680** 1       
V5 In my decision-making, I make the same mistakes as made 
in the past  
.226* .366** .477** .517* 1      
V6 Recent or dramatic events  greatly impact my decision-
making  
.178 .155 .311** .291* .235 1     
V7 My decision-making could be improved by assigning 
weights  
.126 .334** .382** ,364* .296** .335** 1    
V8: I underestimate problems which adversely impact my 
decision-making  
.254** .128 .380** .437** .290 .233** .346** 1   
V9: I continue with projects which should be terminated at an 
earlier stage  
.274** .141 .275** .212** .309 .471** .226** .227 1  
V10: I feel that I could make better quality decisions .332** .311** .383** .424** .410** .312** .305** .314** .416** 1 
*  Correlation is significant at the 0.01 level    ** Correlation is significant at the 0.05 level 
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The MTMM matrix is an established technique for looking at convergent and 
discriminant validation simultaneously (Streiner and Norman, 2008; Trochim, 2006). 
The matrix facilitates the interpretation of construct results and presents the pattern of 
observation results across the constructs tested using the different statistical 
methodologies employed. The MTMM matrix generated from the different statistical 
test methods used in the QoDOS construct validation is presented in Table 6.11. The 
matrix pattern demonstrates the convergent nature of construct results obtained with 
high values for Cronbach’s alpha and ICC reliability of the individual measures across 
all four constructs using the “homotrait–hetromethod” correlations. The matrix 
graphically demonstrates that the internal consistency measured by Cronbach’s α was > 
0.73 for all the four construct scales. The ICC was also >0.73 for all four constructs. In 
addition, the discriminatory nature of the testing is evident from the low correlation 
results across the inter-item correlations throughout the four different constructs.  
Table 6.11: Multi-Trait Multi-Method for QoDOS construct validity 
 ODMA ODMC IDMC IDMS 
Cronbach’s α 0.786    
ICC 0.790 0.743   
Parallel reliability 0.793 0.743 0.731  
Inter-item Covariances 
(mean) 
0.284 0.743 0.731 0.822 
Inter-item correlations (mean) 0.250 0.253 0.731 0.832 
Spearman-Brown Coefficient 
(Split-half) 
0.65 (equal) 
0.79 (unequal) 
0.189 0.132 0.822 
  0.62 (equal) 
0.62 (unequal)  
0.176 0.279 
   0.58 (equal) 
0.58(equal) 
0.320 
    0.76 (equal) 
0.76 (unequal) 
 
ODMA = Organisational decision-making approach, ODMC = Organisational decision-   making culture 
IDMC = Individual decision-making competence                 IDMS = Individual decision-making style 
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Additional evidence of validity was demonstrated graphically from of Box-and-Whisker 
profiles generated as part of the quantitative analyses.  
 
Quantitative Results: Organisation and Individual Related Item Responses 
The data from the 78-person research sample provided quantitative insights into the 
decision-making approaches from the perspective of the individual and the organisations 
and was complimentary to the 120 person research sample results detailed in Chapter 5.  
The results allowed a quantification of the Likert scale ratings for each questionnaire 
item. In addition, it was possible to separate the composite results into two distinct 
categories: those responses which were answered from the Organisational perspective 
and those which were responded to from the perspective of the Individual.   
 
The results provided insight of differing construct dimensions between decision-making 
influences and behaviours for Organisations and that of Individuals. The results also 
showed the discriminatory nature of the organisational and individual findings.  Using a 
‘Box-and-Whisker’ plot technique, a graphical comparison of the results for each of the 
four constructs was generated. The plot graphically describes the shape and 
characteristics of the distribution of the data from the QoDOS component construct 
analyses. The length of the box corresponds to the interquartile range (IQR) which is the 
difference (measure of dispersion) between the 75% and 25% percentile. The plot shows 
the range in distribution of responses for each construct. The median line (green/purple 
interface) describes the central tendency of the scores. The differing distribution of the 
results for each of the four constructs is shown in the Box-and-Whisker plot presented in 
Figure 6.1.  The plot also allows for the organisational decision-making approach 
(ODMA) to be compared with the organisation decision-making-culture (ODMC) and 
for the Individual decision-making competence (IDMC) to be compared with Individual 
decision-making style (IDMS). In the plot of the QoDOS constructs, the length of the 
box tells us the spread or variability of the results for each of the four constructs. The 
range of results is shown by the length of the whiskers. The results show that the ODMS 
presents a symmetrical distribution within the IQR. For the ODMA, IDMC and IDMS 
results, there is a non-symmetrical distribution and the medians are not in the centre of 
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the IQR boxes. These indicate the ‘skewness’ of the results. The IDMS results with a 
median that is closer to the bottom of the box than the top, demonstrates ‘positively 
skewed’ data. For The ODMA and the IDMC, the median is closer to the top and shows 
“negatively skewed” data.  
Figure 6.1: Box-and-Whisker plot of QoDOS construct result loadings’ 
distribution 
 
 
The Box-and-Whisker comparisons of the four plots indicate the range and spread and 
discriminatory patterns of results for each of the constructs. 
 
The construct investigation results of the 78-person research sample provided further 
insight into the decision-making approach, behaviours and influences from the 
perspective of the individual and their organisation. In addition, to the analyses 
performed on the composite sample, each component item of the questionnaire for 23 
organisational items and the 24 individual items was analysed. A selection of four of the 
organisational item response results and four individual related item response results are 
presented in Figures 6.2 - 6.9 respectively.  
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The results obtained infer that a structured approach to decision-making is not used 
routinely in 37 % (not at all /sometimes) of decision-making exercises (Figure 6.2). This 
37% level and especially the 12% ‘not at all’ is surprising and infers that there is the 
potential for improvement in the organisational decision-making and promotion of a 
systematic or framework approach for quality decision-making. 
Figure: 6.2: My organisation uses a structured approach in its decision-making 
 
 
 
Figure 6.3: My organisation quantifies the probability of success in its decision-making 
 
 
 
The strategy of trying to quantify the probability of success (Figure 6.3) appears to be 
the routine approach in only about 5% of situations and is performed in around 45% of 
other situations on a “ frequently/often”  basis and ‘not at all’ in 11% of cases. This 
result is something of an enigma as it infers that decision-makers are not trying to 
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quantify either the probability of success or by inference the probability of failure and 
associated risk factors. The results could be interpreted as indicating a naivety of both 
good business and decision-making. If the 12% cohort is not taking success probability 
into account then it is unlikely that they are considering additional factors both internal 
and external that could influence or impact the decision. The use of a systematic 
approach in this 11% cohort is questionable. 
 
It would appear that re-examination of decision-making as new information is received 
(Figure 6.4) only on occurs a “sometimes” basis around 38% and may not occur in some 
rare exceptions (<5%). The results could infer that re-evaluation is occurring on a 
routine basis (often/always) in at least 35% of cases but also means there is room for an 
improved approach.  
Figure 6.4: My organisation re-examines its decision-making as new information becomes 
available 
 
 
The culture of the organisation was seen to be an influencing factor in decision-making 
with only 27% of responses indicating that the culture did not impact at all in its ability 
to make a decision (Figure 6.5). These results imply that the culture of the organisation 
is a key decision-driver. 
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Figure 6.5: My organisation’s culture has resulted in its inability to make a decision 
 
 
 
In regard to the potential to make better quality decision, almost 95% of the response 
indicated that individuals felt that their decision-making could be improved (Figure 6.6).  
Figure 6.6: I feel that I could make better quality decisions 
 
 
The results on the use of intuition or “gut-feeling” showed that its usage is quite 
common and that less than 10% of individuals would appear not to use it in their 
decision-making approach (Figure 6.7). This is an interesting result when one considers 
again the evidence-driven environment of medicines development, although it could be 
argued that intuition is taking evidence based outcomes into account implicitly.   
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Figure 6.7: I use intuition or “gut-feeling” in my decision-making 
 
More than 35% of study participants indicated that they had not received any training 
in the science of decision-making (Figure 6.8). Only 15% of persons advise that they 
received training on an “often” (regular) basis (Figure 6.8). This is an interesting and 
disappointing finding when one considers the increased industry and agency support 
for a more structured approach to decision-making and the availability and usage of 
qualitative and quantitative decision-making tools. 
Figure 6.8: I receive training in the science of decision-making 
 
The well established technique of using a SWOT analysis in decision-making appears 
to be never considered by 12% of individuals. Another 35% only use the SWOT on a 
“sometimes” basis. This could infer that the individuals surveyed are not familiar with 
the SWOT tool and this might link to the results relating to the training offered and 
received (Figure 6.9). 
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Figure 6.9: I generate a SWOT analysis in my decision-making 
 
 
Organisation Versus Individual Analysis 
A comparative analysis of the decision-making approach of the Organisation versus that 
of the Individual was performed. The results were paired on the basis of 
positive/affirmative and negative responses received for each of the QoDOS questions. 
The results provided insights into the differing importance and approach of both groups. 
A sample of four comparisons is presented in Figures 6.10 – 6.13.  
 
The results indicate that a structured approach is employed more at an individual level 
(60%) than at the organisational level (35%) (Figure 6.10). 
Figure 6.10: Use of a structured approach is used in decision-making 
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In regard to quantifying the probability of success in decision-making, the results 
inferred that less quantification was performed by organisations as compared to the 
approach by persons at an individual level (Figure 6.11). This could relate to factors 
such as a person being more accountable at a micro-level for the decisions they make as 
compared to the organisation on a macro-level, or indeed, their perception of the 
situation. 
Figure 6:11:  Quantification of the probability of success in decision-making by the 
organisation and the individual 
 
The research into training in the science of decision-making showed that only 15% of 
individuals within the research sample had received training in ‘decision-making’ which 
was  similar to the percentage of organisations that had provided training in decision-
making (Figure 6.12). 
Figure 6.12: Training in the science of decision-making 
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Transparency in decision-making showed that there was more transparency in the 
approach of the organisation compared with that of the individual (Figure 6.13).  This 
could be as a result of the widespread usage of defined work practices and quality 
management systems, Standard Operating Procedures (SOPs), templates, decision-
analysis tools within many organisations. The results also infer that a high level of 
subjective non-structured approaches may be in use at the level of the individual. 
Figure 6.13: Transparency in decision-making approach 
 
 
The comparative analyses revealed that QoDOS was able to differentiate the decision-
making behaviours of organisations from that of the individual. It also provided 
additional insights into the weighting or relative importance of decision-making factors 
from the perspective of both groups.  
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Hallmarks of Good Decision-Making Practice 
The qualitative research into decision-making approaches of the individual and the 
organisation resulted in the identification of 19 main decision-making themes:  
 
1. Quality and validity of data  
2. Time considerations  
3. Organisational, hierarchical and cultural influences 
4. Analytical and logical approach 
5. Qualification and experience in previous decision-making 
6. Subjective and personal considerations 
7. Political, financial, competitor and reward influences 
8. Precedents for similar previous decisions 
9. Perpetuating previous decision-making mistakes  
10. Plunging in or procrastination with decision-making 
11. Clear understanding or lack of understanding of the decision in question  
12. Overconfidence in own judgement 
13. Group successes and group failures 
14. SWOT and alternate outcome planning in decision-making 
15. Impact analyses of decisions 
16. Decision-making audit trail 
17. Education and awareness of evolving decision-making techniques 
18. Individual versus Corporate decision-making 
19. Quantitative frameworks. 
 
It was hypothesised that the 19 emergent decision-making themes could also provide 
insight into the ‘Hallmarks of good decision-making’, so these 19 themes were reviewed 
and distilled into 10 good decision-making criteria. These were then mapped against the 
47-items in the final version of the QoDOS (Table 6.12). 
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Table 6.12: Mapping of the QoDOS items to the hallmarks of good decision-
making practice. 
Good decision-making practice hallmark QoDOS item number 
mapped to each hallmark 
1. Employ scientific rigour and understand the 
decision context 
30,31  
2. Apply knowledge and experience 6,9,11,24,27,33,35,37,47 
3. Examine the integrity of information for 
validation and confidence in the decision 
18 
4. Use an objective approach and maintain 
awareness of your biases and preferences  
36,38,39,43,45,46 
5. Consider uncertainty and examine alternative 
solutions 
8,10,26,28 
6. Assign values and relative importance to 
decision criteria 
7,34,44 
7. Re-evaluate as new information becomes 
available 
12 
8. Evaluate both internal and external influences 5,13,14,15, 17, 19, 20, 21,40,42 
9. Apply a structured approach to aid 
transparency and record trail 
2,3,4,16, 25,29,32,41 
10. Perform impact analysis and effectively 
communicate the basis of the decision 
1,22,23 
 
Validation of The Hallmarks 
In order to provide further validity to the list of ten hallmarks, the research sample of 78 
international senior industry and regulatory agency decision-makers were asked to rank 
the “relative importance” of the hallmarks.  They ranked the ten hallmarks in order of 
what they perceived were the most important hallmarks to the least important hallmarks 
on a scale of 1 to 10 (1 being the most important and 10 being the least important). They 
were provided with appropriate notice and background on the research aim of ranking 
the hallmarks and with assurance of confidentiality.  
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Ranking of The 10 Hallmarks of Good Decision-Making Practice  
The composite ranking order of the ten hallmarks was:  
 
 1st Employ scientific rigour and understand the decision context 
2nd Apply knowledge and experience 
3rd  Examine the integrity of information for validation and confidence in 
the decision 
4th  Apply a structured approach to aid transparency and record trail 
5th  Use an objective approach and maintain awareness of your biases and 
preferences 
6th  Re-evaluate as new information becomes available 
7th  Evaluate both internal and external influences 
8th  Assign values and relative importance to decision criteria 
9th  Perform impact analysis and effectively communicate the basis of the 
decision 
10th  Consider uncertainty and examine alternative solutions. 
 
The quantified results of the research were analysed and graphical presentations of the 
10 hallmarks rating placements generated. The two top-rated items represented the 
opinion of the majority of the research sample with regard to the need to employ 
scientific rigour and to understand the decision context (24%) with the need to apply 
one’s knowledge and experience (22%) in decision-making approach (Figures 6.14-
6.15). The results of the ranking exercise did not demonstrate any one wholly 
outstanding decision-making hallmark. 
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Figure 6.14: Employ scientific rigour and understand the decision context (Top rating) 
 
 
Figure 6.15: Apply knowledge and experience (2nd highest rating) 
 
 
 
Application of QoDOS: An immediate application of QoDOS and the emergent 
hallmarks of good decision-making is the ability to generate a profile of an individual’s 
decision-making approach. The 47 items in QoDOS have been mapped against the 10 
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hallmarks as presented in Table 6.12. An algorithm has been generated to apply 
weightings to each hallmark of good decision-making practice. Each hallmark 
component sub-theme has an associated weighting score range of 1-4 (1= sometimes, 
2=frequently, 3=often and 4=always). For each hallmark, a theoretical value for best 
practice approach on the basis that a good hallmark’s approach should be pursued all of 
the time. 
 
For any individual, their responses to the 47 items in the QoDOS instrument can be 
mapped to the hallmarks to present a profile of that person’s decision-making approach 
using the algorithm above. This approach allows for a person’s profile (for the day on 
which it was completed) to be generated from their actual response scores on a 
comparative scale. Their response score can be presented on an assessment scale 
showing theoretical optimum (maximum) and poor (minimum) profile results. This 
profiling allows for an individual to identify their normal approach to decision-making, 
their areas of strength in good decision-making practice and importantly, their areas 
warranting further attention and development. This profiling which is performed as a 
point in time assessment should allow an individual to monitor the changes in their 
decision-making approaches over time. An example of an actual profile for one of the 
participants in the research is presented in the spider plot in Figure 6.16.  
 
The algorithmic approach to profiling an individual’s decision-making technique using 
the QoDOS instrument is an easy to apply technique and should be generalisable outside 
of the research sample in which it has been developed. A simple spider-plot charting 
technique can be used to generate a profile of the decision-making responses, 
developmental areas and to provide a time-course record of the decision-making 
approach for a given individual. This graphical representation provides a focus for 
identification of gaps and issues to address in a person’s decision-making approach 
(Figure 6.16). 
 
The visualisation of an individual’s decision-making profile may also enable better 
communication of the profile and of its interpretation. Such visualisation techniques of 
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decision-making outcomes are actively being progressed and their importance is 
increasingly being recognised (IMI-EFPIA, 2013a; Walker, 2011).  
Figure 6.16: Decision-making profile of an individual 
 
 
 
DISCUSSION 
The QoDOS instrument underwent factor-analysis which yielded four main construct 
domains, two relating to organisation level influences i.e. organisational decision-
making approach (ODMA), organisational decision-making culture (ODMC); and two 
to individual level influences i.e. individual decision-making competence (IDMC) and 
individual level decision-making style (IDMS). The 47-instrument items were grouped 
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into one of the four domains and assessed for appropriate reliability and construct 
validity. 
 
Reliability and construct validity testing was performed on the QoDOS instrument and 
the four component constructs using statistical methodologies complimented by 
additional semi-quantitative techniques. For each of the four construct dimensions, 
reliability was tested and demonstrated using several reliability methods including 
Cronbach’s alpha and ICC testing. In all four construct investigations, reliability was 
shown to be above a Cronbach’s alpha of 0.73 and ICC of > 0.73 in a battery of tests.  
The consistency and reproducibility of the reliability finding across time as well as the 
different items and measurement methodologies used supported the assertion that 
appropriate reliability was observed.  The reliability, the internal consistency and the 
ICC of the measures observed were also indicative of the homogeneity of the 
component items that tapped into each of the four constructs.  
 
Construct validity testing is concerned with how well the results obtained from the use 
of a measure fit the theoretical foundations from which it is designed. Construct 
validation contains two validity sub-categories (convergent and discriminant validity). 
Convergent validity is the degree to which the concepts that should be related 
theoretically are interrelated in reality. Discriminant validity is the degree to which 
concepts should not be related theoretically and are in fact not interrelated in reality. It is 
recognised that the area of construct validation is in itself somewhat theoretical by its 
very nature as it involves a latent theoretical aspect of a measure. There are several 
challenges associated with construct validation of a new instrument. These include items 
such as: the somewhat ethereal definition of what “construct validation” relates to and 
how it is suitably demonstrated (Nunnally and Bernstein, 1994; MacKenzie et al., 2011). 
There is also the challenge that constructs may have more than one conceptually 
distinguishable aspect or sub-dimension which can in itself be confounding. If a 
construct is multidimensional, which was the case with the four QoDOS constructs,  
then it is  important to ensure that the sub-component characteristics are distinctive from 
each other (apart from their common theme). There are three major aspects of construct 
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validation: (1) specifying the correct domain of observables related to the construct; (2) 
determining the extent to which observables tend to measure the same thing from 
empirical research and statistical analyses;  (3) performing subsequent individual 
difference studies and / or experiments to determine  the extent to which supposed 
measures of the construct are consistent "best guesses" about the construct (Nunnally 
and Bernstein, 1994; Holstein, 2001). Overall, the multi-dimensional approach adopted 
in the construct validity evaluation and the triangulation of the complimentary and 
supportive validation techniques provided robust evidence of good construct validity of 
the QoDOS instrument.  
 
The development of QoDOS also facilitated the investigation into the hallmarks of good 
decision-making practice. It enabled the identification and rating of the hallmarks to be 
performed which in itself provided additional insights into the establishment of quality 
decision-making practice. The resultant top-three messages on best practice were: to use 
scientific rigour and ensure one understands the decision context; to apply one’s 
knowledge and experience; and to check the  integrity of the information provided on 
which to make a decision. However, it is also interesting that some items were 
considered to be markedly less important in the ranking order. The hallmarks which 
received the lowest rank ordering related to: performing an impact analysis; clear and 
effective communication of the decision;   considerations of uncertainty, unknowns and 
examination of alternative solutions or options.   
 
The hallmarks investigation included 78 senior decision-makers from regulatory 
agencies and pharmaceutical companies and provided additional insight into their 
approach and considerations in decision-making.  These insights could be deemed to 
warrant further research in this area and to involve a much larger sample to provide 
additional validity and generalisability to the hallmark rating results. The  ten hallmarks 
and their rank-order provide a useful reference to good decision-making practice and 
could also be beneficial to a wider audience outside that of the regulatory agencies and 
pharmaceutical industry. 
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Overall, the main outcome was that of evaluating the reliability and construct validity of 
the QoDOS instrument. Robust and appropriate assessments were performed 
demonstrating the successful reliability and construct validity of the QoDOS decision-
making instrument. Additional and complimentary insights were gained on the decision-
making approaches and influences of individuals in the regulatory agencies and 
pharmaceutical healthcare arena along with recommendations on good decision-making 
practice. The potential of QoDOS to enable better decision-making has been established. 
For organisations, the working environment and the shared beliefs and values of the 
organisation appeared again to be important dimensions in decision-making.  For the 
individual, the subjective elements of: professional experience, competence, personal 
style and autonomy appeared to influence decision-making.  
 
 
SUMMARY 
• The QoDOS instrument that had undergone factor analysis and yielded four 
constructs domains was evaluated for reliability and construct validity 
• Seventy eight experienced decision-makers from regulatory agencies and 
pharmaceutical healthcare companies were involved in this analysis  
• SPSS statistical methodologies and Excel were used in the analyses of the 
research sample findings. The reliability of each construct domain was above 
0.73 and the ICC of each construct domain was above 0.73 
• Convergent and discriminatory validity testing was performed and 
demonstrated. Quantitative analyses also supported the construct validity 
testing performed using the SPSS methodologies 
• The quantitative results provided additional insights into the decision-making 
influences and approaches of individuals and organisations 
• Comparative results were obtained for each of the four constructs. This 
enabled a comparative review of both the Organisational Versus the 
Individual influences, the intra-organisational influences (Approach and 
Culture) and the intra-individual influences (Competence and Style) 
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• Ten hallmarks of good decision-making practice from the investigation into 
decision-making approaches of individuals and organisations were identified 
and mapped against QoDOS  
• The ten hallmarks were ranked in order of perceived importance by a group of 
78 senior decision-makers. The top-three ranking items were: (1) Employ 
scientific rigour and understand the decision context, (2) Apply knowledge 
and experience and (3) Examine the integrity of information for validation and 
confidence in the decision 
• Profiling and visualisation of an individual’s decision-making approach has 
been enabled by the QoDOS instrument.  
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General Discussion 
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The complexity of today’s pharmaceutical development and regulatory decisions has 
created a drive for optimisation of the processes involved. To this end, decision-making 
and its quality have become the central focus for the major stakeholders and policy 
makers. It is this notion that has fuelled the initiative behind this research. 
 
The qualitative research involved the conduct of interviews with a variety of key opinion 
leaders from the European Medicines Agency, national European regulatory agencies, 
the international pharmaceutical industry and clinical research organisations. These 
interviews generated valuable insights into the decision-making approaches both from 
the perspective of the individual and their organisations. The interviews were conducted 
until saturation level was achieved at which point no new decision-making themes 
emerged.  The semi-structured interviews were conducted in an informal environment 
and the key opinion leaders were both engaged and supportive. The confidential and 
open conversation resulted in valuable insights into their decision-making. In addition, 
they identified factors that influenced their decisions and their organisations in which 
they were employed. It was appreciated that the panel of interviewees were all 
experienced key opinion leaders from the regulatory agencies and industry. For the first 
time a number of overarching decision-making factors were identified which have a 
prominent impact on the quality of decision-making from the perspective of the 
individual and the organisation.   
 
For example, the quality and the validity of the data is a fundamental prerequisite to 
making a quality decision. This would ensure that the information that is being used to 
make a decision is valid, is as complete as possible and of optimum quality.  Decisions 
in drug development are made on the basis of information, its analysis and interpretation 
and one should question, where did this evidence come from? How do you know the 
evidence is reliable? Is it factually correct? Has it been analysed and interpreted 
objectively and is it biased? 
 
Another key factor is that of experience and expertise which is directly related to the 
competence and confidence in decision-making. Hindsight into previous decision-
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making and the success and failure of such decisions and their subsequent impact also 
have a significant influence.  These experiences provide a baseline for potential 
outcomes from such decisions and also an appreciation of possible alternative solutions 
that may be incorporated into future decision-making tasks. Furthermore, such 
experiences give the decision maker confidence in their own ability to make such 
decisions. Professional experience and exposure to different challenges are seen as a 
valuable asset and part of the development of a quality decision-maker. 
 
The culture of an organisation and its hierarchy is also a driving factor in regard to 
decision-making within the organisation. In large pharmaceutical organisations, there 
appears to be a defined chain-of-command in how decisions are made. This approach 
impacts on the level of autonomy of the decision-makers and results in a formal 
escalation of requirements and added bureaucracy in reaching a decision. It could also 
be interpreted as stifling an individual’s creativity, diluting accountability in the 
decision-making stages leading to the final decision. This means that more time could be 
required for a decision to be made and by inference suppresses the possibility for quick 
decisions and limits the level of empowerment of people within the organisation.  The 
difference between regulatory agencies and the pharmaceutical industry is that agencies’ 
use of committees may result in the decision being made whereas in the industry they 
are used to facilitate rather than make the final decision.  
 
Intuition or “gut feeling” is seen as a positive attribute within drug development and the 
regulatory review.  The use of intuition by an experienced professional appears to 
expedite the decision-making process and avoids procrastination. It appears to be a non-
quantifiable skill which is a useful and valuable tool in decision-making. However, it is 
not a systematic or structured approach and therefore is not infallible. It may be prone to 
prejudices and biases, but if these are taken into account it can be a valuable asset. Drug 
development and the regulatory review normally operates in a structured and 
standardised manner and therefore it is interesting to appreciate the prominence that has 
been given to intuition in decision-making. 
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Finally, while training in the science of decision-making was considered important, there 
is a limited amount of training investment by both the regulatory agencies and the 
industry. All of the interviewees advised that both they and their organisation would 
benefit from training in decision-making. Such training was recommended to be almost 
mandatory for decision-makers at a managerial or executive level and ideally should be 
incorporated into personal and organisational development plans.  Training in best 
practice decision-making techniques, awareness of the tools to assist with routine best 
practices and frameworks would help in different functions of the organisation. In 
addition, training was perceived as developing the competence, capability and 
confidence in decision-making. 
 
At the level of the individual, the main confirmatory finding of the qualitative 
investigation was the presence of a strong subjective element or style in decision-
making. The other factors included competence based on professional experience, 
education and training,  the ability to focus on the decision to be made and awareness of 
personal biases. The presence of additional extrinsic organisational factors such as the 
size of the organisation, the level of empowerment, autonomy and accountability given 
to the person also are factors to be considered.  
 
In terms of factors influencing organisational decision-making one should consider the 
size, the time/cost, the culture, decision-making hierarchy, internal and external political 
aspects, vested interests of individuals, competitor status and territorial tendencies. 
Additional factors include, the organisation’s approach to marketing, whether current 
projects requiring a decision originated from within or outside the organisation and its 
willingness to embrace new technologies.  
 
It was observed that in smaller organisations and within the regulatory agencies, there 
was some evidence that decisions are made more rapidly than in larger ones. This 
appears to be related to the increased responsibility and demand on individuals to make 
decisions sooner rather than later. There appears to be less time/cost tolerance for 
smaller pharmaceutical organisations and within regulatory agencies compared to larger 
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organisations. Another insight was that different decision-making approaches occur 
within the functional groups of the same organisation.  
 
The qualitative investigation resulted in the identification and consolidation of decision-
making themes into a developmental generic instrument to be used for assessing the 
quality of decision-making. The prototype instrument was subjected to a structured and 
systematic development followed by content validity evaluation by an expert panel. The 
consensus of the panel was that the generic development tool was fit-for-purpose and 
appropriate to progress to further psychometric testing.  
 
The quantitative study recruited participants from several EU countries, the United 
States and China. Ninety-four decision-making themes emerged from the qualitative 
phase of the research and these formed the basis for the development of the QoDOS 
instrument. The combination of the qualitative components supported and complimented 
by the quantitative methodologies, provided confidence in the robustness and fit-for-
purpose evolution of the developmental instrument. The instrument items went through 
several stages of refinement resulting in a final 47-item version of the instrument. The 
instrument demonstrated good reliability and validity and these favourable psychometric 
properties were further underpinned by the previous robust and rigorous qualitative 
phase. This provided extra confidence in the intended utility of the tool.  However, what 
is missing at present from these frameworks and from other decision-making approaches 
within drug development is a mechanism to enable and measure the subjective decision-
making of the individual and that of their organisation. The QoDOS instrument aims to 
bridge this gap. 
 
The main review of a marketing authorisation application or Health Technology 
Assessment are inherently linked to the quality of the dossier submission and the quality 
of the review (Salek et al., 2012). What is again missing at present is a tool to bridge the 
unknown subjective decision-making that is a component of the quality submission and 
the quality review and the QoDOS instrument provides this bridge. Furthermore, the 
QoDOS was applied to a cohort of decision-makers from the industry and the regulatory 
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agencies and it did demonstrate the difference in the comparative approach and 
behaviours of the individual versus that of the organisation. There were a number of 
differences between the organisation and the individual which included: 
 
• Use of structured approaches to decision-making - the results showed that 
individuals within the organisation reported using a structured approach more 
frequently in their personal decision-making than did their organisation 
 
• Quantification of probability of success – these results showed that individuals 
are more disciplined in quantifying such probability than their organisations 
 
• Transparency in decision-making approach - individuals reported that their 
own decision-making approach was not as transparent as that of their 
organisation. This could be related to the quality management systems in 
place which aim to standardise certain decision-making tasks and this in turn 
facilitates transparency  
 
• Training in decision-making - the comparative results showed that the amount 
of training in the science of decision-making that had been received by an 
individual and the level of support offered by their organisation was very 
limited. 
 
What QoDOS is now offering is an addition to the decision-making armamentarium. It 
aims to address that void in the understanding of the quality of the decision-making 
being applied both within the benefit-risk assessment frameworks, drug development 
and beyond. One of the unique, attractive and beneficial features of QoDOS is that it 
allows the individual or their organisation to visualise their decision-making approach. 
This visualisation in turn presents and facilitates profiling and communication of 
decision-making. In addition it provides a time-curve record of changes or 
improvements in a person’s (or an organisation’s) decision-making approach.  It 
presents a platform to add consistency, transparency and communication to the 
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subjective decision-making element. This will in turn allow greater predictability and 
auditability of the individual and their organisation. 
 
QoDOS has also enabled the identification of the hallmarks of good decision-making 
practice and a recommended decision-making framework (Figure 7.1). The structure of 
this framework includes 10 items as outlined: 
 
Figure 7.1: Quality of decision-making framework reflecting good decision-making 
practice 
  
QoDOS 
Framework 
Step 1: Employ 
scientific rigour and 
understand the 
decision context 
Step 2: Apply 
knowledge and 
experience 
Step 3: Collect and 
check validity and 
integrity of 
information  
Step 4: Use 
objective approach 
and be aware of 
biases 
Step 5: Consider 
uncertainties and 
develop alternative 
solutions 
Step 6: Assign 
values and relative 
importance to 
decision criteria 
Step 7: Re-evaluate 
any new 
information  
Step 8: Evaluate 
both internal and 
external influences 
Step 9: Apply a 
structured approach 
to aid transparency 
and audit trail 
Step 10: Make the 
decision, perform 
impact analysis and 
effectively 
communicate the 
basis of the decision 
 172 
The rationale for each of the ten steps in the framework: 
Step 1 – Employ Scientific Rigour and Understand The Decision Context 
For any decision in drug development or the regulatory review it is important that firstly 
the decision-context is clearly understood as if this is not achieved then the decision 
process may be compromised.  
 
Step 2 - Apply Knowledge and Experience 
It has been demonstrated that decision-making knowledge and experience is critical. 
 
 Step 3 - Collect and Check Validity and Integrity of Information 
The quality of any decision is directly related to the validity and integrity of the 
information underpinning the ultimate decision. One should ensure that the information 
collected is of the required quality in order to give the necessary confidence to the 
decision maker.  
 
Step 4 - Use of Objective Approach and Awareness of Biases 
This adds another dimension to the subjective individual judgement and yet again 
improved the robustness of the ultimate decision. Use an objective approach and be 
aware of your personal biases. 
 
Step 5 - Consider Uncertainties and Develop Alternate Solutions 
Uncertainties are a reality of any decision-making. However, not identifying such 
uncertainties could contribute to the risk of failure of the decision. Equally consideration 
of the alternate solutions will lead to a more balanced decision.  
 
Step 6 - Assign Values and Importance to Decision Criteria 
There is a general agreement that not all criteria used either by the individual or the 
organisation is of equal value and importance. It is therefore imperative to involve 
careful examination of the relative importance of such criteria for decision-making.  
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Step 7 - Re-evaluate any New Information  
The dynamic nature of scientific information and the speed with which that travels 
globally in today’s environment makes it absolutely imperative on an individual and 
organisation to revisit criteria used for any previous decision. 
 
Step 8 - Evaluate any Internal or External Influences 
Any organisation or individual must be constantly aware of any internal and external 
influences on their decision-making for example previous experience with medicines in 
a similar therapeutic class, an untoward spontaneous event or considerations such as 
company politics and competitors. 
 
 Step 9 - Use a Structured Approach To Aid Transparency and Audit Trail 
This underlines the fact that using a structured approach will aid transparency as well as 
providing an audit trail to those wishing to understand the basis of the decision.  
 
Step 10 - Perform Impact Analysis and Effectively Communicate The Decision 
It is important in any decision-making to examine the impact the decision has on 
stakeholders. Having a structured systematic framework would enable decisions that are 
made to be effectively communicated, for example from pharmaceutical company to 
regulatory agency, regulatory agency to physician and physician to patient. 
 
 
LIMITATIONS OF THE STUDY  
As with any research there are a number of limitations including the following:   
• The participants in the qualitative phase of the study were all senior decision-
makers or Key Opinion Leaders. Whilst this cohort provided rich insights into 
their decision-making approaches and style, these were not truly 
representative of personnel involved in medicines research and review. 
However, if less experienced people had participated then some  decision-
making themes may have not have emerged 
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• Whereas the sample size achieved in the qualitative phase was satisfactory, 
this was not the case in the quantitative phase. It was disappointing that only a 
20% response rate was achieved in the quantitative phase and this was despite 
using recognised techniques of follow-up including repeat emails and phone 
calls. The number of participants in the final sample should ideally have been 
between 350–760. This would have involved recruiting up to 3,500 people 
and this target was not achievable  
 
• Whilst the QoDOS research was international in nature and did include 
participants from several EU countries, United States and China, it did not 
include South America, Japan, Southeast Asia and the Middle East and 
decision-making in these regions may differ because of experience and culture 
 
• The lack of a validated “gold-standard” instrument could be perceived as a 
limiting factor as it precluded the opportunity for a head-to-head comparison, 
which in turn would have reduced the sample size requirement and would 
have provided a different construct validation approach.  
 
RECOMMENDATIONS 
As a result of this research there are a number of recommendations that can be made: 
• QoDOS should be applied as a strategic planning tool at the different stage-
gates in drug development within the pharmaceutical industry. This would 
include decision points during the nonclinical and clinical development phases 
and would hopefully improve the robustness of decision-making and improve 
attrition rates and delayed/premature terminations in drug development 
 
• QoDOS can provide the opportunity to bridge the gap between the submission 
of a quality dossier and a quality review leading to a seamless and 
comprehensive platform  for more predictable outcomes and increased public 
confidence  
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• QoDOS should be used as a training tool for decision-making which would 
promote a better understanding of the science of decision-making and improve 
the overall quality 
 
• The routine application of QoDOS has the potential to change the 
organisational culture and their approach to decision-making with an 
increased awareness of its quality.  
 
FUTURE WORK 
• It would be of value to initiate a study to assess the quality of decision-making 
within the various functions of the pharmaceutical industry which would 
include: discovery pre-clinical, clinical, regulatory and pharmacovigilance. 
This would allow a comparison of the quality of decision-making between the 
various departments and identify differences between individuals and their 
departments. 
 
• It would be advantageous to compare the decision-making of big Pharma with 
Small and Medium Enterprises (SMEs) and small biotech companies. It is 
hoped that this would identify whether culture and organisational hierarchy 
impact on the quality of decision-making and whether in small companies 
there is a greater demand for accountability of the decisions made.   
 
• Clearly there are differences between the larger mature established regulatory 
authorities and those in the emerging markets. Therefore, it would be of 
interest to design a study to examine whether there is a difference in the 
quality of the decision-making between these two groups. Of specific 
importance, would be to examine the differences between the seven Gulf 
States in the Middle East as they differ in expertise and resources. 
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• QoDOS has identified the importance of examining not only the impact of the 
decision made but also the importance of re-examining the decision when new 
information becomes available. Therefore, it would be important to examine 
the quality of decision-making in the pre-licensing and post-licensing 
divisions within a number of regulatory authorities. 
 
• The regulatory authorities in the emerging markets often have a different 
approach to the evaluation of new medicines depending on where they have 
been approved for marketing. This includes a full review, abridged review and 
a verification review. It would be of value to determine whether the quality of 
decision-making differs according to the type of review. 
 
• Patients are challenged in that the approval of a new medicine for marketing 
does not necessarily mean that the product will be available for 
reimbursement. Therefore a study to examine the quality of decision-making 
within different Health Technology Assessment Agencies may explain why 
some of these differences occur and this will greatly influence patients’ access 
to new medicines. 
 
• It would be of importance to initiate a survey as an urgent piece of future 
work to determine acceptability of the quality of decision-making framework 
by the pharmaceutical industry, regulatory authorities and health technology 
assessment agencies in both the mature and the emerging markets. 
 
The QoDOS has been developed as an instrument for assessing the quality of decision-
making within regulatory agencies and pharmaceutical companies and has identified a 
framework for quality decision-making.  This has the potential to not only revolutionise 
the way in which the whole regulatory submission and review is viewed but also to fill 
the missing piece of the entire process which is building quality into the lifecycle of 
medicines. 
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APPENDIX I 
Quality of Decision-Making: Research Outline 
 
Background: The Centre for Innovation in Regulatory Science (CIRS), formerly known as 
“CMR International Institute for Regulatory Science”, in collaboration with the Welsh 
School of Pharmacy, Cardiff University is currently performing research into the “quality 
of decision-making” within the pharmaceutical development arena and the associated 
regulatory review.  
 
Research Objective: to explore the ways in which different companies/organisations 
manage decision-making. In turn, to help facilitate and promote quality within the 
decision-making processes within the pharmaceutical arena and regulatory authorities 
 
Research Methodology: This research involves a two-stage investigation and involves 
participants from the pharmaceutical arena and the regulatory authorities.  
 
Stage 1: Is an initial validation stage and consists of the conduct of semi-structured 
interviews on the subject of “Quality of decision-making”, with interviewees from the 
pharmaceutical arena and regulatory authorities. The interviews comprise of six main 
questions covering an interviewee’s views on: 
o General understanding or perception of decision-making 
o Decision-making within the drug development arena 
o Decision-making within the regulatory review 
o Decision-making within their organisation 
o Awareness and use of decision-making techniques  
o Impact and monitoring of decisions  
The interviews are all treated with due confidentiality and this is detailed before the start of 
any interview.  The interviews require around 30-45 minutes of an interviewee’s time and 
will be conducted in October and November 2011. 
 192 
The results of the Stage 1 interviews performed should facilitate and validate the generation 
of a quality instrument tool to support and promote quality within the decision-making 
process.  
Stage 2, will comprise of an e-mail questionnaire survey (of the quality instrument tool) to 
a larger sample size of targeted persons working within the pharmaceutical arena and 
regulatory agencies. The questionnaire will comprise of a Likert type response format with 
the option for free text. It will comprise of questions enquiring on how respondents and 
their company/organisation manage the decision-making process. Again, the stage 2 
research will be managed with due confidentiality and the findings of the investigation will 
be made available to all of the research participants. 
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APPENDIX II 
 
Content Validation of a Tool to Assess the Quality of Decision-Making 
 
Introduction 
 
Many people find it hard to believe that there can be a “science of decision-making”.  
However, there is such a science and it is based on a very coherent theory about how to 
make better decisions. 
 
“Contrary to expectations a quality decision and decision-making process should not be 
tested by looking at the outcomes and consequences. In an uncertain world, it is perfectly 
possible to take a good decision that has poor consequences and, equally, to make a bad 
decision and come up with a good outcome. On balance, however, the long-running use of 
good systems for making decisions will generally give better outcomes.” 
  
Companies and regulatory agencies are working to develop frameworks for making 
decisions that are systematic, transparent and accountable.  The question is how good are 
the approaches within companies and agencies for making decisions and what are the 
challenges and enablers to ensure good quality decisions?  One way of testing this, is to 
look at how individuals and organisations make decisions based on custom and practices 
and map this to against best practice decision-making. 
 
Background 
 
The Centre for Innovation in Regulatory Science in collaboration with the Welsh School of 
Pharmacy, Cardiff University, has developed a tool consisting of a number of statements to 
evaluate the quality of decision-making for individuals and their organisations.  This was as 
a result of conducing twenty nine semi-structured interviews with individuals from 
regulatory authorities (nine), pharmaceutical companies (ten) and CROs (ten) when the 
follow themes were explored: 
 
Best practice perceptions of decision-making; 
 
Decision-making within drug development; 
 
Decision-making within the regulatory review; 
 
Decision-making within their individual organisation; 
 
Awareness and use of decision-making techniques; 
 
The impact and monitoring of decisions 
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As an outcome of these interviews, a tool for measuring the quality of decision-making has 
been developed consisting of 94 items (statements) which cover many aspects of decision-
making within an organisation. 
 
Objectives 
 
This measurement tool now needs to be validated for its content and you are asked to rate 
each of the following statements for: 
 
A.  Language clarity: the sentence and wording should be clear, understandable, straight 
forward and simple.  Phrases and wording should be unambiguous and jargon free 
 
B.  Completeness: The sentence should be complete, not broken and should end 
appropriately. 
 
C.  Relevance:  Each item should be relevant to the subject area and target population. 
 
D.  Scaling:  The scoring system uses a four point Likert scale.  You should rate the Likert 
scaling system as to whether the response options fit the question or no 
 
 
Outcome 
 
It is envisaged that this tool will be sent to a number of regulatory authorities and 
pharmaceutical organisations inviting them to complete and assess each statement so that 
an organisation can compare its decision-making approach with the principles of good 
quality decision-making.   
 
As part of the standardised approach for the development of tools of this nature, it is ideal 
for a panel discussion following completion of the ratings by all panel members. 
 
Ronan Donelan, Sam Salek and Stuart Walker 
16 May 2012 
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APPENDIX III 
 
 
A COPY OF THE 94-ITEM CHECKLIST 
 
(The first nine items in the checklist are included for reference example) 
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A copy of the 94-item Checklist 
 
Validation of Questionnaire Feedback Form  
Quality of Decision-making Orientation Scheme (QoDOS) 
  
Name . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .     Specialty . . . . . . . . . . . . . . . . . . .  
 
Thank you for agreeing to take part in the questionnaire feedback as part of the content 
validity. 
 
Each item on the questionnaire needs to be assessed for language clarity, completeness, 
relevance and scaling. The following definitions are provided to ensure standardisation and 
so that each person has the same understanding of these criteria. 
 
Please rate each of the following questionnaire items on the following: 
 
A. Language clarity: the sentence and wording should be clear, understandable, 
straightforward and simple. Phrases and wording should be unambiguous and jargon free  
 
B. Completeness: the sentences should be complete, not broken and should end appropriately. 
 
C. Relevance: each item should be relevant to the subject area and target population. 
 
D. Scaling: the scoring system uses a 4 point Likert scale. You should rate the Likert scaling 
system as to whether the response options fit the question, or not. 
 
 
 
 
 
 
 
A copy of the 94-item Checklist 
Item 1: I use a structured approach in my decision-making 
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                                     Strongly                 Agree              Disagree              Strongly 
                                      agree                                                                           disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 2: My company uses a structured approach in its decision-making 
                                     Strongly                 Agree              Disagree              Strongly 
                                       agree                                                                           disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 3: I evaluate the impact of the decisions I make 
                                     Strongly                 Agree              Disagree              Strongly 
                                      agree                                                                          disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
 
 
A copy of the 94-item Checklist (con’t) 
Item 4: My organisation evaluates the impact of the decisions it makes 
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                                     Strongly                 Agree              Disagree              Strongly 
                                      agree                                                                          disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 5:  I understand the importance of the decisions I make 
                                     Strongly                 Agree              Disagree              Strongly 
                                       agree                                                                           disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 6: My organisation’s decision-making is influenced  by its strategy 
                                     Strongly                 Agree              Disagree              Strongly 
                                      agree                                                                          disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
 
 
A copy of the 94-item Checklist (con’t) 
Item 7:  My organisation’s decision-making is influenced by external stakeholder 
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demands 
                                     Strongly                 Agree              Disagree              Strongly 
                                       agree                                                                          disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 8:  My organisation’s decision-making is influenced by competitors 
                                     Strongly                 Agree              Disagree              Strongly 
                                       agree                                                                          disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
Item 9: My organisation’s decision-making is influenced by the  vested interest of 
individuals 
                                     Strongly                 Agree              Disagree              Strongly 
                                       agree                                                                           disagree 
 
Language Clarity 
 
 
Completeness 
 
 
Relevance 
 
 
Scaling 
 
 
Any 
Comments: 
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APPENDIX IV 
 
 
 
 
 
QoDOS DEVELOPMENTAL INSTRUMENT (VERSION 2) 
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Quality of Decision-Making Orientation Scheme (QoDOS) 
The statements in the questionnaire relate to your views on your personal and organisations 
decision-making processes. Please mark clearly one box for each statement. Please remember, this 
questionnaire is about your/company’s views and not the views of others. 
 Quality of Decision-Making Orientation Scheme (QoDOS) 
 Never Rarely Sometimes Often Always Not 
Applicable 
1. I use a structured 
approach in my 
decision-making 
      
       
2. My company uses a 
structured approach 
in its decision-
making 
      
       
3. I evaluate the impact 
of the decisions I 
make 
      
       
4. My organisation 
evaluates the impact 
of the decisions it 
makes 
      
       
5. I understand the 
importance of the 
decisions I make 
      
       
6. My organisation’s 
decision-making is 
influenced  by its 
strategy 
      
       
7. My organisation’s 
decision-making is 
influenced by 
external stakeholder 
demands 
      
       
8. My organisation’s 
decision-making is 
influenced by 
competitors 
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 Never Rarely Sometimes Often Always Not 
Applicable 
9. My organisation’s 
decision-making is 
influenced by the  vested 
interest of individuals 
      
       
10. My organisation’s 
decision-making is 
influenced by deadlines 
      
       
11. My organisation’s 
decision-making is 
influenced by Company 
politics 
      
       
12. My organisation’s 
decision-making is 
influenced by incentives 
or penalty payments 
      
       
13. My decision-making is 
influenced by my 
previous experience 
      
       
14. My organisation’s 
decision-making is 
influenced by its previous 
experience 
      
       
15. My decision-making is 
influenced by the 
experience of others 
      
       
16. I use intuition or “gut-
feeling” in my decision-
making 
      
       
17. In my organisation, 
people are held 
accountable for their 
decisions 
      
       
18. I am accountable for my 
decisions 
      
       
19. I have acquiesced to my 
line management on 
project decisions 
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 Never Rarely Sometimes Often Always Not 
Applicable 
20. My organisation has 
acquiesced to external 
experts on project 
decisions 
      
       
21. I feel better qualified to 
make a decision 
compared to others who 
are empowered to make  
decisions 
      
       
22. I feel that I could make 
better quality decisions 
      
       
23. My organisation could 
make better quality 
decisions 
      
       
24. I receive training in the 
science of decision-
making 
      
       
25. I use tools e.g. modelling 
or decision trees which 
facilitate my decision-
making 
      
       
26. My professional 
experience is important 
when having to make 
challenging decisions 
      
       
27. I continue with projects 
which should be 
terminated at an earlier 
stage 
      
       
28. My organisation 
continues with projects 
which should be 
terminated at an earlier 
stage 
      
       
29. I have experienced 
“paralysis by analysis” 
caused by my slow 
decision-making 
      
       
30. My procrastination has 
resulted in a negative 
outcome 
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 Never Rarely Sometimes Often Always Not 
Applicable 
31. My organisation has 
suffered a negative 
outcome due to slow 
decision-making 
      
       
32. I have experienced a 
negative outcome by a 
decision not being made 
      
       
33. My organisation’s culture 
has resulted in its inability 
to make a decision 
      
       
34. I qualify the probability of 
success in my decision-
making 
      
       
35. My organisation qualifies 
the probability of success in 
its decision-making 
      
       
36. I quantify the probability of 
success in my decision-
making 
      
       
37. My organisation quantifies 
the probability of success in 
its decision-making 
      
       
38. I  understand the context of 
the decision I am being 
asked to make 
      
       
39. My organisation provides 
clear and unambiguous 
instructions for decision-
making 
      
       
40. My decision-making 
approach is transparent 
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 Never Rarely Sometimes Often Always Not 
Applicable 
41. My organisation’s decision-
making approach is 
transparent 
      
       
42. My decision-making could 
be improved by assigning 
weights 
      
       
43. I present contingencies or 
achievable options as part 
of my decision-making 
      
       
44. I generate a SWOT 
(strengths, weaknesses, 
opportunities, threats ) 
analysis in my decision-
making 
      
       
45. I consider uncertainty and 
unknowns in my decision-
making approach 
      
       
46. I use negotiation in my 
decision-making 
      
       
47. My decision-making is 
consistent 
      
       
48. My organisations decision-
making is consistent 
      
       
49. My organisation re-
examines its decision-
making as new information 
becomes available 
      
       
50. I am open to using better 
alternatives in my current 
decision-making 
      
       
 
 Never Rarely Sometimes Often Always Not 
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Applicable 
51. My organisation is open to 
using better alternatives in 
its decision-making 
      
       
52. In my decision-making, I 
make the same mistakes as 
made in the past 
      
       
53. In my organisations 
decision-making, it makes 
the same mistakes as made 
in the past 
      
       
54. My organisation welcomes 
information supporting 
their existing biases and 
discounts opposing 
information 
      
       
55. I underestimate problems 
which adversely impact my 
decision-making 
      
       
56. My organisation 
underestimates problems 
which adversely impacts its 
decision-making 
      
       
57. I am overcautious when 
estimating uncertainties 
related to my decisions 
      
       
58. My organisation is 
overcautious when 
estimating uncertainties 
related to its decisions 
      
       
59. Recent or dramatic events  
greatly impact my decision-
making 
      
       
 
 
 Never Rarely Sometimes Often Always Not 
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Applicable 
60. Recent or dramatic events 
greatly impact my 
organisations decision-
making 
      
       
61. I weigh up the opinions of 
others in my decision-
making 
      
       
62. My decision-making is 
innovative 
      
       
63. My organisation 
encourages innovative 
decision-making 
      
       
64. I maintain an auditable 
record of my decisions 
      
       
65. My organisation maintains 
an auditable record of its 
decisions 
      
       
66. Emotion is part of my 
decision-making 
      
       
67. My approach to decision-
making is predictable 
      
       
68. My organisation’s approach 
to decision-making is 
predictable 
      
       
69. My decision-making is 
knowledge based 
      
       
70. My organisations decision-
making is knowledge based 
      
       
71. I use benchmarking in my 
decision-making 
      
       
 
 Never Rarely Sometimes Often Always Not 
 208 
Applicable 
72. My organisation uses 
benchmarking in its 
decision-making 
      
       
73. I effectively communicate 
the decisions I make 
      
       
74. My organisation effectively 
communicates the decisions 
it makes 
      
       
75. My organisation effectively 
communicates the decisions 
it makes 
      
       
76. Decision-making in my 
organisation tends to be 
final and not open to 
reinterpretation or 
discussion 
      
 
Please check that you have answered all 76 questions. 
Thank you for your cooperation with this exercise 
Please feel free to add comments, recommendations, suggestions or the like on the 
free text page overleaf. 
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Free Text Commentary 
 
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
...................................................................................................................................................
................................................................................................................................................... 
 
 
Please answer the following questions: 
   
 
Job Title:  
 
 
How many years of professional experience have you to date?    
 
Type of Organisation:  
 
Regulatory Agency     Pharmaceutical Industry       Academia   CRO        Other   
                                                                              
Thank you for your participation. 
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APPENDIX V 
 
 
THE 47-ITEM QoDOS INSTRUMENT (VERSION 3) 
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Quality of Decision-Making Orientation Scheme (QoDOS)© 
The statements in the questionnaire relate to your views on your personal and organisations decision-
making processes. Please mark clearly one box for each statement. Please remember, this questionnaire is 
about your/company’s views and not of others.  
 
Please answer the following questions: 
Job title:  ________________________________________________________________ 
How many years of professional experience have you to date?  _____________________ 
 
Type of Organisation:  
Regulatory Agency     Pharmaceutical Industry       Academia         CRO    Other   
                                                                                              
Part I: Organisational level influences 
A. Decision-making approach 
 Not at  
all 
Sometimes Frequently Often Always 
1. My organisation evaluates the impact of the decisions 
it makes 
     
      
2. My organisation’s decision-making is transparent      
      
3. My organisation’s decision-making is consistent      
      
4. My organisation uses a structured approach in its 
decision-making 
     
      
5. My organisation’s decision-making is influenced by 
external stakeholder’s demands 
     
      
6. My organisation qualifies the probability of success in 
its decision-making 
     
      
7. My organisation quantifies the probability of success 
in its decision-making 
     
      
8. My organisation is open to using better alternatives in 
its decision-making 
     
  
9. My organisation encourages innovative decision-
making  
     
      
10. My organisation considers uncertainties in relation to 
its decision-making 
     
      
11. My organisation provides training in the science of 
decision-making 
     
      
12. My organisation re-examines its decision-making as 
new information becomes available 
     
©MS Salek, R Donelan, SR Walker 
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B. Decision-making culture 
 
 
     
 Not at  
all 
Sometimes Frequently Often Always 
13. My organisation has suffered a negative outcome 
due to slow decision-making 
     
      
14. My organisation’s  culture has resulted in its 
inability to make a decision 
     
      
15. My organisation’s decision-making is influenced 
by company politics 
     
      
16. My organisation’s decision-making, it makes the 
same mistakes as in the past. 
     
      
17. My organisation’s decision-making its 
influenced by the vested interest of individuals 
     
      
18. My organisation underestimates problems which 
adversely impacts its own decisions 
     
      
19. My organisation continues with projects which 
should be terminated at an earlier stage 
     
      
20. My organisation decision-making its influenced 
by competitors  
     
      
21. My organisation’s decision-making is influenced 
by incentives or penalty payments  
     
      
22. My organisation effectively communicates the 
decisions it makes 
     
      
23. My organisation provides clear and unambiguous 
instructions for decision-making 
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PART II: Individual level influences 
A. Decision-making competence 
 
 Not at all Sometimes Frequently Often Always 
24. My decision-making is knowledge based         
 
 
     
25. My decision-making is consistent          
      
26. I consider uncertainty and unknowns in 
my decision-making approach 
         
      
27. I generate a SWOT analysis in my 
decision-making 
     
      
28. I present contingencies or achievable 
options as part of my decision-making 
     
      
29. My decision-making is transparent      
      
30. I understand the context of the decision I 
am being asked to make 
     
      
31. I understand the importance of the 
decisions I make 
     
      
32. I use a structured approach in my decision-
making 
     
      
33. I qualify the probability of success in my 
decision-making 
     
      
34. I quantify the probability of success in my 
decision-making 
     
       
35. I receive training in the science of 
decision-making 
     
      
36. I use intuition or “gut-feeling” in my 
decision-making 
     
      
37. My professional experience is important 
when having to make challenging 
decisions 
     
 
 
 
©MS Salek, R Donelan, SR Walker 
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B: Decision-making style 
 
 Not 
at 
all 
Sometimes Frequently Often Always 
38. Emotion is part of my decision-making      
      
39. I have experienced “paralysis by analysis” caused 
by my slow decision-making 
     
      
40. I have experienced a negative outcome by a 
decision not being made 
     
      
41. In my decision-making, I make the same mistakes 
as in the past 
     
      
42. Recent or dramatic events greatly impact my 
decision-making 
     
      
43. My procrastination has resulted in a negative 
outcome 
     
      
44. My decision-making could be improved by 
assigning weights 
     
      
45. I  underestimate problems which adversely impact 
my decision-making 
     
      
46. I continue with projects which should be terminated 
at an early stage 
     
      
47. I feel that I could make better quality decisions      
      
 
Please check that you have answered all 47 questions. 
Thank you for your cooperation with this exercise 
Please feel free to add comments, recommendations, suggestions or the like on the free text page 
overleaf. 
Please feel free to add comments, recommendations or suggestions below: 
Comments 
 
 
Confidentiality 
All information collected from individual agencies and companies will be kept strictly confidential. No 
data that will identify an individual agency or company will be reported, or detail made to a third party. 
External reports or presentation of the data will include only anonymous figures and any appropriate 
analytical interpretation. Agency or company data will only be provided to the relevant organisation 
concerned. 
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